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ABSTRACT 
 
Diet, and particularly dietary fat quality (i.e., fatty acid composition), is a 
significant modifiable risk factor in the development of metabolic diseases. However, 
whether the manipulation of long-term dietary fat quality may serve as an effective dietary 
strategy to mitigate metabolic disease risk during aging is not well defined. Accordingly, 
this work sought to investigate the role of life-long consumption of bioactive fatty acids 
from various food sources, and particularly dairy fat, on health maintenance and metabolic 
disease risk later in life. To address this issue, I assessed how long-term supplementation 
of dairy fat (butter oil), echium oil, or fish oil to the average U.S. American diet influenced 
glucose homeostasis, insulin sensitivity, and gut microbiota taxa in male and female mice. 
An outbred mouse model, which mimics the genetic diversity of humans, was specifically 
utilized to study the effect of long-term dietary fat quality up to "old age", examining 
markers of glucose homeostasis at regular intervals. At the end of the study, to examine 
potential diet-specific mechanisms that may influence metabolic health, fatty acid 
partitioning in muscle, adipose tissue, liver, and blood was assessed. Investigating the 
complex relationship between diet, gut bacteria, and metabolic phenotype, I observed that 
fish oil and echium oil supplementation improved glucose homeostasis over time in males 
but not in females. Females, however, were consistently more metabolically protected 
compared to males regardless of age. Furthermore, the apparent sex-dependent metabolic 
responses to dietary fat quality may in part be explained by distinct tissue-specific 
partitioning of diet-derived fatty acids. Lastly, sex was found to significantly impact the 
effect of dietary fat quality on colonic bacteria composition as aging progressed. 
Cumulatively, long-term dietary fat quality appears to influence gut microbiota and tissue 
fatty acid stores, in a sex-specific manner, to impact metabolic health and disease risk. My 
findings therefore have important implications for the design of future dietary strategies to 
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Lifestyle is a key modifiable risk factor involved in the manifestation of metabolic 
syndrome and, in particular, diet plays a pivotal role in its prevention and development. 
Current dietary guidelines discourage the consumption of saturated fatty acids (SFA) and 
dietary sources rich in SFA, such as dairy products, despite data suggesting that full-fat 
dairy consumption is protective against metabolic syndrome. This narrative review 
assessed the recent epidemiological and clinical research that examined the consumption 
of dairy-derived SFA on metabolic syndrome risk. In addition, this review evaluated 
studies of individual SFA to gain insight into the potential mechanisms at play with intake 
of a diet enriched with these dairy-derived fatty acids. This work underscores that SFA are 
a heterogenous class of fatty acids that can differ considerably in their biological activity 
within the body depending on their length and specific chemical structure. In summary, 
previous work on the impact of dairy-derived SFA consumption on disease risk suggests 
that there is currently insufficient evidence to support current dietary guidelines which 
consolidate all dietary SFA into a single group of nutrients whose consumption should be 
reduced, regardless of dietary source, food matrix, and composition. 
 
1.2 Introduction 
Metabolic syndrome (MetS) is a serious health condition characterized as a 
minimum of three of the following physiological components: hyperglycemia, abdominal 
obesity, atherogenic dyslipidemia (low HDL-cholesterol and high plasma triacylglycerols), 
and hypertension [1]. While not a disease per se, MetS predisposes an individual to 
developing a wide range of other diseases, including type 2 diabetes, cardiovascular disease 
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(CVD), and strokes [2]. MetS has become an international health crisis and currently 
afflicts approximately 25% of the global population [3]. The risk of MetS incidence varies 
with age [4], sex [5], and genetics [2,5] of an individual, yet lifestyle pattern is recognized 
as the leading modifiable factor in its development [5]. Specifically, dietary intervention 
remains the principal recommendation for the prevention and management of MetS [5]. 
Currently, the U.S. and international dietary guidelines advocate a limited inclusion 
of saturated fat as part of an optimal strategy for prevention of cardiometabolic diseases 
[6–9]. By extension, these dietary guidelines explicitly discourage the consumption of 
foods that are rich in saturated fat, such as full-fat and reduced-fat dairy products. These 
recommendations were originally based on studies performed in the early 20th century that 
indicated a positive association between dietary saturated fat content and CVD [10] while, 
importantly, more recent studies assessing the impact of saturated fat intake on metabolic 
health are inconclusive with widely variable results [11]. A notable example is a recent 
prospective study which found that intake of total saturated fat was positively associated 
with mortality risk, while consumption of medium- and odd-chain saturated fatty acids 
(SFA) was negatively associated with mortality risk [12]. Clearly, these discrepancies are 
likely due, in part, to the heterogeneity of SFA. Depending on the dietary source, SFA vary 
significantly in carbon length and structure [13,14]. Hence, the importance of dietary SFA 
chemical heterogeneity is more complex than previously recognized, and the physiological 
impact of dietary SFA depends not only on the dietary source and food matrix, but also the 
SFA type(s) and composition [12,15,16]. As part of the scientific debate surrounding the 
assumption that saturated fat consumption accounts for an increased incidence of 
cardiometabolic diseases, the role of dairy consumption as a component of a healthy diet 
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remains a central theme of discussion. While SFA are quantitatively the predominant class 
of fatty acids (FA) in dairy fat, it is rather unique as it is also comprised of a wide and 
complex variety of SFA, including short-, medium-, long-, odd-, and branched-chain FA 
[17]. Epidemiological studies have shown that habitual consumption of dairy products may 
reduce risk of metabolic diseases [18,19], and in particular, that dairy fat may have 
protective properties to attenuate development of MetS in adult and elderly populations 
[20,21]. Therefore, it is likely that the diverse array of SFA constituents within full-fat 
dairy foods contributes to favorably modulating cardiometabolic health. Whereas 
considerable research effort has been devoted to health effects of dietary saturated fat in 
general, rather little attention has been paid to the effects of dairy-derived SFA on the risk 
of MetS. 
The overarching goal of this narrative review is to evaluate the current evidence on 
the effects of dairy-derived SFA consumption on MetS risk and assess whether SFA type 
and composition influences cardiometabolic risk. The first objective was to review recent 
literature that focused on the effects of dairy-derived SFA on MetS and any of its individual 
risk factors (i.e., hyperglycemia, (abdominal) obesity, dyslipidemia, or hypertension). The 
second objective was to identify the potential mechanisms involved through the discussion 
of mechanistic studies that examined the effects of individual SFA found in dairy. Finally, 
this review discusses the gaps and limitations present in the literature and assesses whether 
there is sufficient evidence to support current national dietary guidelines which regard 
dietary SFA as a single group of nutrients. 
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1.3 Background of SFA Found in Dairy 
Dairy fat is composed of more than 400 different identified FA and FA derivatives, 
but only about 15 FA represent quantities greater than 1% of total FA [22]. SFA are 
quantitatively the predominant FA class in milk fat, accounting for a range approximately 
of 64–73% of total FA (Table 1.1) [17,23,24], or 5 g per serving of whole milk [25]. 
However, unlike other animal-derived fats, milk fat’s SFA uniquely consists of SFA with 
varying carbon chain length ranging from 4 to 24 carbon atoms [22]. The majority of SFA 
are long-chain FA (14:0–21:0, 58% of total FA; Table 1.1), primarily derived from the diet 
or tissue stores of the ruminant itself, with palmitic acid (16:0) being the prominent SFA 
(35% of total FA) followed by stearic acid (18:0) and myristic acid (14:0) (9 and 12% of 
total FA, respectively (Table 1.1)). The content of medium-chain SFA (7:0–13:0) and 
short-chain SFA (4:0–6:0) in milk fat, both synthesized in the mammary gland via de novo 
lipogenesis [17], is about 8% and 5% of total FA, respectively (Table 1.1). 
Branched-chain FA (BCFA) are distinctive, well-established constituents of milk 
fat and have their origin in the rumen where they are synthesized de novo or metabolized 
from phytol by rumen microorganisms [27]. Accounting for almost 2% of milk (Table 1.1), 
BCFA are commonly SFA substituted with one (mono-) or more (di-/poly-) methyl 
branch(es) on the carbon chain. Typically, BCFA possess either an iso structure where the 
FA has the branch point on the penultimate carbon atom (n-2 carbon atom) or an anteiso 
structure where the branch point is located on the antepenultimate carbon atom (two from 
the end, n-3 carbon atom). Iso- and anteiso-mono-methyl BCFA with chain lengths from 
13 to 17 carbon atoms are quantitatively the most abundant BCFA in milk fat [28]. Milk 
fat also contains a minor amount (3% of total FA; Table 1.1) of bacterial-derived odd-chain 
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FA (OCFA), primarily comprised of pentadecanoic acid (15:0) and heptadecanoic acid 
(17:0), each about 1% of total FA (Table 1.1), respectively. These two OCFA are measured 
in plasma, serum phospholipids, erythrocyte membranes, and adipose tissue, and are used 
as biomarkers of dairy fat intake [29,30]. 
 
1.4 Dairy-Derived SFA Intake Recommendations in Dietary Guidelines 
The “diet-heart hypothesis”, which postulates that diets high in saturated fat cause 
CVD [31], is a paradigm that has influenced U.S. national dietary guidelines since their 
establishment (Figure 1.1) [6]. Looking back at the 1977 dietary goals for the U.S. [32], 
dairy fat has historically been targeted because of its high content of saturated fat, 
prompting public health authorities to caution against consuming full-fat dairy products 
(Figure 1.1). Since then, U.S. dietary guidelines have remained steadfast in their 
recommendation to substitute fat-free or low-fat dairy for higher-fat dairy products [6]. 
Mounting evidence, however, supports that the “diet-heart hypothesis” is an 
oversimplification of dietary saturated fat and that health effects of saturated fat are 
considerably dependent upon other important factors, such as food source and matrix [33], 
the overall dietary pattern of an individual, and the health status of the individual [34,35]. 
Paradoxically, despite a more thorough understanding of the heterogenous health effects 
of dietary SFA, dietary guidelines outside of the U.S. also continue to discourage full-fat 
dairy products (Figure 1.1). For example, Canada’s recently released 2019 food guide 
discourages the consumption of higher-fat containing dairy products [9]. Furthermore, in 
2018, the World Health Organization recommended the consumption of reduced-fat dairy 
for the first time [8]. 
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1.5 Epidemiological and Clinical Studies: The Effects of Dairy-Derived SFA on 
MetS or One of Its Four Risk Factors 
1.5.1 Methods 
The Ovid MEDLINE database was searched, combining the three following search 
term categories with AND: (1) “exp Cholesterol/” OR “Dyslipidemias/” OR “Obesity/” 
OR “Obesity, Abdominal/” OR “exp Hyperglycemia/” OR “exp Insulin Resistance/” OR 
“Hypertension/” OR “Cardiometabolic.mp.”, (2) “exp Dairy Products/”, and (3) “exp Fatty 
Acids/” OR “Saturated Fat.mp.” OR “Saturated Fatty Acids.mp.”. Search results were 
limited to publications written in the English language and published over the past ten years 
between December 2008 and December 2018. Studies were excluded if they did not 
identify dairy-derived SFA or did not assess an outcome of MetS or any of its individual 
physiological components. The references of the included articles, as well as any relevant 
meta-analyses or review articles, were manually searched to identify other eligible studies. 
 
1.5.2 MetS 
Observational research supports that dairy fat intake is protective against MetS 
development [20,21]. A complete description of the observational and clinical studies 
discussed in this portion of the review can be found in Table S1. Two cross-sectional 
studies were identified, which evaluated the influence of consumption of SFA within dairy 
on the risk of MetS (Table 1.2) [21,36]. In a cohort of 9835 middle-aged and elderly men 
and women in Brazil, Drehmer et al. [21] observed a graded, inverse, and independent 
relationship of total and full-fat dairy consumption with the MetScore (a score to estimate 
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MetS risk of a participant). This study also revealed, by adjusting for dairy SFA intake in 
their model, that SFA in dairy may be critical nutrients in the relationship between full-fat 
dairy intake and MetS prevention. In a small cohort study from Spain, 427 elderly 
participants with high risk of CVD were enrolled to examine the relationship between 
plasma FA and MetS prevalence. When subjects were segregated into quartiles based on 
the proportion of 17:0 in their plasma, the second quartile, but not the third or fourth 
quartile, was associated a decreased risk of MetS [36]. Taken together, cross-sectional 




Large-scale cross-sectional studies provide evidence that dairy fat consumption 
plays a role in glucose homeostasis [37,38]. Since the 1980s, it has been known that insulin 
resistance is a critical risk factor of MetS development [39]. Insulin resistance is likely 
established in an individual for several years before hyperglycemia develops [40], hence, 
indices of glucose tolerance, insulin sensitivity, and β-cell function are valid measurements 
to assess risk of metabolic diseases, such as type 2 diabetes and MetS. A study with a 
multiethnic population of adult men and women free of type 2 diabetes from the U.S. 
observed that serum concentrations of 15:0 were positively associated with log SI (insulin 
sensitivity index) and log DI (disposition index), both proxies for insulin sensitivity and β-
cell function, respectively (Table 1.2) [41]. As FA composition in adipose tissue reflects 
long-term dietary intake, Iggman et al. [42] investigated the FA profile in adipose tissue in 
a cohort of 1221 elderly Swedish men and found that 17:0, but not 15:0, was positively 
 9 
correlated with insulin sensitivity indices (Table 1.2). In a recent cohort study of 5675 non-
diabetic, middle-aged Dutch participants, Wanders et al. [43] demonstrated that the 
consumption of SFA from dairy products was inversely associated with fasting insulin 
concentrations and homeostatic model assessment of β-cell function (HOMA-B) in 
overweight adults (Table 1.2). Drehmer et al. [44] observed a beneficial relationship 
between total dairy intake and glycemia measurements in adult and elderly men and 
women, and found that consumption of 14:0 was likely involved in this mechanism. Thus, 
results from cross-sectional studies across various geographic regions support an inverse 
relationship between dairy-derived SFA biomarkers and the risk of hyperglycemia and 
insulin resistance (Table 1.2) [41–45]. 
In a feeding trial in Denmark, abdominally overweight participants were provided 
foods totaling 63 g/d of butter consisting of either a high (8.5 g/d) or slightly lower (6.9 
g/d) amounts of medium-chain SFA (6:0–12:0; Table 1.3) [46,47]. After 12 weeks, neither 
group differed from one another in measurements of insulin sensitivity (HOMA of insulin 
resistance (HOMA-IR) and Matsuda Index), fasting glucose and insulin, or hemoglobin 
A1C. Similarly, Werner et al. [48] investigated Danish adults for the effect of butter 
consumption (39 g/d) containing two different proportions of SFA (59% and 64% SFA) 
for 12 weeks on metabolic risk factors and reported no changes in glucose or insulin 
measurements between groups (Table 1.3). A multicenter (Finland, Norway, and Sweden) 
study, whereby overweight men and women with risk factors of MetS consumed either 3–
5 servings of dairy products daily, or maintained their habitual diet (control group) for six 
months, observed improved insulin sensitivity (via HOMA-IR) in the dairy group [49] 
(Table 1.3). However, no significant correlation between insulin sensitivity and a 
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biomarker of dairy SFA intake (15:0; % of total serum cholesterol esters) was detected. In 
addition, findings from other clinical trials that compared the consumption of dairy-derived 
vs. plant-derived FA showed no differences in glucose homeostasis parameters (Table 1.3) 
[50,51]. Overall, results from clinical studies examining direct measures of glucose 




Abdominal obesity is the most common risk factor observed in patients with MetS 
[52]. Although it is poorly understood, accumulation of fat in the abdominal region, 
specifically visceral fat, poses a greater risk for development of cardiometabolic diseases 
than in other fat depots within the body [53–55]. Overall, literature thus far supports that 
high-fat dairy intake is neutral or protective against obesity development [37,38]. This 
review considered all epidemiological or clinical research that examined the effects of 
dairy SFA on parameters of obesity, rather than abdominal obesity specifically, due to the 
scarcity of studies available. In one clinical trial in Swedish, abdominally overweight adults 
examined the difference between a diet rich in SFA from butter vs. a diet rich in n-6 PUFA 
from sunflower oil and margarine consumed over ten weeks (Table 1.3) [50]. Body weight, 
waist circumference, and total fat mass remained unchanged in the SFA group compared 
to the n-6 PUFA group, although there was a small decrease in visceral/subcutaneous 
adipose tissue ratio in the n-6 PUFA vs. the SFA group. In other clinical trials, ranging in 
intervention duration from three to six months, similar neutral findings were observed 
(Table 1.3) [48,49,56]. Bohl et al. [47] found no differences in body weight of abdominally 
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overweight subjects consuming either butter low in medium-chain SFA (6.9 g/d) or high 
(8.5 g/d) in medium-chain SFA, but in a follow-up analysis, the latter coincided with 
increased lean mass and decreased body fat percentage (Table 1.3) [46]. In general, clinical 
trials suggest that an increased consumption of dairy-derived SFA resulted either in neutral 
[47–51,56,57] or favorable [46,58] changes in body weight and body composition (Table 
1.3). 
 
1.5.5 Atherogenic Dyslipidemia 
Abnormal blood lipid levels that are characteristic of MetS, such as low HDL-
cholesterol and high plasma triacylglycerols, are an important indicator for 
cardiometabolic risk, as they are inextricably linked to poor energy homeostasis, insulin 
resistance, and ectopic and visceral fat accumulation [59]. Research has shown that dairy 
fat intake is associated with favorable blood lipids, including higher HDL cholesterol and 
lower triacylglycerol levels [37,38]. Generally, clinical trials that compared the relative 
amount of SFA within the same dairy food matrix [46–48,56,60] (e.g., butter with two 
different FA profiles) did not find any alterations in blood lipids among treatment groups 
(Table 1.3). One exception was a randomized, controlled trial (RCT) that found 
inconsistent effects on cholesterol levels of participants consuming a diet with 55 g/d of 
dairy fat comprising either 72%, 63%, or 57% SFA in French adults (Table 1.3) [61]. After 
three weeks, those consuming the 63% SFA, yet not 57% SFA, dairy fat had a lower 
LDL/HDL cholesterol ratio than those consuming the 72% SFA butter. Pintus et al. [57] 
tested the effect of cheese intake quantity (45 vs. 90 g/d) and SFA composition (59% vs. 
46% SFA) on blood lipids (Table 1.3). There were no differences in blood lipid 
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measurements when hypercholesterolemic participants consumed 45 g/d of cheese, 
regardless of the proportion of SFA, but 90 g/d of cheese containing 59% SFA resulted in 
increased HDL cholesterol. Notably, while the majority of studies compared SFA 
composition within dairy products, some studies were designed to compare the health 
effects of dairy-derived vs. plant-derived FA and reported variable results (Table 1.3) 
[50,51]. Therefore, variable study designs among RCTs [46–51,56,57,60,61] make it 
challenging to draw comparisons and conclusions, and to ascertain a genuine relationship 
between dairy SFA consumption and dyslipidemia (Table 1.3). 
 
1.5.6 Hypertension 
Hypertension impairs cardiovascular function and significantly predisposes an 
individual to CVD. Relatively less attention has been given to hypertension in the context 
of MetS, however, and the mechanisms by which elevated blood pressure and the other 
three main pathophysiological components of MetS are related are not well defined [3]. 
While there is limited research available that evaluates the relationship between full-fat 
dairy intake and hypertension, results from a recent randomized, controlled trial suggest a 
neutral effect of high-fat dairy consumption on blood pressure [63]. While only a few 
studies assessing hypertension or its risk factors were covered under this review, the limited 
number of relevant studies available also does not support a role for dairy-derived SFA in 
blood pressure modulation (Table 1.3) [46,49]. 
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1.5.7 Limitations of Epidemiological and Clinical Studies Examining Dairy-Derived 
SFA Consumption and MetS 
Epidemiological and clinical studies that assess the role of dairy-derived SFA on 
MetS risk have significant limitations to be considered when interpreting the findings. For 
example, three studies relied on estimated dairy SFA intake that was assessed through a 
one-time food frequency questionnaire [21,43,44], in some cases covering the previous 
twelve months [21,44]. Consequently, the accuracy of self-reported data must be 
considered with caution. Another study correlated odds ratios of MetS with FA biomarkers 
analyzed from plasma [36]; however, because plasma contains primarily FA from 
triacylglycerols, this analysis does not reflect long-term dietary intake, but rather the 
previous meal consumed [64]. Additionally, within any cross-sectional study, it cannot be 
discounted that the apparent association between dairy-derived SFA and MetS is due, at 
least in part, to other nutrients within dairy. 
While randomized, clinical trials have many advantages over cross-sectional 
studies (e.g., determination of causality), they depend on a properly controlled study 
design. Accordingly, a significant limitation in most of the clinical trials to date is that the 
study design did not control for the dietary intake of participants [46–50,56–58,60–62]. 
The heterogeneity of diets between subjects severely restricts the reliability of these data, 
particularly when the intervention depended on small dietary changes (e.g., approximately 
1.6 g/d difference in FA intake [46,47,58,62]). Additionally, some studies examined dietary 
dairy fat vs. plant-derived oils with the goal of comparing health effects of SFA vs. PUFA, 
respectively. Yet, because these fats are sufficiently distinct from one another in taste and 
appearance, the ability of researchers to properly blind participants to a treatment is 
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challenging, if not impossible [50,51]. Lastly, matrix differences between foods, and even 
within dairy products (e.g., milk vs. yogurt vs. cheese), may confound results, which might 
have impacted the findings. Some clinical trials controlled for food matrix by comparing 
one type of dairy product (e.g., butter) with differing proportions of SFA. However, similar 
to an inherent limitation of cross-sectional studies, it is difficult to parse whether observed 
physiological effects are due to a fluctuation of other nutrients, such as a decrease in MUFA 
and/or PUFA, rather than an increase in SFA. 
A general limitation that is important to acknowledge is the reliance on biomarkers 
such as 15:0 and 17:0 to estimate dairy fat consumption. For example, 15:0 and 17:0 occur 
in all ruminant-derived products, such as meat [65], and other non-ruminant foods [66–69], 
and can also be synthesized endogenously [70]. Moreover, technical issues can also arise 
during the fatty acid analysis via gas-liquid chromatography; 15:0 and 17:0 might be 
incorrectly identified as well as overestimated due to coelution with other FA [71]. 
However, despite this potential limitation, epidemiological and clinical research to date has 
demonstrated that dairy fat intake, compared to other foods, has shown stronger and 
consistent correlations with 15:0 and 17:0 blood concentrations. Therefore, while more 
research is needed to determine whether other biomarkers of dairy fat intake can be utilized, 
15:0 and 17:0 for now seem to be appropriate indicators of dairy fat consumption. 
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1.6 Potential Mechanisms Driving Differential Effects of SFA Found in Dairy on 
MetS Components 
1.6.1 Short-chain FA 
Butyric acid (4:0; Figure 1.2a) is hallmarked as an inhibitor of histone deacetylase 
[72–74] and an agonist of specific G protein-coupled receptors [75,76]. Consuming three 
servings of whole milk translates into ~700 mg butyric acid/day of (Table 1.1). In a four-
week pilot study, healthy lean males vs. obese males with MetS were given oral doses of 
4 g butyrate/day. Notably, butyrate improved peripheral and insulin sensitivity in healthy 
lean males but not in the obese males [34]. In addition, butyrate caused modest changes in 
colonic bacterial composition, but changes were different depending on whether males 
were healthy and lean versus obese with MetS. Thus, this study suggests that butyrate 
influences insulin sensitivity, and implicates that these beneficial actions may be achieved 
in part through modification of the gut bacterial community structure. Using the same 
cohort, Cleophas et al. [35] performed ex vivo experiments with the participants’ peripheral 
blood mononuclear cells and found that butyrate treatment led to a reduction of the overall 
inflammatory phenotype of circulating monocytes. 
Animal studies also support that butyrate supplementation of the diet can induce 
positive changes in whole body metabolism. For example, in rodents, butyrate provided 
with a high-fat (HF) diet has been shown to mitigate weight gain [77–83] and adiposity 
[77,79–81]. Butyrate has also been observed to enhance FA substrate oxidation [79–81], 
and in some cases, to increase total energy expenditure [79,81]. Moreover, a HF diet 
enriched in butyrate resulted in improved glucose metabolism [77–82], lower blood lipid 
levels [82,83], and atherosclerosis protection [84]. Two studies demonstrated that dietary 
butyrate increases uncoupling protein UCP-1 expression in brown adipose tissue, 
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suggesting that butyrate may enhance thermogenesis [77,79]. Li et al. [77] additionally 
found that UCP-1 expression was attenuated when mice received a subdiaphragmatic 
vagotomy, suggesting that butyrate acts, in part, through the so-called gut–brain axis. 
Moreover, there is evidence that dietary butyrate acts via the gut by inducing intestinal 
hormone secretions of GLP-1, GIP, and PYY [78]. Recent evidence suggests that that 
dietary butyrate possesses a range of biological activities, including the capability to 
regulate energy metabolism via activation of AMP kinase in skeletal muscle [79], 
downregulate lipogenic pathways in the liver [74,81] and adipose tissue [81], improve β-
cell function [82], reduce inflammation [35,83], and modify gut bacterial composition 
[34,77,83] and/or short-chain FA receptor expression [83]. Lastly, the role of butyrate on 
satiety has been of increased interest, however, whether or not dietary butyrate is involved 
in appetite reduction is controversial [77,78,80,81] and needs to be further examined. 
Relatively limited work has investigated valeric (5:0) and caproic (6:0) acids. 
Recently, it has been found that dietary valerate has anti-inflammatory properties and, like 
butyric acid, has histone deacetylase inhibitor activity [85]. In addition, studies performed 
in chicken hepatocytes show that dietary caproate may beneficially modulate lipid 
metabolism [86,87]. 
 
1.6.2 Medium-chain FA 
Caprylic acid (8:0; Figure 1.2b) is unique because it is the only FA known to be 
involved in the acylation of ghrelin, a post-translational modification that is required for 
the peptide hormone’s ability to stimulate hunger sensing and growth hormone release [88]. 
Caprylate may also influence energy homeostasis via downregulating mRNA transcription 
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of enzymes of FA uptake and synthesis in adipocytes [89]. In chicken hepatocytes, 
caprylate has been shown to reduce secretion of apolipoprotein B, a component of low 
density cholesterol particles [87], reduce VLDL-cholesterol synthesis [90], and inhibit FA 
synthase activity, a key enzyme in de novo lipogenesis [86]. Caprylic acid has been 
documented to enhance glucose-stimulated insulin secretion [91], and two recent studies 
indicate that caprylic acid can induce this response in a dose-dependent manner [92,93]. 
Moreover, in mechanistic studies using a murine β-cell line (MIN6), these effects of 
caprylic acid on insulin secretion are likely mediated by the olfactory receptor OLFR15 via 
the phospholipase C-inositol triphosphate-dependent pathway [92,93]. Thus, research 
suggests that caprylic acid intake may beneficially influence glucose and energy 
homeostasis. 
Like caprylic acid, research supports that capric acid (10:0) may also positively 
modulate lipid metabolism. In rodents, diets enriched with capric acid improved blood lipid 
profiles, including a reduction of total cholesterol and triacylglycerol [94,95]. Caprate has 
been found to transcriptionally regulate lipogenesis and reverse fat accumulation in 
steatotic hepatocytes in vitro [96]. Incubation of chicken hepatocytes with caprate has also 
shown a dose-dependent reduction of apolipoprotein B mRNA [87]. Notably, one study 
provided insight into a direct mechanism of fatty acid induced gene expression 
demonstrating capric acid binding to peroxisome proliferator-activated receptor γ, a key 
regulator of lipogenesis, in a unique binding pocket [94]. Lee et al. [97] investigated in 
vitro and in vivo effects of capric acid on intestinal health. When IPEC-J2 cells, a non-
transformed porcine intestinal epithelial cell line, were treated with the immunosuppressant 
cyclophosphamide, the addition of capric acid attenuated inflammation and oxidative 
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stress, and enhanced mRNA expression of proteins related to improved intestinal barrier 
function. More strikingly, when pigs fed diets enriched with capric acid were challenged 
with cyclophosphamide, a similar phenotype was observed. Capric acid may therefore 
contribute to overall reduced metabolic risk via effects on cholesterol metabolism and 
intestinal inflammatory status. 
Potential mechanisms of lauric acid (12:0) are underrepresented in the literature. 
Consuming three servings of whole milk translates into ~800 mg lauric acid/day of (Table 
1.1). In a small crossover RCT, eight patients with type 2 diabetes were given a prescribed 
breakfast and lunch each with an enteric-coated pellet containing 2.35 g lauric acid [98]. 
This study provided evidence that lauric acid may lower postprandial glucose levels 
through stimulation of GLP-1 release. In spontaneously hypertensive rats, lauric acid, 
administered intravenously, lowered heart rate and blood pressure [99]. In addition, 
treatment of THP-1 macrophages with lauric acid decreased expression of A disintegrin 
and metalloproteinase with thrombospondin motifs (ADAMTS) −1, −4, and −5, which are 
key enzymes in the development of atherosclerosis [100]. Thus, the limited body of 
evidence suggests that lauric acid may exert anti-hypertensive and anti-atherosclerotic 
properties. 
 
1.6.3 Long-chain FA 
Myristic acid (14:0) is involved in the acetylation of at least 0.5% of total proteins 
[101]. In addition, myristic acid has been found to have the highest binding potency with 
the human G protein-coupled receptor 40 (GPR40), a major LCFA receptor expressed in 
enteroendocrine and β-cells, compared to 6:0–23:0 SFA in experimental conditions [102]. 
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Human studies thus far have primarily focused on myristic acid’s unfavorable impact on 
blood lipid levels [103,104]. Recent work in mice showed that dietary supplementation 
with myristic acid enhances glucose tolerance and insulin sensitivity [105]. Further 
investigation in C2C12 murine myotubes demonstrated that these beneficial effects may 
be mediated by promoting glucose uptake via stabilization and therefore increased 
expression of diacylglycerol kinase in skeletal muscle [106,107]. There is additional 
evidence that myristic acid enhances incorporation of n-3 FA into tissues [108,109], 
however, this mechanism is still not well understood. 
The covalent linkage of palmitic acid (16:0) or stearic acid (18:0; Figure 1.2c) to a 
protein, known as palmitoylation and stearoylation, respectively, is a common post-
translational modification. Whereas palmitoylation is well-established as an essential 
process in the proper function of variety of proteins, no significance was ascribed for this 
process with stearic acid until 2015, when Senyilmaz et al. [110] demonstrated that 
stearoylation may play a critical role in mitochondrial function. In vitro studies in human 
and Drosophila cell cultures showed that post-translational attachment of stearic acid to 
transferrin receptor 1 protein inhibits c-Jun n-terminal kinase signaling and subsequent 
mitochondrial fragmentation. Furthermore, experiments in Drosophila revealed that dietary 
stearic acid increased mitochondrial fusion, thus preserving cellular oxygen consumption 
capacity. Extension of this work demonstrated that in healthy and diabetic adults inclusion 
of 24 g stearic acid into a breakfast meal also induced mitochondrial fusion [111]. It is 
important to note that three servings of whole milk per day provide approximately 2 g of 
stearic acid (Table 1.1). In rodent models, dietary stearic acid has been observed to lower 
total plasma cholesterol [112,113] and its absorption [113], increase fecal excretion of FFA 
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[114], and mitigate HF diet-induced body weight and fat accumulation [114]. The neutral 
effects of stearic acid on cholesterol in humans has been well confirmed and thoroughly 
reviewed elsewhere [115]. Additionally, results from Cowles et al. [116] indicate that 
stearic acid may impact cholesterol metabolism via modulation of secondary bile acid 
composition. Stearic acid has also been implicated in modulating inflammation [117,118]. 
Using rat cortical neurons, Wang et al. [119] provided additional evidence that stearic acid 
protects against lipid peroxidation, an indicator of oxidative stress, via activation of 
peroxisome proliferator-activated receptor γ. Overall, research demonstrates that dietary 
stearic acid has dynamic biological actions that may be beneficial for whole body energy 
metabolism. 
 
1.6.4 Odd- and Branched-chain FA 
Mechanistic studies that examined the metabolic influence of OCFA consumption 
are limited, although, in general, OCFA are thought to enhance plasma membrane fluidity 
[120]. Similarly to OCFA, BCFA enhance fluidity of the lipid bilayer [121,122], 
potentially contributing to beneficial downstream consequences on cellular signaling and 
transport. In vitro studies have demonstrated iso 15:0 to have anti-tumorigenic properties 
[123,124], and iso 17:0 improved β-cell function [125]. In neonatal rats, dietary enrichment 
with a BCFA mixture (iso 14:0, anteiso 15:0, iso 16:0, anteiso 17:0, iso 18:0, and iso 20:0) 
reduced the incidence of necrotizing enterocolitis, induced shifts in cecal bacterial 
composition, and increased expression of anti-inflammatory IL-10 [126]. Yan et al. [127] 
challenged Caco-2 cells with LPS and observed that treatment with individual BCFA (iso 
18:0, iso 20:0, anteiso 13:0, anteiso 15:0, or anteiso 17:0) attenuated transcription of the 
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inflammatory mediators IL-8 and NF-κB. Similar findings were observed when LPS-
stimulated Caco-2 cells treated with a mixture of BCFA that was isolated from the vernix 
of 20 newborns [128]. Drawing from the limited research available, evidence indicates that 
BCFA may beneficially modulate health through attenuation of inflammatory responses. 
 
1.6.5 Limitations of Mechanistic Studies Examining Dairy-Derived SFA 
Consumption on MetS Components 
Single nutrient studies are a practical and valuable means to ensure that observed 
results are unequivocally induced by the dietary component of interest. While this is an 
appealing advantage compared to studies that utilize whole foods, such a study design 
possesses its own set of considerable challenges. Most notably, these studies cannot 
compensate for the fact that humans do not eat dietary FA in isolation. The food matrix, in 
essence the entire structure and composition of nutrients consumed by an individual, is 
gaining scientific recognition for its role in modulating the properties and metabolism of 
any single nutrient it contains [15,16]. Specifically, consumption of isolated dairy-derived 
nutrients has been found to impact the risk of cardiometabolic disease differently compared 
to a whole dairy matrix [33]. Dairy products considerably differ in the complexity of their 
food matrix due to processing methods (e.g., milk vs. cheese), which alters their nutrient 
types and composition, as well as physical structure [33]. Moreover, studies have shown 
that differences in food matrix, even within types of dairy products, can modify 
cardiometabolic risk [129]. Another important consideration is that studies focused on the 
effects of the consumption of single nutrients often evaluate a very high amount of the 
nutrient of interest (e.g., 4 g/d butyrate [34,35]). Future research should carefully consider 
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the concentration of a single nutrient that may be attained in an average, balanced diet to 
enhance the study design’s applicability. 
 
1.7 Conclusions 
The broad scope of this narrative review provides a concise glimpse of the current 
evidence available on the relationship of dairy-derived SFA and MetS risk. A key strength 
of this review is that it assesses relevant epidemiological and clinical research, as well as 
mechanistic research from cell culture, animals, and human populations. Recent 
epidemiological and clinical studies on this subject indicate that intake of dairy-derived 
SFA is either protective or neutral on cardiometabolic health. Additionally, mechanistic 
research to date demonstrates that SFA constituents found in dairy fat have additional 
biochemical functions beyond substrate oxidation, which can have specific and potent 
consequences on systemic metabolism. 
Another strength of this review is the discussion of the evolution of international 
dietary guidelines, and in particular the alignment of these guidelines with current scientific 
evidence. This review supports that SFA are a heterogenous class of FA that can vary 
significantly in their mode of action based their length and structure. However, a lack of 
relevant controlled clinical trials and mechanistic studies hinders the formation of a clear 
relationship between dairy-derived SFA consumption and cardiometabolic health. Hence, 
this review calls into question whether or not dietary guidelines, which discourage the 
intake of full-fat dairy on the basis of its SFA content, are appropriate. Importantly, this is 
a narrative review and, as such, the research presented here is not fully comprehensive of 
all work performed in this field of study. Nevertheless, it is evident that additional research 
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is needed to understand the complex interaction between SFA, food matrix, and disease 
risk. Future controlled mechanistic and well-designed RCT that consider the complexity of 
the dairy matrix are needed to clarify the role of dairy-derived SFA intake on MetS. 
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1.14 Tables 
Table 1.1 Typical composition (g/100 g) and content (mg/three daily servings) of key 
saturated fatty acids in bovine-derived milk. Fatty acids are median values in milk, pre-
averaged by breed at four different timepoints across a lactation [13]. 




(mg/Three Daily Servings) 8 
Total SCFA 1 5.18 (4.83–7.44) 1150 
4:0 3.05 (2.90–5.37) 677 
6:0 2.01 (1.86–2.25) 445 
Total MCFA 2 8.34 (4.03–9.77) 1850 
8:0 1.18 (0.82–1.37) 261 
10:0 2.86 (1.48–3.38) 635 
12:0 3.60 (1.53–4.20) 798 
Total LCFA 3 58.13 (43.02–67.66) 12,903 
14:0 12.14 (8.56–12.57) 2695 
16:0 34.83 (25.01–36.60) 7730 
18:0 9.05 (7.91–15.94) 2008 
Total VLCFA 4 0.13 (0.08–0.14) 29 
Total OCFA 5 2.8 (1.83–2.91) 622 
15:0 1.28 (0.72–1.39) 284 
17:0 0.71 (0.70–0.97) 158 
Total BCFA 6 1.65 (1.49–1.8) 366 
Total SFA 7 72.81 (62.88–76.73) 16,162 
1 Total SCFA: all short-chain fatty acids (4:0, 5:0, 6:0). 2 Total MCFA: all medium-chain 
fatty acids (7:0, 8:0, 9:0, 10:0, 11:0, cyclohexyl 11:0, 12:0, 13:0). 3 Total LCFA: all long-
chain fatty acids (14:0, 15:0, 16:0, 17:0, 18:0, 20:0, 21:0). 4 Total VLCFA: all very long-
chain fatty acids (22:0, 23:0, 24:0). 5 Total OCFA: all odd-chain fatty acids (5:0, 7:0, 
9:0,11:0, cyclohexyl 11:0, 13:0, 15:0, 17:0, 21:0, 23:0). 6 Total BCFA: all branched-chain 
fatty acids (iso 13:0, anteiso 13:0, iso 14:0, iso 15:0, anteiso 15:0, iso 16:0, iso 17:0, anteiso 
17:0, iso 18:0). 7 Total SFA: all saturated fatty acids (SCFA, MCFA, LCFA, VLCFA, 
BCFA). 8 Median (mg/three daily servings): Median fatty acids mg/serving of whole milk 
(3.25% milk fat), calculated from median FA g/100 g as described in Bainbridge et al. 






Table 1.2 Summary of clinical evidence on the effect of the intake of dairy-derived saturated fatty acids on metabolic syndrome risk. 
Reference Population Study Design Adjustments 
Risk Factors 
Hyperglycemia Metabolic Syndrome (Risk or Prevalence) 
Drehmer et al. (2015) 
[44] 
Brazilian adults (10,010; 35–74 yr old) 
Cross-
sectional  
↓ NA 1 
Drehmer et al. (2016) 
[21] 
Brazilian adults (n = 9835; 35–74 yr old); Cross-
sectional  
NA ↓ 
Iggman et al. (2010) 
[42] 




Kratz et al. (2014) 
[45] 
American adults with non-alcoholic fatty liver disease (n = 





al. (2014) [36] 
Spanish adults, asymptomatic with cardiovascular disease risk 




Santaren et al. (2014) 
[41] 
Hispanic, African American, and non-Hispanic white 
American adults, free of type 2 diabetes at baseline (n = 




Wanders et al. (2017) 
[43] 
Dutch adults, overweight (n = 5675; 45–65 yr old) Cross-
sectional  
↔ NA 
1 Parameter not measured or reported. 2 Results from parameters measured were a combination of results indicative of 




Table 1.3 Summary of clinical evidence on the effect of the intake of dairy-derived saturated fatty acids on metabolic syndrome risk. 




Hyperglycemia Obesity Dyslipidemia Hypertension 
Amer et al. (2017) [62], 
Bohl et al. (2015) [47], 
Bohl et al. (2017) [46], 
Matualatupauw et al. 
(2017) [58] 
Danish adults, abdominally 
overweight (n = 52; ³18 yr old) Parallel 12 weeks  -
1 ↔	2 - - 
Bjermo et al. (2012) [50] 
Swedish adults, abdominally 
overweight (n = 61; 30–65 yr old) Parallel 10 weeks  - ↔ ↔ NA 
3 
Iggman et al. (2011) [51] 
Swedish adults, hyperlipidemic (n 
= 20; 25–68 yr old) 
Crossover 9 weeks  - - ↔ NA 
Intorre et al. (2011) [60] 
Italian adults (n = 60; 20–40 yr 
old) 
Crossover 16 weeks  NA NA - NA 
Malpuech-Brugere et al. 
(2010) [61] 
French adults (n = 111; 18–50 yr 
old) 
Parallel 4 weeks  NA NA ↔ NA 
Pintus et al. (2013) [57] 
Italian adults, 
hypercholesterolemic (n = 42; 30–
60 yr old) 
Crossover 9 weeks  NA - ↔ NA 
Venkatramanan et al. 
(2010) [56] 
Canadian adults, overweight and 
borderline hyperlipidemic (n = 15; 
30–60 yr old) 
Crossover 32 weeks  NA - - NA 
Wennersberg et al. (2009) 
[49] 
Finnish, Norwegian, and Swedish 
adult men and postmenopausal 
women, overweight with traits of 
MetS (n = 121; 30–65 yr old) 
Parallel 6 months  ↔ - ↔ - 
Werner et al. (2013) [48] 
Danish adult and elderly subjects 
(n = 38; 50–70 yr old) Parallel 12 weeks  - - - NA 
1 No differences in parameters measured among treatments. 2 Parameters measured were a combination of results indicative of 




Table 1.S1 Summary of clinical and observational evidence on the effect of the intake of dairy-derived saturated fatty acids on 
metabolic syndrome risk. 
Reference Study objective Population Study design 
Study 
duration Adjustments Results 
Randomized, controlled trials 






influence of milk 
lipids with 
high or low content of 
medium-chain fatty 
acids and milk protein 
consumption on the 

















- High vs. low medium-chain 
SFA butter diet: 
• ↑	urinary levels of adipic 
acid 
Bjermo et al. 
(2012) [50] 
Investigate the effects 
of SFA or PUFA-rich 






(n = 61; 30-65 yr old); 
Role of Dietary Fatty 





- SFA vs. PUFA diet: 
• No difference in glucose 
measurements 
• No difference in body 
weight, BMI, waist 
circumference, percent 
body fat or adipose tissue 
gene expression 
• ↑	visceral/subcutaneous 
adipose tissue ratio 
• No difference in plasma 
triacylglycerols, HDL 
cholesterol, or LDL 
cholesterol 




























- High vs. low medium-chain 
SFA butter diet: 
• No difference in glucose 
measurements 
• No difference in body 
weight and adipose tissue 
gene expression 
• No difference in blood 
lipids 
Bohl et al. 
(2017) [46] 
Investigate whether 
intake of whey protein 
and butter naturally 
enriched in medium-
chain SFA affects 
body composition, 
insulin sensitivity, 



















- • High vs. low medium-chain 
SFA butter diet: 
• ↑	lean body mass and ↓ 
total body and gynoid fat 
percentage 
• No difference in glucose 
homeostasis 
• No difference in blood 
lipids 
• No difference in blood 
pressure 
Iggman et al. 
(2011) [51] 
Investigate effect of 
replacing dietary dairy 
fat or rapeseed oil on 
blood lipids, glucose 
metabolism, and 
coagulation factors 
Adult Swedish subjects, 
hyperlipidemic (n = 20; 
25-68 yr old) 
Crossover 9 weeks Body weight Dairy fat vs. rapeseed oil diet: 
• ↑ total cholesterol, LDL 
cholesterol, total/HDL 
cholesterol ratio, and 
triacylglycerols 
• No difference in HDL 
cholesterol, insulin 
sensitivity, fasting glucose, 
and glucose tolerance 
Intorre et al. 
(2011) [60] 
Investigate 
effect of intake of two 
cheese varieties 
differing 
in fat quality on blood 
lipids and redox status 
Italian adults (n = 60; 20-
40 yr old) 
Crossover 16 wk - Control vs. experimental diet: 
• No difference in plasma 









Brugere et al. 
(2010) [61] 
Investigate impact on 
CVD risk factors of 
milk fats with varying 
ratios between trans 
fatty acids, SFA, 
MUFA13, and PUFA 
French adults (n = 111; 
18-50 yr old) 
Parallel 4 weeks - 72%, 63%, or 57% SFA milk 
fat diet: 
• No difference in HDL 
cholesterol. 
• ↓	total cholesterol, LDL 
cholesterol, and LDL/HDL 
cholesterol ratio in 63% 
SFA milk fat diet compared 
to 72% diet and ↓
	total/HDL cholesterol ratio 
compared to 72% and 57% 
milk fat diet 
Matualatupauw 
et al. (2017) 
[58] 
Investigate effects of 
high medium-chain 
SFA vs. low medium-
chain SFA diet on 
subcutaneous 


















- High vs. low medium-chain 
SFA butter diet: 
• ↑ expression of gene sets 
related to citric acid cycle, 
oxidative phosphorylation, 
and adipogenesis 
• PPAR$ and PPAR % 
coactivator 1-$	were 
predicted to be activated 
by medium-chain SFA 
Pintus et al. 
(2013) [57] 
Investigate effects of 
sheep cheese enriched 
in $-linolenic, 
conjugated linoleic, 
and vaccenic acids on 





= 42; 30-60 yr old) 
Crossover 9 weeks - 59% vs. 46% SFA cheese diet: 
• No difference when 
consuming 45 or 90 g/d of 
cheese on BMI or waist 
circumference 
• No difference when 
consuming 45 g/d of cheese 
on blood lipids 
• ↑	total cholesterol, HDL 
cholesterol, and LDL 
cholesterol when 





et al. (2010) 
[56] 
Investigate whether 
consumption of milk 
enriched with 9c,11t 
and 10t,12c 18:2 
isomers alters  
blood lipids; 
liver function; C-
reactive protein; tumor 
necrosis factor-alpha; 





hyperlipidemic (n = 15; 
30-60 yr old) 
Crossover 32 
weeks 
- 60% vs. 48% SFA milk diet: 
• No difference in body 
weight or composition 
• No difference in 
triacylglycerols, total 
cholesterol, LDL 
cholesterol, or HDL 
cholesterol 
Wennersberg et 
al. (2009) [49] 
Investigate whether 
increased intake of 
dairy products in 
subjects who 
habitually consumed a 




other factors of MetS 
Finnish, Norwegian, and 
Swedish adult men and 
postmenopausal women, 
overweight with traits of 
MetS (n = 121; 30-65 yr 
old) 
Parallel 6 months - Milk vs. control diet: 
• No difference in glucose 
homeostasis measurements 
except ↑	insulin sensitivity 
• No difference in body 
weight, BMI, waist 
circumference, body fat 
mass and proportion 
• No difference in blood 
lipids except ↑	total 
cholesterol 
Werner et al. 
(2013) [48] 
Investigate effects of 
intake of butter from 
mountain-pasture 
grazing cows 
compared to butter 
from conventionally-
produced cows on risk 
markers of 
cardiovascular disease 
and type 2 diabetes 
Danish adult and elderly 
(n = 38; 50-70 yr old) 
Parallel 12 
weeks 
- 59% vs. 64% SFA butter diet: 
• No difference in insulin, 
plasma glucose, or glucose 
tolerance 
• No difference in body 
weight 
• No difference in serum 














consumption of dairy 
products and glycemic 
status 
Brazilian adults (10,010; 
35-74 yr old); Brazilian 
Longitudinal 




- Age, sex, race, 
occupational status, 
education, family 
income, study center, 
menopause, family 
history of diabetes, 
smoking status, alcohol 
intake, physical 
activity, calorie intake, 
and non-dairy foods, 
height, waist, and hip 
measurements 
• Inverse association between 
dairy intake and fasting 
glucose, 2 hr post-load 
glucose, and hemoglobin 
A1c was attenuated when 
myristic acid was included 
as an adjustment to the 
model. 
Drehmer et al. 
(2016) [21] 
Investigate association 
of dairy, type of dairy, 
and dairy fat intake on 
MetS 
Brazilian adults and 
elderly (n = 9,835; 35-74 
yr old); Brazilian 
Longitudinal 




- Age, sex, race, 
occupational status, 
education, family 
income, study center, 
menopausal status, 
family history of 
diabetes, smoking 
status, alcohol intake, 
physical 
activity, and nondairy 
variables 
• Inverse association between 
total and full-fat dairy 
intake with MetScore was 
attenuated when dairy-
derived SFA intake was 
included as an adjustment 
to the model. 




adipose tissue fatty 
acids and insulin 
sensitivity 
795 Swedish men (~71 yr 
old); Uppsala 
Longitudinal Study of 
Adult Men (ULSAM) 
Cross-
sectional 
- BMI, smoking, alcohol 
intake, and physical 
activity 
• 17:0 (% of total fatty acids) 
of adipose tissue biopsies 
was positively correlated 
with insulin sensitivity 




of intake of trans-16:1 
n-7 and intake of dairy 
fat with 
glucose tolerance, 
American adults with 
NAFLD (n = 17) with 
age- and BMI-matched 
controls (n = 15) 
Cross-
sectional 
- Age, sex, BMI, liver-
spleen ratio 
• Plasma phospholipid 15:0 
and 17:0 (% of total 
phospholipid) of was 





insulin sensitivity, and 
β-cell function 
• Phospholipid 17:0 and FFA 
15:0 (% of total 
phospholipid and FFA, 
respectively) was 
associated with glucose 
tolerance 
• No association of plasma 
phospholipid (% of total 
phospholipid) or FFA 15:0 
and 17:0 (% of total FFA) 
with insulin resistance or β-
cell function 
Mayneris-
Perxachs et al. 
(2014) [36] 
Analyze plasma fatty 
acid composition and 
estimated desaturase 
activities in relation to 
MetS status; examine 
associations between 
these patterns and 
MetS and its 
components 
Spanish adults, 
asymptomatic with high 
risk of cardiovascular 
disease (n = 427; 55-80 





- Sex, age, energy 
intake, BMI, smoking 
status, occupation, and 
educational level 
• Second quartile of plasma 
17:0 (% of total fatty acids) 
was associated with ↓ risk 
of MetS compared to first 
quartile, but not third or 
fourth quartiles 
Santaren et al. 
(2014) [41] 
Investigate association 
of dairy fatty acid 
biomarkers, 15:0 acid 
and trans-16:1 n-7, 
with insulin 
resistance and β-cell 
function, and with 
incident type 2 




Hispanic white American 
adults, free of type 2 
diabetes at baseline (n = 
659; 40-60 yr old) 
Cross-
sectional 
- Age, sex, ethnicity, 
center, physical 
activity, smoking 




red meat/ soft 
drink/fiber intakes 
• 15:0 concentration was 
positively associated to log 
SI (insulin sensitivity 
index) and log DI 
(disposition index) 
• Additional adjustment for 
BMI and waist 
circumference attenuated 
this association 
Wanders et al. 
(2017) [43] 
Investigate 
relationship of intake 
of total fatty acids, 
SFA, 
MUFA, PUFA and 
trans fatty acids with 
Dutch adults, overweight 
(n = 5675; 45-65 yr old); 
Netherlands 




- Age, sex, energy 
intake, alcohol intake, 
fiber intake, body fat 
percentage, smoking 
status, education level, 
physical activity, 
• Dairy-derived SFA intake 
was inversely associated 









sources of FA on these 
associations 
family history of 












Figure 1.1 Timeline of the evolvement of dietary recommendations of total, saturated, and 





Figure 1.2 Graphical summary of the potential mechanisms of (a) butyric acid, (b) caprylic 
acid, and (c) stearic acid that beneficially modulate risk of metabolic syndrome.  
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The fatty acid (FA) composition and content of whole milk (3.25% fat) from 
organic, omega-3 (n-3) FA fortified, and conventional retail brands available in the 
northeastern U.S. were assessed monthly via gas chromatography. Among the retail labels, 
organic milk stood out as it contained a distinct and more healthful FA profile, consistently 
comprised of a higher content of unique bioactive FAs (short-chain FAs, odd- and 
branched-chain FAs, vaccenic acid, and conjugated linoleic acids) per serving, particularly 
during the warm season. The total content of saturated FAs did not differ by retail label. 
While organic and n-3 fortified milk contained a similar content of total n-3 FAs, the 
proportion of individual n-3 FAs differed significantly (organic milk: 18:3 n-3; n-3 fortified 
milk: 20:6 n-3) as a result of the production system and process, respectively. Overall, per 
serving, the FA profile of organic milk may provide added nutritional and health benefits. 
 
2.2 Introduction 
The dairy industry is a significant agricultural sector in the U.S., generating $40 
billion in revenue and accounting for 9% of total agricultural sales annually1. While annual 
per-capita consumption of milk has declined over the past 40 years by 39%, from 106 liters 
(28 gallons) to 65 liters (17 gallons)1, milk continues to be an integral staple food in the 
U.S. American diet consumed on a regular basis. Milk provides not only energy but a large 
variety of essential nutrients like protein, fat, vitamins, and minerals and is considered the 
most significant source of natural bioactive components2. Fat and its fatty acid (FA) 
composition are the most variable components in milk accounting for many nutritional, 




has shown that the nutritional value of milk and its fat component can be altered through 
various management strategies3–8. Bovine milk fat is generally high in saturated fatty acids 
(SFAs) and low in polyunsaturated fatty acids (PUFAs), especially omega-3 fatty acids (n-
3 FAs), yet is distinguished by an array of unique rumen microbe-synthesized FAs that also 
include trans isomers of octadecenoic acid (18:1 t4 through t16). The latter may become 
of particular interest because ruminant-derived products, such as milk (and meat), are the 
sole source of trans-fatty acids (TFAs) in the human diet following the mandatory removal 
of industrially produced TFAs (i.e., from partially hydrogenated oils) from the U.S. food 
supply as mandated by the U.S. Food and Drug Administration as of January 1, 20209.  
 Traditionally, the U.S. retail market for milk has been fulfilled with conventionally-
produced milk. There is, however, a growing consumer interest in functional milk (and 
dairy products) to maximize health promotion and disease prevention. For example, 
organically produced milk has gained remarkable popularity among consumers for the past 
two decades1. In fact, the U.S. is the leading market globally for organic dairy products and 
organic milk is the largest segment within organic dairy products, earning $1.17 billion in 
U.S. sales in 2015 alone10. Organic milk brands frequently claim nutritional superiority of 
organic milk when compared to conventional milk, and accordingly, organic milk is often 
conceived by the consumer as a source of desirable nutrients with healthful properties. 
Organic dairy production, which centers on maximizing dairy livestock’s access to and 
feed intake from pasture1, increases fresh forage in the cow’s diet that in turn results in 
enhanced milk concentrations of desirable FAs11 such as n-3 FAs. However, to date, there 
is no scientific evidence that supports the assumption that consumption of organic milk 




gaining momentum in consumer demand for milk produced from forage-only fed dairies7. 
These dairy producers follow more rigid guidelines than organic milk producers, including 
a dietary regime which consists of only forage-based feedstuffs while grain or grain-based 
forages are prohibited. Consequently, milk from forage-only dairies may feature a greater 
content of beneficial FAs (e.g., n-3 FAs and conjugated FA isomers7) than organic milk, 
but research assessing these differences is limited. Another recently developed niche retail 
market is fortified (i.e., supplemented) milk.  Milk fortified with n-3 FAs is typically 
produced by supplementing fish or algal oil post-harvest to enhance the content of long-
chain n-3 FAs in milk12.  
Consumers pay a premium for organic and n-3 fortified milk, yet, it is unclear 
whether these specialty milks actually reflect physiologically-meaningful differences in the 
FA composition of milk to improve health or prevent chronic diseases compared to 
conventional milk. The purpose of this study was to compare the FA composition and 
content, on a per serving basis, between the three types of retail milk, i) conventional milk, 
ii) organic milk, and iii) n-3 fortified milk, commercially available in retail stores in the 
Northeast of the U.S. We collected the milk samples on a monthly basis over the course of 
one year to additionally capture the influence of season on the milk FA profile.  
 
2.3 Materials and Methods 
2.3.1 Milk collection and analysis 
Eight conventional, six organic (including one with milk from forage-only fed 
cows), and three n-3 fortified milk brands, that were available for purchase, were included 




enriched post-harvest with a supplement, according to the label on the carton, to achieve a 
specific content of long-chain n-3 FAs. One to two liters of whole milk (3.25% fat) was 
purchased from regional retail markets in Vermont, Massachusetts, and New York on a 
monthly basis for twelve consecutive months (February to January), totaling 204 milk 
samples. From the original carton, cream was collected from milk via centrifugation (8°C, 
30 min at 17,800 g)13.  
Total lipids were extracted from cream according to the method developed by Hara 
and Radin14. Cream was vortexed for 10 min with n-hexane/2-propanol solution (3:2 v/v), 
then vortexed for 2 min after the addition of aqueous sodium sulfate solution (67g/1 L). 
Following centrifugation of the samples (5 min at 1,500 g), the upper phase was filtered 
through sodium sulfate and then dried under N2. The lipid extract was weighed and 
reconstituted in n-hexane (1% solution). Subsequently, transesterification reaction of lipids 
was performed with 0.5 M sodium methoxide as described by Bainbridge et al.13.  
 
2.3.2 Gas-liquid chromatography 
FA composition was determined via gas-liquid chromatography based on a method 
described previously15. Gas-liquid chromatography was performed on a GC-2010 gas 
chromatograph (Shimadzu, Kyoto, Japan) equipped with an AOC-20s autosampler, an 
AOC-20i autoinjector, a split/splitless injector (250°C), a SP-2560 fused-silica capillary 
column (100 m × 0.25 mm i.d. × 0.2 μm film thickness; Supelco Inc., Bellefonte, PA, 
USA), and a flame-ionization detector (250°C; gas flow rates: hydrogen at 40 mL/min, 
purified air at 400 mL/min, and nitrogen at 30 mL/min). Injection volume was 1 μL of 




rate of 1 mL/min with a head pressure of 400 kPa. The oven was programmed as follows: 
initial temperature of 45°C held for 4 min, increased to 175°C at 13 °C/min and held for 
27 min, then to 215°C at 4°C/min and held for 35 min, for a total run time of 86 min. Short-
chain FAMEs were corrected for mass discrepancy based on the theoretical response 
factors defined in Wolff et al.16. 
 
2.3.3 Data Interpretation  
FA integration and determination was accomplished with GCsolution software 
(version 2.30.00). Approximately 85 FAMEs, ranging from 4:0 through 24:0, were 
identified for each sample by comparing their retention times to known retention times of 
the following FAME standards: #463, #674, and CLA mixture from Nu-Check Prep 
(Elysian, MN, USA), PUFA-3 mixture from Supelco (Bellefonte, PA, USA), iso and 
anteiso BCFA mixtures from Larodan Fine Chemicals AB (Malmö, Sweden), and a milk 
standard prepared in-house. FA composition (g/100g of total FAs) was determined as FA 
percentage of the area under the curve of total FAs identified. FAs detected to be less than 
0.01 g/100g of total FAs were not reported. FA content (mg/serving) was calculated from 
FA composition (g/100g of total FAs), accounting for 93.3% of milk fat as FAs17, 3.25% 
of whole milk as fat1, and 248g (based on the density of whole milk; 1.033 g/cm3) of whole 
milk per one serving. Thus, FA content per serving whole milk was determined as follows: 
 
Total fat per serving (g) = 248g x 0.0325 
Total FA per serving (mg) = 8.06g fat/serving x 0.9333 x 1000 





2.3.4 Data Analysis 
Retail milk collected monthly was divided into two seasonal groups: cool season 
(milk collected from November through April) and warm season (May through October). 
Months were grouped based on when organic, pasture-fed, or conventional dairy herds are 
most commonly provided access to pasture. As a result of poor lipid extraction, no data 
were obtained for three samples of conventional milk during the warm season, three 
samples of organic milk during the warm season, three samples of n-3 fortified milk during 
the cool season, and one sample of n-3 fortified milk during the warm season. Thus, a final 
total of 194 milk samples were used for statistical analysis. 
FA data was analyzed via two-way ANOVA in JMP® (Version 14, SAS Institute 
Inc., Cary, NC, USA). The main effects included in the model were retail label 
(conventional, organic, and n-3 fortified milks) and season (cool and warm seasons). To 
verify proper fit of the FA data within the model, histograms of the distribution of residuals 
for each dependent variable were assessed for normality. The following FA data were 
transformed as follows: LNA via log, EPA and DHA via square root, aiso BCFAs via 
square (g/100g); OCFAs via log (mg/serving); 18:1 t9 and 18:1 t10 via log (% of total 
18:1); 18:2 t9,t12 and 18:2 c12,t16 via rank, 18:2 t9,c12 via cube, 18:2 t10,c15/t11,c1518 
via square (% of total 18:2); RA and 18:2 t10,c12 via rank, 18:2 t11,t13 and 18:2 t7,t9 to 
t10,t12 via square root (% of total CLA). Other data residuals were normally distributed 
and thus not transformed. Significance was determined at P < 0.05. A post hoc Tukey test 
was utilized to determine adjusted pairwise differences for the main effect of retail label 




for statistical analysis, tables and figures display non-transformed data. To visualize 
similarities and differences among milk brands and determine whether milk brands would 
cluster (to emphasize variation and highlight patterns) based on retail brand or season19, 
principal component analysis was performed in R version 3.4.2 with the package 
ggfortify20. No statistical conditions assumed by the package were modified. Other data 
visualizations were rendered in GraphPad Prism version 7.00 (GraphPad Software, La 
Jolla, CA, USA).  
 
2.4 Results 
2.4.1 Effects of retail label 
FA composition (g/100g) in milk was influenced by retail label and season (Table 
S1). Sample chromatograms displaying the representative FA composition of 
conventional, organic, and n-3 fortified milk are included as supplementary information 
(Fig. 2.S1-2.S3, respectively). Principal component analysis revealed that the overall FA 
composition of organic milk was the least similar to conventional milk (Figure 2.1). Of 
note, the FA composition of one conventional milk brand exhibited striking similarities to 
the FA composition of organic milk, while one organic milk brand (milk from forage-only 
fed cows; Brand ‘O1’) distinguished itself significantly from the other organic milk brands 
(Fig. S4). With one exception, the FA composition of the n-3 fortified milk label was 
comparable to that of organic milk.  
 Compositional differences of the FAs in retail milk translated into distinct 




conventional milk (Table 2.1). Although the total content of SFAs per serving did not differ 
in milk by retail label, the total content of PUFAs was greater in a serving of organic milk 
(12% greater) and n-3 fortified milk (25% greater) compared to conventional milk (P < 
0.05). A serving of organic or n-3 fortified milk provided twice as much n-3 FAs than 
conventional milk (P < 0.05; Figure 2.2A) and, in particular, the content of EPA and DHA 
was almost 600% greater in a serving of n-3 fortified milk than in conventional milk (P < 
0.05; Figure 2.2B; separated content of EPA (Fig. S5A) and DHA (Fig. S5B) in milk by 
retail label is displayed in the supporting information). Compared to conventional milk, n-
3 fortified milk contained more n-6 FAs per serving (15%), while organic milk contained 
less n-6 FAs (20%; P < 0.05; Figure 2.2C). Both organic and n-3 fortified milk had a more 
favorable n-6/n-3 ratio than conventional milk (59% and 43% lower, respectively, P < 0.05; 
Figure 2.2D). When assessing the median content of n-3 FAs in the analyzed milks by 
brand, the brand of milk from forage-only fed cows (Brand ‘O1’), contained approximately 
150% more total n-3 FAs per serving than the average content in conventional milk brands 
(84.7 versus 33.3 mg/serving, respectively; Table S2). Additionally, Brand ‘O1’ was found 
to have the lowest median n-6/n-3 FA ratio compared to all other brands analyzed (1.2; 
Table S2). Surprisingly, the n-3 fortified milk on average did not contain the expected 
content of specific n-3 FAs per serving that was marketed by its respective brand (Table 
S2). Furthermore, one n-3 fortified milk brand (Brand ‘F3’) was found to never contain its 
marketed content of n-3 FAs per serving. Notably, overall organic milk was the richest 
source of unique dairy-derived FAs per serving (comprised of SCFAs, OCFAs, BCFAs, 




 The content of total TFA per serving was greater in organic milk than conventional 
milk, as well as the contents of total trans isomers of 18:2, including CLA (Table 2.2). In 
particular, Brand ‘O1’ was markedly different than organic milk brands, having the greatest 
median content of CLA per serving of all brands (88.1 mg/serving) and almost double as 
much CLA than the average content found in conventional brands (45.8 mg/serving; Table 
S2).  The total content of 18:1 trans isomers was not different among retail labels, however, 
the relative proportion of individual 18:1 trans isomers differed (Table 2.2). Specifically, 
the proportions of all 18:1 trans isomers were lower in organic milk compared to 
conventional milk with the exception of VA. Moreover, in organic milk and n-3 fortified 
milk, VA, which accounted for approximately half of the total 18:1 trans isomer content, 
was 37% and 15% greater, respectively, compared to conventional milk (P < 0.05). Within 
the 18:2 trans isomers, in both organic and n-3 fortified milk, the proportions of 18:2 
t8,c12/c9,t13, 18:2 c9,t14, and 18:2 t10,t14 were lower (P < 0.05), while 18:2 
t10,c15/t11,c15 was greater (P < 0.05), than in conventional milk. The proportion of 18:2 
t9,c12 was 154% greater in organic milk than in conventional milk (P < 0.05). Sample 
chromatograms displaying the representative trans-FA chromatogram region of retail milk 
are included as supplementary information (Fig. 2.S6). 
 
2.4.2 Effects of season 
Principal component analysis highlights that FA composition in organic and n-3 
fortified milk was strikingly different in the warm season versus the cool season (Fig. S7). 
In comparison, there was minimal seasonal variation in conventional milk (Fig. S7). On a 




season, the content of PUFAs was 10% greater than during the cool season (P < 0.0001; 
Table 2.1), although unexpectedly, no seasonal variation in the n-6/n-3 ratio was found 
(Figure 2.2D). Milk collected during the warm season contained more unique, dairy-
derived FAs per serving than during the cool season (P < 0.0001; Table 2.1), including 
total BCFAs and CLA (P = 0.0016 and P < 0.0001, respectively; Table 2.1). The content 
of total TFA was 23% greater in a serving of milk during the warm season compared to the 
cool season (P < 0.0001; Table 2.2). Furthermore, season had an effect on the contents of 
total trans isomers of 18:1 and 18:2 (Table 2.2). For example, a serving of milk during the 
warm season contained more total trans 18:1 (P < 0.0001), total trans 18:2 (P < 0.0001), 
and total trans CLA (P < 0.0001) compared to milk collected during the cool season (Table 
2.2). Examination of the interactive effect of retail label and season showed that organic 
milk during the warm season contained the highest content of total unique dairy-derived 
FAs (1190 mg/serving). Specifically, compared to conventional milk year-round (1003 
mg/serving), a serving of organic milk provided 19% more total unique dairy-derived FAs 
in a serving of milk during the warm season (P < 0.0001). 
 
2.4.3 Comparisons of fatty acid intake from retail milk to international dietary 
recommendations 
To ascertain whether the variance observed in the FA constituents of milk by retail 
label imparted physiologically-meaningful differences, FA content (mg/serving) was 
extrapolated to determine hypothetical FA content consumed in three servings whole milk 
daily (Table 2.3). Overall, FA content per three servings of whole milk was within a similar 




from the American Heart Association21, our findings indicate that three servings of whole 
milk of any retail label would exceed the recommended SFA intake in mg/serving by 
approximately 15-38% (based on a recommended SFA intake of 5-6% of total energy). In 
contrast, the projected intake of SFAs would be well below the maximum daily intake 
values recommended by the Dietary Guidelines for Americans22, Canada’s Food Guide23, 
and World Health Organization24 (providing approximately 70% of total recommended FA 
intake in mg/serving). Canada’s Food Guide23 and the World Health Organization24 advise 
limiting the consumption of TFA to less than approximately 2,000 mg per day (based on a 
recommended trans-FA intake of <1% total energy and an average 2,200 kcal diet, 
respectively), yet TFA from three servings of whole milk would constitute approximately 
45% of this total recommended intake. Additionally, UFAs from three servings of whole 
milk would provide either 16% of total UFA intake (based on recommended values by 
World Health Organization24) or 12-31% of total UFA intake (based on recommended 
values by Dietary Guidelines for Americans22), respectively. 
2.5 Discussion 
Understanding how varying production strategies of retail milk impact human 
nutrition is an important step in optimizing the relationship between agriculture and public 
health. Currently, consumers pay a premium for organic and fortified milks which are 
marketed as nutritionally superior to conventional milk. Yet, whether consumption of these 
specialty milks indeed provide added health benefits is not clear.  We sought to determine 
whether physiologically-meaningful differences are present in the FA profile of milk 
among different retail labels. Accordingly, the objective of this study was to compare the 




conventional milk commercially available in the northeastern region of the U.S. In 
addition, we intentionally analyzed the FA content of milks by serving size (mg/serving) 
to evaluate differences in FAs among retail labels in a nutritionally relevant manner.  
In this study, organic milk was found to have the greatest content of TFA, in 
particular RA and its precursor, VA. In general, research has shown that due to 
biohydrogenation within the rumen, increased intake of PUFAs from fresh pasture by the 
dairy cow leads to a greater content of escaped biohydrogenation intermediates, such as 
TFA, within milk25. Other studies have also observed a greater content of total TFA or 
various 18:1 and 18:2 trans isomers in organic milk compared to conventional milk3,8,26,27. 
For example, Stergiadis et al. found that VA, RA, and total TFA were greater in organic 
milk than conventional milk8. Recently, trans-FA consumption and its dietary sources have 
received increased scrutiny with the announcement by the Food and Drug Administration 
that industrially-produced TFA will be eliminated from the U.S. food supply by January 1, 
20209. This mandate arose in response to substantial scientific evidence demonstrating that 
foods containing industrially-produced TFA negatively impact cardiovascular health28,29. 
To address this concern, Dietary Guidelines for Americans 2015-2020 and the World 
Health Organization have discouraged the consumption of all sources of TFA, including 
artificial and naturally-occurring (i.e., ruminant-derived) TFA22,24. Importantly, evidence 
thus far does not support that industrially-produced and naturally-occurring TFA have 
similar detrimental health effects. In fact, the relationship between trans-FA intake from 
ruminant-derived food sources and cardiovascular disease is understudied and not well 
characterized, and research available suggests beneficial or neutral effects on health29. In 




functions30,31. Nevertheless, more studies are needed to elucidate the biological actions of 
pure trans-FA isomers, as well as the manner in which food source, composition, and 
matrix influence these health effects. 
Our results revealed that organic milk contained a greater content of unique FAs 
(comprised of SCFAs, OCFAs, BCFAs, CLA, and TFAs), particularly during the warm 
season. This may in part have contributed to the striking variation in the FA profile 
exhibited via principal component analysis in organic milk compared to the other retail 
milks (Figure 2.1). Previous studies have also found these FAs to be in greater quantities 
in organic milk than in conventional milk27,32,33. A milk survey by Kusche et al.27 collected 
bulk milk samples from dairy farms in Southern Germany and observed that biodynamic 
(i.e., organic) milk had a greater total content of OCFAs and BCFAs than conventional 
milk. Chung et al.33 assessed the FA content of organic and conventional milk in Korea 
and also found organic milk to be higher than conventional milk in individual SCFAs (e.g., 
6:0 but not 4:0) and OCFAs (e.g., 17:0), although these FA classes were not summed 
together for statistical analysis. These data suggest that a higher content of unique FAs may 
be a signature of organically-produced milk. Furthermore, our findings have important 
nutritional implications, as these FA moieties have purported health benefits. For example, 
both OCFAs and BCFAs appear to play a role in cell membrane fluidity and signaling34, 
and previous research suggests that BCFAs have potent anti-inflammatory properties34. In 
addition, CLA consumption has been implicated in lowering the risk of obesity, 
cardiometabolic diseases, and cancers35, while SCFA intake has been shown to positively 
modulate inflammatory status and glucose homeostasis34. More studies with a 




content of unique FAs is consistent across organic milks. Moreover, further research should 
assess whether various factors (e.g., dietary regime or genetic background of dairy herd) 
influence the content of these FAs in milk. 
Previous research established that the FA composition of milk differs in production 
systems where dairy herds obtain a substantial proportion of their diet from fresh pasture 
in contrast to production systems that primarily rely on conserved forages4–6. Thus, organic 
milk is typically characterized by greater content of  n-3 FAs, in particular LNA, and a 
lower n-6/n-3 FA ratio than conventional milk3,8,36. In particular, one study which analyzed 
the FA composition of U.S. milk across seven regions found that organic milk was higher 
in LNA, EPA, DHA, and had a lower n-6/n-3 FA ratio compared to conventional milk36. 
In alignment with previous work, we found that retail organic milk contained a greater 
content of n-3 FAs and had a more favorable n-6/n-3 FA ratio than conventional milk. Our 
results also demonstrate a similar enrichment of total n-3 FAs in the n-3 fortified milk, 
though the proportion of individual n-3 FA constituents differed considerably between the 
organic and n-3 fortified milk. Organic milk contained the greatest amount of LNA, a key 
essential FA that appears to have a protective role against cardiovascular disease and type 
2 diabetes37. In contrast, the DHA content was greater in n-3 fortified milk, possessing 
properties that beneficially modulate brain function38, inflammation39, cancers39, and type 
2 diabetes risk39.  
An additional objective of our study was to assess whether n-3 fortified milk and 
milk from forage-only fed cows contained the expected amount of FA labeled by the 
respective brands. Relative to conventional milk, n-3 fortified milk had a greater content 




is the first to determine the FA content in a serving of retail n-3 fortified milk, surprisingly 
indicates that n-3 fortified milks rarely contain the specified quantity of supplemented FAs 
on the retail label. Here we show that the FA profile of Brand ‘O1’ is distinct from all other 
milk brands, in particular the other organic milk brands included in this study (Fig. S4).  
Brand ‘O1’ was confirmed to have an n-6/n-3 FA ratio of approximately 1:1 and the overall 
lowest n-6/n-3 FA ratio among all brands analyzed (Table S2). Brand ‘O1’ also exceeded 
its marketed content of total n-3 FAs and CLA, containing 154% and 92% more total n-3 
FAs and CLA, respectively, per serving than the average content in conventional milk 
brands. The high content of total n-3 FAs, and corresponding low n-6/n-3 FA ratio, is likely 
driven by the high content of LNA (Table S2) derived from increased forage in the diet of 
the forage-only fed dairy cows. Our observations align with a recent study by Benbrook et 
al.7 that compared the FA composition of milk from forage-only fed cows to organic and 
conventional milk from a recent study. Thus, our study lends support that the utilization of 
a dietary regime for a dairy herd consisting primarily of grass and eliminating grain is a 
promising strategy for producing milk with a higher content of health-beneficial FAs.  
Several milk surveys have reported that milk produced during the warmer half of 
the year contains a greater proportion of TFA (such as VA3,40, RA or total CLA3,40,41), n-3 
FAs3,40 (including LNA3,8,36) and a lower ratio of n-6/n-3 FA3,40. In our study, we found 
that milk in the warm season (May through October) had a greater content of total TFA, 
including total 18:1 trans isomers, total 18:2 trans isomers, and total trans CLA than in the 
cool season (November through April). We also observed a strong interaction between 
retail label and season whereby organic milk during the warm season had a greater content 




seasonal variation in the total n-3 FA content or n-6/n-3 FA ratio of milk (Figure 2.2A and 
Figure 2.2D, respectively). Although these results were unexpected, evidence suggests that 
other factors besides season can strongly influence the FA profile of milk. For example, 
Larsen et al.41 reported no difference between summer (April through September) and 
winter (December through April) months, but instead, observed an effect of region on the 
relative amount of LNA (g/kg total FAs) in milk. Our study assessed the FA composition 
of retail sale milk, and accordingly, we did not have sufficient information to account for 
potential on-farm factors that may have affected the FA milk content. Nevertheless, it is 
possible that differences among farms (e.g., climate, management practices, etc.) 
contributed to less pronounced seasonal changes in milk n-3 FA content42. 
Overall, our findings show that organic milk has a unique FA profile setting it apart 
from n-3 fortified and conventional milk with a greater content of unique FAs, n-3 FAs, 
and TFA. These data therefore suggest that the FA profile of organic milk has a favorable 
nutritional quality. However, the observed differences in milk FA content by retail label 
were diminished when extrapolated to determine FA intake from three daily servings of 
whole milk and compared to current dietary guidelines. Importantly, national and 
international dietary guidelines do not distinguish FA types beyond the three major classes 
of SFAs, UFAs, and TFA. Accordingly, this may explain why variations in more specific 
FA classes among retail whole milk (e.g., SCFAs and BCFAs within SFAs) were lost.  
Additionally, we found that SFAs, UFAs, and TFA content in milk, when extrapolated to 
determine hypothetical FA content consumed in three servings whole milk daily, was 
considerably lower than recommended maximum daily intake values (with exception of 




study therefore supports that three servings per day of either organic, n-3 fortified, or 
conventional milk can fit into a balanced diet. 
Certain limitations in our study must be considered when interpreting our findings. 
Regarding the number of samples and brands included for analysis, we analyzed one 
sample of each milk brand monthly, and lost 12 samples during processing. Additionally, 
because only three n-3 fortified milk brands were available for purchase in the Northeast 
U.S., only three could be included in our analysis. In particular, as mentioned above, 
follow-up milk surveys are necessary to establish whether a greater content of unique FAs, 
other than LNA and CLA, is a signature feature of organic milk as compared to 
conventional milk. Utilization of streamlined, comprehensive FA analysis is also needed 
so that findings can be readily compared to one another before a consensus can be formed. 
Our study utilized gas-liquid chromatography equipped with a 100m SP-2560 column, 
which provides high-quality and sufficient separation of the major fatty acids found in 
milk. However, as with any type of analytical methodology, the use of gas-liquid 
chromatography for fatty acid analysis has its limitations, namely that a single temperature 
program may not be able to elute all individual FA within a sample for identification. It is 
noteworthy that many complementary analytical methods exist for FAs that would allow 
for an improved resolution of several minor FAs in milk, namely trans- and conjugated FA 
isomers. For example, we were unable to determine whether 18:2 t9,c12, 18:2 t11,c15, 18:2 
c9,t11, or 18:2 t9,c11 coeluted with other fatty acids. Such methods include the use of silver 
ion high-performance liquid chromatography, the combination of temperature programs 
via gas-liquid chromatography, silver ion thin-layer chromatography prior to gas-liquid 




Nevertheless, as our manuscript is centered on the health implications of the FA profile of 
different retail milks, further complimentary analysis to resolve the proportion of every 
single minor FA isomer would not impact the main findings or conclusions of our study. 
Future work which examines the FA profile of other commercially available niche milks, 
such as a2 Milk® and “grass-fed” (i.e., forage-only fed) milk, would also be informative. 
Furthermore, randomized clinical trials determining the physiological impact of these 
specialty milks compared to conventional milk are necessary to clearly establish the 
nutritional relevance of observed differences in the FA content. For example, studies that 
assess the effects of dairy-derived FAs on health, via study designs that examine isolated 
FAs (i.e., single nutrient studies) or that capture the influence of the dairy food matrix, will 
be instrumental for this scientific effort.  
In this study, we critically evaluated the FA composition of organic, n-3 fortified, 
and conventional retail milk commercially available in the northeastern region of the U.S. 
Our work is the first to assess the FA composition and content of n-3 fortified milk. 
Furthermore, this study provides important information of the FA profile of retail milk in 
a nutritionally relevant manner by analyzing FA content on a per serving basis of whole 
milk. Taken together, we show that organic milk has a unique FA profile compared to 
conventional and n-3 fortified milk, comprising of a greater content of unique FAs, TFA, 
and n-3 FAs. Yet, when comparing the FA content of these three types of milk to current 
dietary guidelines, only minor differences are observed. Lastly, our results demonstrate 
that consuming three daily servings of whole milk, regardless of retail label, would be well 
below recommended fat intake according to the majority of national and international 




forage-only fed cows, may impart added health benefits compared to other retail milks, 
particularly on a per serving basis of whole milk. Yet, regardless of retail label, our findings 
signify that three daily servings of whole milk fit into a balanced healthy eating pattern.   
 
2.6 Abbreviations used 
a-LNA: alpha linolenic acid; BCFA: branched-chain fatty acids, CLA: conjugated 
linoleic acids, DHA: docosahexaenoic acid, EPA: eicosapentaenoic acid, FA: fatty acid, 
FAME: fatty acid methyl esters, MUFA: monounsaturated fatty acids, n-3 FA: n-3 fatty 
acids, n-6 FA: n-6 fatty acids, OCFA: odd-chain fatty acids, PUFA; polyunsaturated fatty 
acids, RA: rumenic acid, SCFA: short-chain fatty acids, SFA: saturated fatty acids, TFA: 
trans-fatty acids; UFA: unsaturated fatty acids; VA: vaccenic acid 
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Figures include representative chromatograms of whole milk by retail label, 
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Table 2.1 Key fatty acids (FA; mg/serving) in conventional, organic, and n-3 fortified retail milk and all retail milk collected during 
the cool season (November through April) and warm season (May through October). Values are expressed as mean ± standard error 
of the mean; values within a row without a common letter differ by retail label.  
  Conventional  Organic  n-3 fortified  Cool season  Warm season  P value 
Key FA  Mean SEM  Mean SEM  Mean SEM  Mean SEM  Mean SEM  L1 S2 L*S 
∑ SFA3    5076 12  5112 25  5054 27  5167 14  5000 13  - <.0001 <.0001 
∑ MUFA4   2020 a 9  1916 b 20  1958 b 21  1910 13  2038 10  <.0001 <.0001 <.0001 
∑ PUFA5   288 c 3  322 b 5  360 a 5  298 4  327 5  <.0001 <.0001 <.0001 
∑ Unique, dairy-derived FA6   1003 c 9  1114 a 15  1052 b 19  1013 7  1089 14  <.0001 <.0001 <.0001 
      ∑ SCFA7  359 b 2  368 a 3  361 ab 5  359 3  366 2  .0255 .0720 - 
      ∑ OCFA8   179 b 1  206 a 3  198 a 2  195 3  189 2  <.0001 .0208 .0152 
      ∑ BCFA9   124 c 1  149 a 2  140 b 3  133 2  138 2  <.0001 .0016 - 
      ∑ CLA10   48 b 2  69 a 3  55 b 4  49 1  64 3  <.0001 <.0001 <.0001 
 
1L = Retail label. 2S = Season. 3∑ SFA: 4:0-24:0. 4∑ MUFA: 14:1–24:1. 5∑ PUFA: 18:2-22:6. 6∑ Unique, dairy-derived FA: 
SCFA, OCFA, BCFA, CLA, TFA (4:0-24:0). 7∑ SCFA: 4:0-6:0. 8∑ OCFA: 5:0-23:0. 9∑ BCFA: iso and anteiso BCFA (13:0-




Table 2.2 Trans fatty acids (TFA) in conventional, organic, and n-3 fortified retail milk and all retail milk collected during the cool 
season (November through April) and warm season (May through October). Values are expressed as mean ± standard error of the 
mean; values within a row without a common letter differ by retail label.  
  Conventional  Organic  n-3 fortified  Cool season  Warm 
season 
 P value 
TFA  Mean SEM  Mean SEM  Mean SEM  Mean SEM  Mean SEM  L1 S2 L*S 
  mg/serving     
∑ TFA3  341.9b 6.9  387.1a 13.6  349.3b 15.4  322.9 5.8  396.9 10.5  .0002 <.0001 <.0001 
∑ 18:1 trans 
isomers  
 252.7a 4.8  267.3a 8.9  249.4a 9.7  232.7 4.2  283.0 6.6  .0460 <.0001 <.0001 
  % of ∑ 18:1 trans     
      18:1 t4   0.53a 0.01  0.33c 0.02  0.44b 0.03  0.46 0.02  0.43 0.02  <.0001 - - 
      18:1 t5  0.40a 0.01  0.24b 0.02  0.37a 0.03  0.35 0.02  0.34 0.02  <.0001 - - 
      18:1 t6-8   7.2a 0.2  4.8c 0.2  5.6b 0.3  6.5 0.2  5.7 0.2  <.0001 .0001 - 
      18:1 c6-
8/t13/t14  
 17.2a 0.3  14.0b 0.4  15.9a 0.6  16.7 0.3  14.9 0.4  <.0001 <.0001 .0102 
      18:1 t9   6.8a 0.1  5.9b 0.2  6.5a 0.2  6.6 0.1  6.2 0.2  <.0001 .0045 .0081 
      18:1 t10  12.3a 0.3  8.3c 0.4  9.9b 0.7  10.7 0.4  10.2 0.4  <.0001 - - 
      18:1 t11   37.2c 0.7  50.9a 1.2  42.8b 2.1  40.1 0.9  46.0 1.2  <.0001 <.0001 .0034 




      18:1 c14/t16   8.8b 0.1  8.8b 0.2  9.4a 0.3  9.5 0.1  8.3 0.1  .0253 <.0001 <.0001 
  mg/serving     
∑ 18:2 trans 
isomers 
 36.2b 0.6  47.2a 1.8  40.9b 2.1  37.1 0.8  44.9 1.4  <.0001 <.0001 <.0001 
  % of ∑ 18:2 trans     
      18:2 
t8,c12/c9,t13  
 40.1a 0.6  29.1c 0.8  34.6b 1.2  36.7 0.7  33.8 0.9  <.0001 .0005 .0600 
      18:2 t9,t12   0.23 0.05  0.29 0.10  0.23 0.12  0.33 0.09  0.16 0.04  - - - 
      18:2 t9,c12   9.5b 1.1  24.1a 2.8  13.0b 3.2  14.8 1.7  15.7 2.0  <.0001 - - 
      18:2 c9,t14   16.6a 0.5  12.1c 0.4  14.5b 0.8  15.8 0.4  13.3 0.5  <.0001 <.0001 .0926 
      18:2 t10,t14   7.7a 0.2  5.4b 0.2  5.1b 0.4  6.7 0.2  6.2 0.2  <.0001 .0205 - 
      18:2 
t10,c15/t11,c15  
 17.0b 1.3  20.9 a 2.8  23.8a 3.7  17.8 1.7  21.3 2.0  .0003 .0175 - 
      18:2 t12,c15  5.3a 0.2  4.4b 0.3  5.2ab 0.5  4.5 0.3  5.4 0.2  .0468 - - 
      18:2 c12,t16   3.7 0.3  3.5 0.3  3.6 0.6  3.4 0.3  3.8 0.3  - .0568 .0677 
  mg/serving     
∑ CLA trans 
isomers  
 46.0b 1.5  63.3a 2.9  51.2b 3.5  46.0 1.3  60.3 2.5  <.0001 <.0001 <.0001 
  % of ∑ CLA  trans isomers     
      18:2 t7,t9 to 
t10,t12  
 3.3a 0.2  2.2b 0.2  3.7a 0.8  3.3 0.3  2.6 0.2  .0007 .0007 .0449 




      18:2 c9,t11   92.2b 0.4  94.8a 0.3  92.0a 1.4  92.4 0.6  93.9 0.3  <.0001 .0074 - 
      18:2 t10,c12   0.81a 0.25  0.21b 0.07  0.71ab 0.25  0.79 0.24  0.36 0.06  <.0001 .0007 - 
      18:2 t11,t13   2.4 0.2  2.4 0.1  2.9 0.5  2.7 0.2  2.3 0.1  - - - 
  mg/serving     
∑ Other TFA4   7.0b 0.2  9.3a 0.4  7.7b 0.5  7.1 0.2  8.7 0.3  <.0001 <.0001 .0016 
 
1L = Retail label. 2S = Season. 3∑ TFA: 14:1 t9; 16:1 t9; 18:1 t4; 18:1 t5; 18:1 t6-8; 18:1 c6-8/ t13/t14; 18:1 t9; 18:1 t10; 18:1 t11; 
18:1 t12; 18:1 c14/t16; 18:2 t7,t9 to t10,t12; 18:2 t8,c12/c9,t13; 18:2 t9,c11; 18:2 c9,t11; 18:2 t9,t12; 18:2 t9,c12; 18:2 c9,t14; 18:2 




Table 2.3 Recommended maximum daily intake of key classes of fatty acids (FA) compared to the median FA content in three 
servings of conventional, organic, and n-3 fortified retail milk.  
 Recommended maximum intake
1 



















Conventional Organic n-3 fortified 
 mg/day mg/three servings 












∑ TFA4 - - < 2,200 < 2,200 975 (753-1,769) 992 (672-2,019) 974 (626-1,588) 
        
1Values displayed are based on a 2,000 kcal/day diet. FA intake (mg/day) was calculated from %kcal/day by converting total 
kcal to g (based on 1g fat = 9 kcal) x 1000. 2∑ SFA: 4:0-24:0.3∑ UFA: 14:1-22:6. 4∑ TFA: 14:1 t9; 16:1 t9; 18:1 t4; 18:1 t5; 
18:1 t6-8; 18:1 c6-8/ t13/t14; 18:1 t9; 18:1 t10; 18:1 t11; 18:1 t12; 18:1 c14/t16; 18:2 t7,t9 to t10,t12; 18:2 t8,c12/c9,t13; 18:2 
t9,c11; 18:2 c9,t11; 18:2 t9,t12; 18:2 t9,c12; 18:2 c9,t14; 18:2 t10,c12; 18:2 t10,t14; 18:2 t11,t13; 18:2 t10,c15/t11,c15; 18:2 





Table 2.S1.  Key fatty acids (FA; g/100g) in conventional, organic, and n-3 fortified retail milk and all retail milk collected during 
the cool season (November through April) and warm season (May through October). Values are expressed as mean ± standard error 
of the mean; values within a row without a common letter differ by retail label.  
  Conventional  Organic  n-3 fortified  Cool season  Warm season  P value 
Key FA  Mean SEM  Mean SEM  Mean SEM  Mean SEM  Mean SEM  L1 S2 L*S 
16:0   32.8 a 0.2  32.1 b 0.3  31.2 b 0.4  33.3 0.2  31.2 0.2  .0002 <.0001 <.0001 
18:0   10.1 b 0.1  10.7 a 0.2  10.7 a 0.2  10.0 0.1  10.8 0.1  .0008 <.0001 <.0001 
18:1 t11   1.3 b 0.1  1.9 a 0.1  1.5 b 0.1  1.3 0.0  1.8 0.1  <.0001 <.0001 <.0001 
18:1 c9   19.5 a 0.1  18.1 c 0.2  18.7 b 0.2  18.3 0.1  19.4 0.1  <.0001 <.0001 <.0001 
18:2 c9, t11   0.6 b 0.0  0.8 a 0.0  0.6 b 0.0  0.6 0.0  0.8 0.0  <.0001 <.0001 <.0001 
18:2 c9,c12   2.0 b 0.0  1.6 c 0.0  2.3 a 0.1  1.9 0.0  2.0 0.0  <.0001 - - 
18:3 c9,c12,c15   0.3 c 0.0  0.7 a 0.0  0.6 b 0.0  0.5 0.0  0.5 0.0  <.0001 .0302 - 
20:5 c5,c8,c11,c14,c17  0.03 b 0.00  0.06 a 0.00  0.08 a 0.02  0.1 0.0  0.0 0.0  <.0001 .0133 .0919 
22:6 c4,c7,c10,c13,c16,c19   0.00 b 0.00  0.01 b 0.00  0.14 a 0.03  0.0 0.0  0.0 0.0  <.0001 .0224 .0926 
 
FA classes greater in conventional milk 
∑ MUFA3   26.9 a 0.1  25.5 b 0.3  26.0 b 0.3  25.4 0.2  27.1 0.1  <.0001 <.0001 <.0001 
 
FA classes greater in organic milk 
∑ SCFA4   4.8 b 0.0  4.9 a 0.0  4.8 ab 0.1  4.8 0.0  4.9 0.0  .0272 .0711 - 
∑ BCFA5   1.6 c 0.0  2.0 a 0.0  1.9 b 0.0  1.8 0.0  1.8 0.0  <.0001 .0009 - 
∑ iso BCFA6   0.8 c 0.0  1.1 a 0.0  1.0 b 0.0  0.9 0.0  0.9 0.0  <.0001 .0169 .0697 
∑ CLA7   0.6 b 0.0  0.9 a 0.0  0.7 b 0.0  0.7 0.0  0.9 0.0  <.0001 <.0001 <.0001 
 
FA classes greater in n-3 fortified milk 
∑ n-6 FA8  2.3 b 0.0  1.8 c 0.0  2.6 a 0.1  2.1 0.0  2.2 0.0  <.0001 - - 
 
FA classes greater in organic and n-3 fortified milk 
∑ aiso BCFA9   0.8 b 0.0  0.9 a 0.0  0.9 a 0.0  0.9 0.0  0.9 0.0  <.0001 .0095 - 
∑ OCFA10   2.4 b 0.0  2.7 a 0.0  2.6 a 0.0  2.6 0.0  2.5 0.0  <.0001 .0164 .0207 
∑ PUFA11   3.8 c 0.0  4.3 b 0.1  4.8 a 0.1  4.0 0.0  4.4 0.1  <.0001 <.0001 <.0001 






1L = Retail label. 2S = Season. 3∑ MUFA: 14:1–24:1. 4∑ SCFA: 4:0-6:0. 5∑ BCFA: iso and anteiso BCFA (13:0-18:0). 6∑ iso BCFA: 
iso BCFA (13-18:0). 7∑ CLA: 18:2 t7,t9 to t10,t12; 18:2 t9,c11; 18:2 c9,t11; 18:2 c9,c11; 18:2 t10,c12; 18:2 t11,t13. 8∑ n-6: 18:2 
c9,c12; 18:3 c6,c9,c12; 20:2 c11,c14; 20:3 c5,c8,c11; 20:4 c5,c8,c11,c14; 22:4 c7,c10,c13,c16; 22:5 c4,c7,c10,c13,c16. 9∑ aiso 
BCFA: aiso BCFA (13-18:0). 10∑ OCFA: 5:0-23:0. 11∑ PUFA: 18:2-22:6. 12∑ n-3: 18:3 c9,c12,c15; 20:5 c5,c8,c11,c14,c17; 22:5 





Table 2.S2 Median content (mg/serving) of total CLA, n-3 FA, and n-6/n-3 FA ratio in n-3 fortified, organic, and conventional retail 
milk by brand. 
 ∑ CLA1  LNA2  DHA3  ∑ EPA4 and DHA  ∑ LNA, EPA, DHA  ∑ n-35 FA  n-6/n-3 FA ratio 
 mg/serving 
n-3 fortified milk              
Brand F16 65.7 (46.5-99.1)  53.3 (36.2-61.4)  27.4 (6.5-35.1)  33.1 (10.3-38.8)  75.5 (53.7-96.9)  83.4 (60.9-105.1)  2.0 (1.7-2.7) 
Brand F27 32.4 (25.2-46.4)  35.2 (24.5-46.4)  0.9 (0.0-17.3)  4.5 (2.8-51.3)  41.9 (35.5-87.0)  49.0 (41.1-96.4)  5.1 (2.4-6.5) 
Brand F38 68.5 (41.4-74.2)  52.8 (36.1-60.6)  0.0 (0.0-1.2)  4.2 (3.2-7.6)  56.1 (41.1-65.9)  64.0 (47.9-73.4)  2.7 (2.2-3.3) 
              
Organic milk              
Brand O19  88.1 (54.4-125.4)  66.5 (50.5-87.6)  0.6 (0.0-1.4)  7.3 (3.3-9.1)  74.7 (57.8-90.9)  84.7 (60.9-102.0)  1.2 (0.9-1.6) 
Brand O2  53.0 (34.6-96.0)  46.7 (29.6-59.1)  0.0 (0.0-73.6)  4.0 (2.6-77.1)  50.4 (33.0-127.7)  58.1 (38.6-135.5)  2.8 (1.1-5.2) 
Brand O3  73.7 (41.2-109.7)  52.2 (42.3-66.2)  0.0 (0.0-0.7)  5.2 (3.1-6.0)  55.8 (47.4-71.8)  63.1 (54.9-79.6)  2.1 (1.7-2.9) 
Brand O4 45.0 (35.3-107.3)  51.5 (34.4-63.1)  0.0 (0.0-0.6)  4.0 (3.4-6.1)  55.1 (38.4-66.8)  63.2 (45.8-73.2)  2.3 (1.9-3.0) 
Brand O5 55.2 (41.5-97.6)  50.9 (23.8-65.3)  0.0 (0.0-0.8)  4.7 (0.0-7.0)  55.4 (26.0-69.6)  62.9 (30.4-77.1)  2.3 (1.9-5.6) 
Brand O6 62.6 (24.5-106.2)  45.5 (28.8-61.8)  0.1 (0.0-18.1)  4.7 (2.5-31.7)  53.1 (31.3-69.1)  59.9 (35.9-79.2)  2.3 (1.6-4.7) 
              
Conventional milk              
Brand C1  40.6 (36.4-109.5)  22.5 (17.1-60.2)  0.0 (0.0-0.4)  2.0 (1.6-4.5)  24.4 (19.1-64.6)  28.1 (22.9-72.5)  6.1 (1.8-7.8) 
Brand C2  45.6 (35.5-57.9)  25.9 (18.6-56.1)  0.0 (0.0-0.4)  2.4 (2.0-3.6)  28.5 (20.9-59.7)  33.2 (24.7-66.6)  5.2 (1.9-7.0) 
Brand C3  40.4 (36.4-48.4)  26.9 (20.0-30.3)  0.0 (0.0-0.3)  2.4 (2.1-2.8)  29.4 (22.0-33.0)  33.5 (26.7-37.8)  5.3 (4.3-6.6) 
Brand C4  39.8 (30.1-46.7)  23.5 (14.3-29.1)  0.0 (0.0-1.0)  2.2 (1.7-3.2)  25.7 (16.1-31.5)  29.5 (19.9-35.9)  6.0 (5.2-8.2) 
Brand C5 43.0 (36.2-69.2)  22.0 (13.9-25.3)  0.0 (0.0-0.4)  1.9 (1.6-2.8)  23.6 (15.6-28.0)  27.8 (19.0-32.0)  6.1 (4.7-8.9) 
Brand C6  43.0 (30.1-54.4)  21.7 (15.9-26.4)  0.0 (0.0-3.9)  1.9 (0.0-5.5)  23.5 (17.8-28.9)  27.4 (21.8-33.1)  6.0 (5.1-8.2) 
Brand C7  41.6 (38.2-51.3)  25.8 (18.4-29.9)  0.0 (0.0-0.0)  2.2 (2.0-3.6)  28.0 (20.6-32.0)  32.3 (24.9-36.7)  5.3 (4.4-7.6) 
Brand C8  72.6 (35.3-108.2)  45.2 (19.9-56.5)  0.0 (0.0-1.4)  3.1 (2.6-4.0)  48.1 (22.5-59.4)  54.4 (26.4-64.8)  3.6 (2.7-6.5) 
1∑ CLA: 18:2 t7,t9 to t10,t12; 18:2 t9,c11; 18:2 c9,t11; 18:2 c9,c11; 18:2 t10,c12; 18:2 t11,t13. 2LNA: 18:3 c9,c12,c15. 3DHA: 22:6 
c4,c7,c10,c13,c16,c19; 4EPA: 20:5 c5,c8,c11,c14,c17; 5∑ n-3: 18:3 c9,c12,c15; 20:5 c5,c8,c11,c14,c17; 22:5 
c7,c10,c13,c16,c19; 22:6 c4,c7,c10,c13,c16,c19; 6Marketed n-3 FA content per serving: 32 mg DHA; 7Marketed n-3 FA content per 
serving: 50 mg EPA and DHA; 8Marketed n-3 FA content per serving: 100 mg LNA, EPA, DHA; 9Marketed FA content per serving: 







Figure 2.1 Principal component analysis of FA composition (g/100g) of milk by retail 
label. Each data point signifies the representative FA composition of an individual retail 
milk brand marketed as conventional, organic, or n-3 fortified. FA composition of each 
retail milk brand is based on the average proportion of each individual FA identified from 
























Figure 2.2 Content of n-3 and n-6 FA per serving whole milk (mg/serving) by retail label 
and season. (A) Sum of n-3 FA, (B) Sum of EPA and DHA, (C) Sum of n-6 FA, (D) n-6/n-
3 FA ratio. Values are expressed as mean, minimum, and maximum. Means without a 
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Figure 2.S1 Representative chromatogram of a representative conventional retail milk. 
*Not a fatty acid.
 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.S3 Representative chromatogram of a representative n-3 fortified retail milk.
 









































































































































































































































Figure 2.S4 Principal component analysis of FA composition (g/100g) of milk by retail 
label and brand. Each data point signifies the representative FA composition of an 
individual retail milk brand marketed as conventional, organic, or n-3 fortified. FA 
composition of each retail milk brand is based on the average proportion of each individual 








































Figure 2.S5 Content of (A) EPA and (B) DHA per serving whole milk (mg/serving) by 





































Figure 2.S6 Representative chromatogram segments of the trans fatty acid composition of 
whole (3.25% fat) retail milk. (A) 18:1 trans isomers, (B) 18:2 trans isomers, (C) 














































































































































































































































Figure 2.S7 Principal component analysis of FA composition (g/100g) of milk by retail 
label, brand, and season. Each data point signifies the representative FA composition of an 
individual retail milk brand marketed as conventional, organic, or n-3 fortified collected 
during the cool or warm season. FA composition of each retail milk brand is based on the 
average proportion of each individual FA identified from milk collected and analyzed on a 
monthly basis either during the cool season (November through April) or warm season 

























CHAPTER 3: DIETARY FAT QUALITY IMPACTS 
METABOLIC IMPAIRMENTS OF TYPE 2 DIABETES RISK 
DIFFERENTLY IN MALE AND FEMALE CD-1Ò MICE 
 
Allison L. Unger1, Thomas L. Jetton2, Jana Kraft1,2*  
 
1 Department of Animal and Veterinary Sciences, The University of Vermont, 
Burlington, VT 05405, USA 
2 Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, The 
University of Vermont, Colchester, VT 05446, USA 
 
* To whom correspondence should be addressed: 
Jana Kraft 
570 Main Street 
219 Terrill Building 
Burlington, VT 05405 
Phone: +1-802-656-5489 
Fax: +1-802-656-8196  
E-mail: Jana.Kraft@uvm.edu 
 
Running Title:   






Key words:  
Aging, Dairy fat, Diet-derived fatty acids, Echium oil, Fish oil, Glucose tolerance, Gut 






Metabolic impairments associated with type 2 diabetes, including insulin resistance 
and loss of glycemic control, disproportionately impact the elderly. Lifestyle interventions 
such as manipulation of dietary fat quality (i.e., fatty acid (FA) composition) have been 
shown to favorably modulate metabolic health. Yet, whether or not chronic consumption 
of beneficial FAs can protect against metabolic derangements and disease risk during aging 
is not well-defined. We sought to evaluate whether long-term dietary supplementation of 
fish-, dairy-, or echium-derived FAs to the average FA profile of a U.S. American may 
offset metabolic impairments in males and females during aging. One-month-old CD-1Ò 
mice were fed isoenergetic, high-fat (40%) diets with the fat content comprised of either 
100% control fat blend (CO) or 70% CO with 30% fish oil, dairy fat, or echium oil for 13 
months. Every three months, parameters of glucose homeostasis were evaluated via 
glucose and insulin tolerance tests. Glucose tolerance improved in males consuming a diet 
supplemented with fish oil or echium oil as aging progressed, but not in females. Yet, 
females were more metabolically protected than males regardless of age. Additionally, 
spearman correlations were performed between indices of glucose homeostasis and 
previously reported measurements of diet-derived FA content in tissues and colonic 
bacterial composition, which also revealed sex-specific associations. This study provides 
evidence that long-term dietary fat quality influences risk factors of metabolic diseases 
during aging in a sex-dependent manner, thus, sex is a critical factor to be considered in 






The U.S. Census Bureau has reported a staggering increase in the elderly population 
worldwide (i.e., 65 years and older). As of 2015, there are approximately 617 million aged 
individuals, representing 9% of the total population(1,2). From a healthcare perspective, a 
significant concern is the disproportionate susceptibility of the elderly to disease. In 
particular, insulin resistance, weight gain, and progressive pancreatic !-cell dysfunction 
are concomitant with the aging process(3–6), and thus, aging is considered an important risk 
factor for metabolic diseases such as type 2 diabetes (T2D)(7,8).  With T2D prevalence 
doubled in the elderly (20%) compared to the general population(9) and the rising life 
expectancy of the older population(1), T2D in the elderly is a fast-growing public health 
issue. 
Lifestyle intervention is considered to be the most effective strategy to prevent 
metabolic diseases, even compared to traditional medication regimens(10–14). For example, 
physical activity, weight loss, and restriction of total energy or macronutrients consumed 
(e.g., carbohydrates) are commonly employed to combat metabolic abnormalities(15). 
Recently, manipulation of dietary fat composition (i.e., fatty acid (FA) profile) to mitigate 
metabolic impairments has also become of considerable scientific interest. The benefits of 
supplementing the diet with cold-water fatty fish or its derived oils are well-established, 
underscoring the favorable physiologic effects of long-chain n-3 FAs (i.e., 
eicosapentaenoic acid, 20:5; and docosahexaenoic acid, 22:6)(16–18). Furthermore, 
epidemiological studies indicate that consumption of full-fat dairy products, with a 
uniquely complex dietary FA composition (>400 FA(19); short-, odd-, and branched-chain 




risk(21–24). However, detailed clinical evidence and mechanistic data validating this 
relationship are not available. Additionally, the impact of consumption of plant-derived n-
3 and n-6 FAs on T2D susceptibility is not clear(25–28). Echium oil is promising as a source 
of pro-health FAs(26,29) because of its unusually high content of a-linolenic acid (18:3 n-3), 
stearidonic acid (18:4 n-3), and "-linolenic acid (18:3 n-6) (Chapter 4), an n-6 FA with 
purported anti-inflammatory properties(30). Importantly, whether or not chronic 
consumption of beneficial FAs can protect against metabolic abnormalities and disease 
development during aging is unclear. 
We sought to determine whether long-term effects of diets differing in fat quality 
influence metabolic derangements associated with T2D risk in male and female CD-1Ò 
mice. We hypothesized that dietary supplementation with fish-, dairy-, and echium oil 
would attenuate metabolic impairments induced by consumption of a FA composition 
representative of the average U.S. American diet. Our specific objectives were to i) 
measure glucose tolerance and insulin sensitivity every three months of experimental 
feeding, ii) assess the effects of dietary fat quality, sex, and age on glucose tolerance and 
insulin sensitivity, and iii) investigate potential diet-induced biological mechanisms 
influencing glucose tolerance and insulin sensitivity in CD-1Ò mice. 
 
3.3 Experimental methods 
3.3.1 Animals and experimental design 
 The outbred CD-1Ò mouse stock (IGS #022) were chosen as a preclinical model to 




stages because of its genetic heterogeneity(31) (representative of a human population) and 
documented longevity(32). After weaning (three weeks of age), male and female CD-1Ò 
mice (n = 81, n=40-41 per sex) were shipped from Charles River (Raleigh, NC, USA) to 
The University of Vermont (Colchester, VT, USA). Upon arrival, mice were immediately 
randomized (no specific randomization technique used) into same-sex pairs and one group 
of three male cage mates. Cages were kept in ventilated racks (Thorens Caging Systems, 
Hazelton, PA, USA) on a 12 hr light/dark cycle at 23.6°C with 64% humidity. Wooden 
blocks and igloo shelters were provided as enrichment.  
 For one week while mice adjusted to their new housing conditions, mice were fed 
a standard laboratory pelleted chow (26% protein, 60% carbohydrate, and 14% fat; 
LabDiet, St. Louis, MO, USA). At four weeks of age, mice (n=10-11 per sex/diet group) 
were switched over to one of four isoenergetic high-fat (40% of total energy) diets. 
Investigators were not blinded to the group allocation for any stage of the experiment but 
were blinded during analysis. Mice consumed their designated diets until the conclusion of 
the study (14 months of age). Throughout the study, mice had ad libitum access to feed and 
water. 
 All experimental procedures with animals were approved by and performed in 
accordance with The University of Vermont Institutional Animal Care and Use Committee 
(protocol #16-007). Animal protocols also adhered to the ARRIVE Guidelines for 
Reporting Animal Research (The ARRIVE Essential 10 and The Recommended Set)(33). 
 
3.3.2 Experimental diets 




macronutrients (protein, carbohydrate, and fat as 17, 43, and 40% energy, respectively) and 
differ only in FA composition (Table 3.1). Each experimental diet was designed to supply 
40% of daily kcal as fat, 5% greater than what is generally recommended by U.S. dietary 
guidelines(34), yet still feasible for human consumption. The fat content in the control diet 
(CO) was comprised of an in-house designed U.S. fat blend, formulated to mimic the FA 
composition of the average U.S. American diet(35). The fat content of the other three 
experimental diets contained 70% of the U.S. fat blend and 30% of a supplementary fat 
source, either i) dairy fat derived from butter oil (BO diet), ii) echium oil from the seed of 
Echium plantagineum (EO diet), or iii) fish (menhaden) oil (FO diet). The BO-, EO-, and 
FO- diets were intentionally supplemented as 30% of the respective fat source into the U.S. 
fat blend to approximate a feasible dietary pattern of an average U.S. American who 
replaced a portion of their typical fat with an alternative source. In-house preparation and 
FA analysis of the experimental fat blends(36) and a full ingredient list of the experimental 
pelleted diets (Chapter 4) (formulated by Research Diets, Inc. (Brunswick, NJ, USA)) has 
been previously described. 
 
3.3.3 Parameters of health and glucose homeostasis 
Each mouse was considered an experimental unit. For the duration of the study, 
feed intake and body weight were measured to assess growth and health. Feed intake was 
evaluated weekly on a cage basis. Body weight was measured every week for the first three 
months and subsequently every month. If an animal was observed to rapidly lose a 





Every month during the intervention, whole blood was collected via tail-nick for 
determination of fed (9:00 am) glucose and insulin concentrations. In addition, mice were 
subjected to intraperitoneal glucose tolerance tests (GTTs) and insulin tolerance tests 
(ITTs) every three months to evaluate glucose homeostasis and insulin sensitivity. These 
procedures have been previously described in detail in Unger et al.(37). Briefly, after a six-
hour fast, GTTs (120 min in duration) began with an intraperitoneal injection of sterile 2 
g/kg glucose (Sigma-Aldrich, St. Louis, MO, USA). From this procedure, the following 
measurements were assessed: fasted glucose and insulin, homeostatic model of insulin 
resistance (HOMA-IR), GTT area under the curve of glucose (AUC), and final (120 min) 
blood glucose measurement of GTT. Similarly, fasted mice were challenged during ITTs 
(60 min in duration) with intraperitoneal administration of insulin (Humulin® R (U-100); 
0.75 U/kg; Eli Lilly and Company, Indianapolis, IN, USA). From this procedure, the 
following measurements were assessed: ITT AUC, final (60 min) blood glucose 
measurement of ITT, and percent change in blood glucose during ITT. 
To minimize potential confounding of results, such as treatment order, during 
procedures and measurements, two to three cages of each sex and treatment group were 
assessed together. Procedures and measurements were then staggered over the course of 
approximately one week. In this manner, procedure day and procedure time of day were 
controlled for each treatment group and sex. 
 
3.3.4 Colonic bacterial composition 
The effects of the experimental diets on the colonic bacterial composition (relative 




of age, have been established previously(36). To examine the relationship between dietary 
fat quality, metabolic health, and colonic bacteria, we performed correlation tests with 
these previously published data. 
 
3.3.5 Tissue collection and analysis 
We also sought to correlate dietary FA tissue content with metabolic responses to 
the experimental diets. Previous measurements of diet-derived FAs (percent of total FA 
methyl esters) into body tissues collected at harvest (14 months of age) have been reported 
in Unger et al. (Chapter 4). 
 
3.3.6 Statistical analysis 
Data were analyzed via linear mixed model with an unstructured covariance in IBM 
SPSS Statistics for Macintosh, Version 25.0 (MIXED function; IBM Corp., Armonk, NY, 
USA). Diet, sex, and time (age) were included as fixed effects, while body weight was 
included as a covariate. Normality in the distribution of residuals in the model were 
evaluated via Q-Q plots, and data that were not normally distributed were transformed. The 
following dependent variables were transformed as follows: feed efficiency, body weight, 
body weight gain, and ITT AUC via square root; fed glucose and insulin, fasted glucose 
and insulin, GTT AUC, HOMA-IR, and final blood glucose measurement of GTT and ITT 
via log. If significance for a main effect or an interaction between two main effects on a 
dependent variable was present, unadjusted pairwise differences (COMPARE function) 
were examined. An unadjusted post-hoc test was specifically chosen due to the large 




3.4.2). For all data, significance was determined as P < 0.05, and a trend was determined 
as P = 0.05-0.10. Non-transformed data are stated in all tables and figures. Heat maps for 
correlations were generated in R (version 3.4.2), and all other graphic visualizations of the 
data were created with GraphPad Prism version 7.00 (GraphPad Software, La Jolla, CA, 
USA).  
Data was excluded during statistical analysis due to premature animal mortality. 
For example, when analyzing parameters of glucose homeostasis derived from GTTs and 
ITTs, there were five animal mortalities due to: euthanasia secondary to severe weight loss 
(n = 1, BO-fed male), fatal fight wounds (n = 1, FO-fed male), coronary blood clot (n = 1, 
CO-fed male), atrial thrombosis (n = 1, EO-fed female), and an unknown cause (n = 1, CO-
fed female). Data points for parameters of glucose homeostasis were also excluded if the 
animal failed to respond appropriately to the glucose or insulin challenge (e.g., no change 
in blood glucose or severe hypoglycemia, respectively). We attributed an occasional lack 
of response to technical issues with intraperitoneal injection. Exclusion was made without 
consideration of assigned treatment or sex of the animal. 
 
3.4 Results 
3.4.1 Feed intake, weight gain, and feed efficiency 
Diet had no effect on feed intake, animal weight, weight gain, or feed efficiency of 
mice (Table 3.2). As expected, animal weight and weight gain were 60% and 110% greater 
in males compared to females, respectively, which was also reflected in a 100% greater 
feed efficiency in males (P < 0.001; Table 3.3). Animal weight and weight gain increased 




and 26.3g by 12 months of experimental feeding (Table 3.4). Accordingly, feed efficiency 
steadily decreased as mice aged (P < 0.001; Table 3.4). An interaction between the main 
effects of diet and sex on feed intake (P = 0.004) and weight gain (P = 0.02) of mice 
revealed that diet influenced these outcomes in a sex-specific manner. For instance, feed 
intake was 18%, 21%, and 18% greater in FO-, BO-, and EO-fed males, respectively, 
compared to CO-fed males (3.48, 3.57, and 3.48g vs. 2.94g, respectively, P < 0.05; Fig. 
3.1(a)). Similarly, weight gain was 34%, 52%, and 42% greater in FO-, BO-, and EO-fed 
males, respectively, compared to CO-fed males (28.7, 32.5, and 30.3g vs. 21.4g, 
respectively, P < 0.05; Fig. 3.1(b)). Yet, these comparative differences were not observed 
for feed efficiency (Fig. 3.1(c)). In sum, diet influenced feeding behavior and weight gain 
differently in males vs. females. 
 
3.4.2 Parameters of glucose tolerance and insulin sensitivity 
The final blood glucose measurement of ITT was 10% lower in EO-fed mice than 
in CO-fed mice (P < 0.05), an indicator that EO-fed mice exhibited improved peripheral 
insulin sensitivity (Table 3.2). In addition, ITT AUC tended to be lower in EO-fed mice 
(7%) compared to CO-fed mice (P = 0.07). By all metrics used to assess glucose 
homeostasis in this study, except percent change from baseline in blood glucose during 
ITT, glucose tolerance and insulin sensitivity were greater in females compared to males, 
regardless of diet (P ≤ 0.001; Table 3.3).  
Unexpectedly, when examining the effect of time (i.e., age) on parameters of 
glucose homeostasis, GTT AUC was found to be 21% lower at 12 months of experimental 




improved with age. To investigate this finding further, we examined the interaction 
between the effects of diet, sex, and time on GTT AUC (P = 0.001) and final blood glucose 
measurement of GTT (P < 0.001); at three months of experimental feeding, FO-, BO-, and 
EO-fed males had an 81%, 90%, and 56% greater GTT AUC, respectively, than CO-fed 
males (28565, 30085, and 24712 vs. 15816, respectively, P < 0.05; Fig. 3.2(a)). Yet, this 
phenotype disappeared three months later, and by 12 months of experimental feeding, FO- 
and EO-fed males had a 33% and 26% lower GTT AUC, respectively, than CO-fed males 
(14704 and 16230 vs. 22043, respectively, P < 0.05; Fig. 3.2(a)). Notably, no diet-induced 
changes over time were detected in females. Similar results were observed for the final 
blood glucose measurement of GTT (Fig. 3.2(b)), but no interaction between the effects of 
diet, sex, and age were found for ITT AUC (Fig. 3.2(c)). Compared to CO-fed males, EO-
fed males had a lower final blood glucose measurement of ITT at six months (28% 
difference, 64 vs. 46mg/dL, respectively, P < 0.05) and at nine months (32% difference, 
76 vs. 52 mg/dL, respectively, P < 0.05) of experimental feeding. However, there were no 
differences at 12 months of experimental feeding (Fig 2(d)). Taken together, long-term 
supplementation of dietary fat with sources of unique FA compositions, particularly fish 
and echium oil, may beneficially modulate glucose homeostasis in a sex- and age-
dependent manner. 
 
3.4.3 Correlations of parameters of glucose homeostasis with tissue fatty acids 
Spearman correlations were performed to assess the relationship between 
parameters of glucose homeostasis and dietary FA content measured in insulin-sensitive 




(Fig. 3.3(e) and 3.3(f)). Due to the pronounced sex-differences observed in measurements 
of metabolic health in mice, all correlations for this study were performed separately for 
males and females. In liver, muscle, and adipose tissue of males, fish-derived FAs were 
negatively associated with GTT AUC and final blood glucose measurement of GTT ($ = -
0.36-0.42, P < 0.05), indicating that fish-derived FAs beneficially modulate glucose 
tolerance. Similar results were found in the muscle tissue, but not liver or adipose tissue, 
of female mice (P < 0.05; Fig. 3.2(d)). Yet, unexpectedly, fish-derived FA content in 
adipose tissue of females were positively correlated with ITT AUC ($ = 0.37) and final 
blood glucose measurement of ITT ($ = 0.41, P < 0.05). Overall, diet-derived FAs in tissue 
may play a role in glucose tolerance and insulin sensitivity, however, this effect may be 
more pronounced in males than females. 
 
3.4.4 Correlations of parameters of glucose homeostasis with colonic bacterial 
composition 
In males, the abundance of the colonic genera Clostridium and Oscillospira was 
negatively correlated with fasting glucose ($ = -0.52 and -0.45, respectively, P < 0.05; (Fig. 
3.4(a)). In addition, observed genera (an index of alpha diversity), was negatively 
associated with fasted insulin ($ = -0.60) and HOMA-IR ($ = -0.56), while Akkermansia, 
Bacteroides, and Parabacteroides were all positively associated with AUC GTT ($ = 0.44-
0.52) in males (P < 0.05). In females, abundance of Ruminococcus and Turicibacter was 
negatively correlated with fed glucose and fed insulin, respectively ($ = -0.55 and -0.56, 
respectively, P < 0.05; (Fig. 3.4(b)). Abundance of Lachnoclostridium, Parabacteroides, 




measurement of ITT in females ($ = 0.52-0.67, P < 0.05). Collectively, abundance and 




Aging is a significant risk factor in the development of metabolic diseases such as 
T2D, yet, there is a lack of effective lifestyle prevention strategies to protect against age-
related metabolic impairments. Research shows that diet, and specifically dietary fat 
quality, can significantly influence glucose homeostasis, however, whether or not life-long 
consumption of beneficial FAs can attenuate glucose intolerance and insulin resistance 
during aging is not clear. Our study therefore sought to evaluate whether long-term 
supplementation of a diet with fish oil, dairy fat, or echium oil attenuates age-related 
glucose intolerance and insulin resistance induced by consumption of a FA composition 
mixture representative of the average U.S. American diet in outbred mice. 
A principal finding of our work is the prominent sexual divergence in the metabolic 
response of mice to diets varying in fat quality. Diet per se had a minimal impact on 
parameters of glucose homeostasis, but when males and females were assessed separately, 
we observed that dietary fat quality influenced glucose tolerance notably in males but not 
females. In particular, consumption of echium oil or fish oil had a protective effect against 
deterioration of glucose tolerance in males. Echium oil is a seed oil which may have unique 
health properties due to its high content of PUFAs, particularly ∝-linolenic acid and 
stearidonic acid (both n-3 FAs), as well as "-linolenic acid (n-6 FA) (Chapter 4). In 




aged, hyperglycemic and hyperinsulinemic monkeys, which aligns with our work showing 
that EO-fed mice, regardless of sex, lowered blood glucose following an insulin bolus. 
Consumption of echium oil-derived stearidonic acid results in an increased tissue content 
of downstream long chain n-3 FAs (e.g., eicosapentaenoic acid) (Chapter 4)(38), which are 
known to modulate atherogenic risk factors (18,39–41). Additionally, research also suggests 
that "-linolenic acid is another FA constituent in echium oil that favorably influence lipid 
metabolism(42). Fish, fish oil, and n-3 FA supplements, have been extensively studied as 
nutritional interventions to protect against metabolic diseases(18,39–41). However, 
observational studies assessing the effect of fish oil consumption on T2D risk are highly 
controversial(17). For example, research has generally observed that fish oil intake is 
positively associated with T2D in U.S. populations (17). Here, we demonstrate via a 
controlled experiment that fish oil supplementation to a base diet with a FA composition 
reflecting the average U.S. American FA composition can improve metabolic predictors of 
T2D risk in males. 
Males have a higher prevalence of T2D than females(9), however, the differential 
influence of dietary fat quality on T2D risk by sex is not well characterized. Studies 
assessing dietary FA content and composition and metabolic health outcomes using animal 
models have often used only males or females(42–45), while human trials may not explicitly 
test the effect of sex (46–49) (e.g., sex included as a covariate in statistical analysis). In our 
study, sex was the most consistent effect on parameters of glucose tolerance and insulin 
sensitivity, even when considering known risk factors of diet and age. The biological 
mechanisms underlying the observed differences in metabolic health of male and female 




important role in T2D risk(50–53). However, the significance of circulating sex hormones in 
the context of our study, particularly as mice aged, should be carefully considered. From 
the age of 10-15 months, reproductive senescence in mice begins(54), and as a result 
estrogen levels in females begins to decline(55). Although mice are not considered elderly 
until 18 months of age(54), it is highly plausible that estrogen levels had significantly 
declined by 12 months of age in the female mice of our study. Nevertheless, for the duration 
of the study and regardless of age, females surprisingly remained more protected against 
T2D risk than males. Therefore, to fully understand the implications of our work, more 
long-term studies are warranted, particularly focused on the intersection of dietary fat 
quality, sex and sex hormones, and T2D risk in a frank elderly population. 
Notably, we found that the content of fish-derived FAs (i.e., eicosapentaenoic acid, 
docosapentaenoic acid, and docosahexaenoic acid) in liver, muscle, and adipose tissue 
correlated with improved glucose tolerance in males, with similar results found in females 
but in skeletal muscle only. This points to a relationship between diet-derived FAs from 
fish oil as well as from echium oil, as we have shown previously that echium oil 
consumption increases tissue content of long-chain n-3 FAs (Chapter 4). These results align 
with the current consensus that fish-derived n-3 FAs are potent regulators of tissue-specific 
gene expression and function (as reviewed in(56)). For example, eicosapentanoic acid and 
docosahexaenoic acid can beneficially regulate membrane fluidity and signaling pathways 
when incorporated into the membrane phospholipids, as well as promote homeostasis by 
modulating gene expression for lipid metabolism and inflammation. In this study, no 
correlations between the content of diet-derived FAs in liver tissue and measurements of 




adipose tissue was associated with indices of insulin resistance, in female mice. However, 
the physiologic relevance of these findings is ambiguous, as females were at very low risk 
of metabolic abnormalities. Of note, minimal metabolic benefits were found in mice 
supplemented with dairy fat, and no correlations between dairy-derived FAs in tissues and 
metabolic outcomes were found. This finding is in contrast to several epidemiological 
studies showing that dairy fat intake is negatively associated with T2D(57,58) and related 
metabolic impairments(22,24). Yet, it is important to note that epidemiological studies cannot 
completely account for exposures (or lifestyle factors) occurring simultaneously in the 
complex lives of humans. 
Gut microbiota are increasingly recognized as a critical factor for health 
maintenance and disease pathogenesis(59–63), and studies have established that diet is 
integral to this relationship(44,45,64). Our study demonstrates that colonic bacterial genera 
may differentially impact metabolic outcomes in mice after feeding a controlled diet long-
term. For example, an index of alpha diversity (i.e., observed genera) was associated with 
measurements of insulin sensitivity (in males only), consistent with previous studies(65–67). 
Unexpectedly, however, we also found that the abundance of Akkermansia was positively 
associated with glucose intolerance (i.e., AUC GTT) in male mice. Akkermansia 
muciniphila, a recently discovered genus and species(68), is a mucin-degrading bacterium 
largely observed as beneficial to systemic metabolism in rodent(69,70) and human 
studies(61,71,72). While this paradoxical relationship between Akkermansia and glucose 
intolerance in our work is surprising, it is noteworthy that the field of gut microbiota and 
human disease is still in its infancy. Thus far, it appears that the association of bacterial 




are needed to fully define the function of specific bacteria in isolation and as part of the 
collective microbial population. To that end, future research utilizing metagenomics and 
metatranscriptomics to evaluate functional pathways of gut bacteria should resolve the 
direct or indirect role of gut bacterial composition and their derived metabolites on the net 
effectiveness of specific diets to mitigate disease risk. 
Mice are an adequate but imperfect model organism to study the effectiveness of 
nutritional interventions on disease risk in humans, as the murine gastrointestinal tract has 
certain differences when compared to that of humans(75). Yet, an advantage of our 
experimental approach was the utilization of an outbred mouse stock to mimic the genetic 
heterogeneity of the human population. In addition, by using a relatively short-lived mouse 
model, we were capable of examining diet effects over several different life stages. 
However, due to progressive morbidity in our study population, we did not study the effects 
of dietary fat quality in a frank elderly population, hence, more work is needed to 
contextualize our research in a human population over 65 years of age. Furthermore, since 
dietary sources of unique FAs were incorporated with a diet typical of a U.S. American, 
our results may not be generalizable to other populations with distinct, complex, and 
varying dietary patterns. 
Our work demonstrates that long-term supplementation of dietary fat with sources 
of unique FAs, notably fish oil and echium oil, can beneficially modulate glucose 
homeostasis during aging in a sex-dependent manner. Our study sheds light on the sex-
specific role of tissue FA content and colonic bacterial composition on metabolic health. 
Overall, our findings underscore the importance of sex in formulating future dietary 




adulthood. Moving forward, clinical trials examining the metabolic impact of long-term 
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Table 3.1 Composition (g/kg) of experimental high-fat diets 
 CO FO BO EO 
Diet component (g/kg diet)     
Protein 200 200 200 200 
Carbohydrate 500 500 500 500 
Fat 210 210 210 210 
     
Basal diet mix1 790 790 790 790 
U.S. fat blend2 210 147 147 147 
Fish oil supplement3 - 63 - - 
Dairy fat supplement - - 63 - 
Echium oil supplement - - - 63 
     
FA classes (g/kg diet)4     
Σ	SFA 70 66 86 61 
Σ MUFA 81 67 76 73 
Σ PUFA 44 48 34 75 
     
Σ Dairy-derived FAs5 3 6 9 2 
Σ Echium-derivedFAs6 4 5 3 34 
Σ Fish-derived FAs7 0 14 0 0 
CO, 100% U.S. fat blend. FO, 70% CO supplemented with 30% fish oil. BO, 
70% CO supplemented with 30% dairy (butter) fat. EO, 70% CO 
supplemented with 30% echium oil. FA, fatty acid. SFA, saturated fatty acids. 
MUFA, monounsaturated fatty acids. PUFA, polyunsaturated fatty acids. 
1 Formulated by Research Diets Inc. 
2 U.S. fat blend consisted of lard, walnut oil, high-oleic sunflower oil, 
coconut oil, and palm oil in a ratio of 18.8:3.6:2.8:1.8:1.0.  
3 Fish oil supplement was derived from menhaden and supplied by Research 
Diets Inc. 
4 Analysis FAs was performed via gas-liquid chromatography as described in 




Table 3.2 Daily feed intake, feed efficiency, body weight, and parameters of glucose homeostasis of CD-1Ò mice fed one of four 
experimental isoenergetic, high-fat (40% fat of total energy) diets. 
 Diet1 P value 
 CO FO BO EO D S T D x S D x T S x T D x S x T 
 Mean SEM n Mean SEM n Mean SEM n Mean SEM n        
Daily Feed 
Intake (g) 
3.14 0.07 79 3.29 0.07 78 3.23 0.08 79 3.32 0.05 80 - 0.07 <0.001 0.004 <0.001 0.02 0.005 
Feed efficiency2 0.007 0.000 78 0.009 0.001 77 0.007 0.001 73 0.008 0.001 78 - <0.001 <0.001 - - <0.001 0.07 
Body weight 
(g) 42.8 1.2 78 49.2 1.8 77 48.0 1.9 79 47.4 1.7 81 0.09 <0.001 <0.001 0.009 0.02 0.004 0.09 
Body weight 
gain (g) 
17.4 1.0 78 23.3 1.5 77 21.9 1.5 79 21.3 1.4 81 - <0.001 <0.001 0.02 0.03 0.004 - 
Fed glucose 
(mg/dL) 
98 2 79 104 4 78 102 3 79 104 4 79 - <0.001 0.02 - 0.009 0.002 0.03 
Fed insulin 
(ng/mL) 3.71 0.52 70 5.72 0.69 69 5.66 0.68 73 6.19 0.72 71 - <0.001 <0.001 - - <0.001 - 
Fasted glucose 
(mg/dL) 
88 3 76 84 3 76 91 4 77 84 3 79 - <0.001 - - - 0.09 - 
Fasted insulin 
(ng/mL) 
1.29 0.23 57 1.23 0.22 59 1.59 0.32 60 1.85 0.28 58 - 0.001 - - - <0.001 - 
HOMA-IR3 9.57 1.89 57 7.49 1.24 55 11.71 1.89 59 11.76 1.70 57 - <0.001 - - - <0.001 - 
Area under the 
curve (GTT) 17696 999 73 17583 877 74 20664 1349 75 16921 847 76 0.09 <0.001 <0.001 - 0.001 0.001 0.001 
Blood glucose 
(120 min of 
GTT) 
104 7 72 104 6 74 122 10 75 97 6 76 - <0.001 <0.001 - 0.01 0.03 <0.001 
Area under the 
curve (ITT) 3716 193 61 3807 161 58 3843 250 60 3446 148 58 0.07 <0.001 - 0.04 - 0.03 - 
% change from 





(60 min of ITT) 
48a 3 59 51a 2 56 50a 3 56 43b 2 58 0.03 <0.001 - 0.02 - 0.02 0.009 
CO, diet comprised of 100% U.S. fat blend. FO, diet comprised of 70% U.S. fat blend and 30% fish (menhaden) oil. BO, diet 
comprised of 70% U.S. fat blend and 30% dairy (butter oil) fat. EO, diet comprised of 70% U.S. fat blend and 30% echium oil. D, 
diet. S, sex. T, time (month of data collection). GTT, glucose tolerance test. ITT, insulin tolerance test. 
1 Values are expressed as mean ± standard error of the mean and are collapsed by sex and time. Means without a common letter differ 
(P < 0.05). 2 Feed efficiency = total weight gain (g) / total feed intake (kcal). 3 HOMA-IR, homeostatic model of assessment of insulin 
resistance = (glucose0 min*insulin0 min) / 405. 4 % change from baseline = ((Final blood glucose – initial blood glucose) / initial blood 






Table 3.3 Daily feed intake, feed efficiency, body weight, and parameters of glucose homeostasis of male and female CD-1Ò mice.  
 Sex1 P value 
 Male Female D S T D x S D x T S x T D x S x T 
 Mean SEM n Mean SEM n        
Daily Feed Intake (g) 3.37 0.04 160 3.12 0.05 156 - 0.07 <0.001 0.004 <0.001 0.02 0.005 
Feed efficiency2 0.010a 0.000 153 0.005b 0.000 153 - <0.001 <0.001 - - <0.001 0.07 
Body weight 
(g) 
57.6a 0.7 159 35.9b 0.9 156 0.09 <0.001 <0.001 0.009 0.02 0.004 0.09 
Body weight gain (g) 28.3a 0.7 159 13.5b 0.9 156 - <0.001 <0.001 0.02 0.03 0.004 - 
Fed glucose (mg/dL) 116a 3 158 88b 1 157 - <0.001 0.02 - 0.009 0.002 0.03 
Fed insulin 
(ng/mL) 
8.65a 0.42 155 1.29b 0.20 128 - <0.001 <0.001 - - <0.001 - 
Fasted glucose 
(mg/dL) 
101a 3 157 72b 1 151 - <0.001 - - - 0.09 - 
Fasted insulin 
(ng/mL) 
2.20a 0.20 140 0.42b 0.07 94 - 0.001 - - - <0.001 - 
HOMA-IR3 15.47a 1.21 136 2.34b 0.46 92 - <0.001 - - - <0.001 - 
Area under the curve (GTT) 23231a 772 152 12998b 359 146 0.09 <0.001 <0.001 - 0.001 0.001 0.001 
Blood glucose (120 min of GTT) 138a 6 151 75b 2 146 - <0.001 <0.001 - 0.01 0.03 <0.001 
Area under the curve (ITT) 4901a 150 94 2918b 71 143 0.07 <0.001 - 0.04 - 0.03 - 
% change from baseline (ITT)4 20.4 1.8 94 36.0 1.7 143 - - - - 0.06 0.03 - 
Blood glucose (60 min of ITT) 65a 2 94 35b 1 135 0.03 <0.001 - 0.02 - 0.02 0.009 




Values are expressed as mean ± standard error of the mean and are collapsed by diet and time. Means without a common 
letter differ (P < 0.05). 2 Feed efficiency = total weight gain (g) / total feed intake (kcal). 3 HOMA-IR, homeostatic model of 
assessment of insulin resistance = (glucose0 min*insulin0 min) / 405. 4 % change from baseline = ((Final blood glucose – initial 





Table 3.4 Daily feed intake, feed efficiency, body weight, and parameters of glucose homeostasis of CD-1Ò mice at 3, 6, 9, and 12 
months of experimental feeding. 
 Month1 P value 
 3 6 9 12 D S T D x S D x T S x T D x S x T 
 Mean SEM n Mean SEM n Mean SEM n Mean SEM n        
Daily Feed Intake 
(g) 
3.19bc 0.07 81 3.33a 0.07 79 3.32ab 0.06 79 3.15c 0.06 77 - 0.07 <0.001 0.004 <0.001 0.02 0.005 
Feed efficiency2 0.011a 0.001 80 0.008b 0.000 77 0.006c 0.000 76 0.005d 0.000 73 - <0.001 <0.001 - - <0.001 0.07 
Body weight 
(g) 
39.1d 1.3 80 46.8c 1.6 80 49.6b 1.7 79 52.3a 1.8 76 0.09 <0.001 <0.001 0.009 0.02 0.004 0.09 
Body weight gain 
(g) 
13.3d 1.0 80 20.9c 1.3 80 23.6b 1.4 79 26.3a 1.5 76 - <0.001 <0.001 0.02 0.03 0.004 - 
Fed glucose (mg/dL) 99ab 2 80 110a 5 79 96b 2 79 103ab 3 77 - <0.001 0.02 - 0.009 0.002 0.03 
Fed insulin 
(ng/mL) 
3.54b 0.44 81 4.66a 0.46 68 8.20a 0.93 76 4.82b 0.46 58 - <0.001 <0.001 - - <0.001 - 
Fasted glucose 
(mg/dL) 
83 3 79 87 4 79 92 4 79 85 2 71 - <0.001 - - - 0.09 - 
Fasted insulin 
(ng/mL)3 
0.76 0.09 65 1.41 0.23 72 2.03 0.34 64 2.05 0.36 33 - 0.001 - - - <0.001 - 
HOMA-IR3,4 5.21 0.78 63 9.69 1.56 71 13.19 1.84 63 15.23 2.81 31 - <0.001 - - - <0.001 - 
Area under the curve 
(GTT) 
18309a 1040 77 20419a 1242 75 18722a 965 76 15210b 788 70 0.09 <0.001 <0.001 - 0.001 0.001 0.001 
Blood glucose (120 
min of GTT) 
104a 7 77 122a 10 74 108a 7 76 94b 5 70 - <0.001 <0.001 - 0.01 0.03 <0.001 
Area under the curve 
(ITT) 
3753 243 58 3437 170 57 3796 156 62 3816 197 60 0.07 <0.001 - 0.04 - 0.03 - 
% change from 
baseline (ITT)5 




Blood glucose (60 
min of ITT) 
48 3 55 44 3 57 50 2 60 49 3 57 0.03 <0.001 - 0.02 - 0.02 0.009 
D, diet. S, sex. T, time (month of data collection). GTT, glucose tolerance test. ITT, insulin tolerance test. 
1 Values are expressed as mean ± standard error of the mean and are collapsed by diet and sex. Means without a common letter differ 
(P < 0.05). 2 Feed efficiency = total weight gain (g) / total feed intake (kcal). 3 Results of statistical analysis similar when data from 
month 12 is excluded.  4 HOMA-IR, homeostatic model of assessment of insulin resistance = (glucose0 min*insulin0 min) / 405. 5 % 







Figure 3.1 Feed intake (a), body weight gain (b), and feed efficiency (c) of male and female 
of CD-1Ò mice fed one of four experimental isoenergetic, high-fat (40% fat of total energy) 
diets with fat content consisting of either 100% U.S. fat blend (CO) or 70% U.S. fat blend 
and 30% fish oil (FO), dairy fat (BO), or echium oil (EO), respectively. Values are 
expressed as mean ± standard error of the mean. Ɨ = P = 0.07, males vs. females collapsed 
by diet and time. *** = P < 0.001, males vs. females collapsed by diet and time. & = P < 
0.05, FO-, BO-, or EO-fed males vs. CO-fed males collapsed by time. # = P < 0.05, BO-
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model with an unstructured covariance, specifying diet, sex, and time as fixed effects and 
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Figure 3.2 Area under the curve of glucose tolerance test (a), final blood glucose 
measurement of glucose tolerance test (b), area under the curve of insulin tolerance test (c), 
and final blood glucose measurement of insulin tolerance test of male and female of CD-
1Ò mice at 3, 6, 9, and 12 months of feeding one of four experimental isoenergetic, high-
fat (40% fat of total energy) diets with fat content consisting of either 100% U.S. fat blend 
(CO) or 70% U.S. fat blend and 30% fish oil (FO), dairy fat (BO), or echium oil (EO), 
respectively. Values are expressed as mean ± standard error of the mean. *** = P < 0.001, 
males vs. females collapsed by diet and time. & = P < 0.05, FO-, BO-, or EO-fed males vs. 
CO-fed males within each respective month. # = P < 0.05, FO-fed females vs. CO-fed 
females within the respective month. Data were analyzed via linear mixed model with an 
unstructured covariance, specifying diet, sex, and time as fixed effects and body weight as 






Figure 3.3 Spearman correlation matrices between metabolic parameters and fatty acids 
measured in liver tissue of male (a), liver tissue of female (b), muscle tissue of male (c), 
muscle tissue of female (d), adipose tissue of male (e), and adipose tissue of female (f) CD-
1Ò mice. A positive correlation (closer to 1) is signified by a darker shade of blue; a 
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negative correlation (closer to −1) is signified by a darker shade of red (P < 0.05). HOMA-
IR, homeostatic model of assessment of insulin resistance = (glucose0 min*insulin0 min) 
/ 405. GTT, glucose tolerance test. ITT, insulin tolerance test. Percent change in baseline 
= ((Final blood glucose – initial blood glucose) / initial blood glucose)) * 100. FAs, fatty 
acids. Dairy-derived FAs include the sum of 15:0, 16:1 t9, 17:0, 18:1 t11, and 18:1 c9,t11. 
Echium-derived FAs include the sum of 18:3 c6,c9,c12 (n-6), 18:3 c9,c12,c15 (n-3), and 
18:4 c6,c9,c12,c15 (n-3). Fish-derived FAs include the sum of 20:5 c5,c8,c11,c14,c17 (n-
3), 22:5 c7,c10,c13,c16,c19 (n-3), and 22:6 c4,c7,c10,c13,c16,c19 (n-3). Variables of 
fasted insulin and HOMA-IR were not included in analysis with females due to the low 
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Figure 3.4 Spearman correlation matrices between metabolic parameters, diversity indices 
of colonic bacteria, and abundance by counts of colonic bacterial genera (mean relative 
abundance > 1%) of male (a) and female (b) CD-1Ò mice. A positive correlation (closer 
to 1) is signified by a darker shade of blue; a negative correlation (closer to −1) is signified 
by a darker shade of red (P < 0.05). HOMA-IR, homeostatic model of assessment of insulin 
resistance = (glucose0 min*insulin0 min) / 405. GTT, glucose tolerance test. ITT, insulin 
tolerance test. Percent change in baseline = ((Final blood glucose – initial blood glucose) / 
initial blood glucose)) * 100.  Variables of fasted insulin and HOMA-IR were not included 
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4.1 Abstract Page 
4.1.1 Background 
Epidemiological studies frequently rely on the measurement of fatty acid (FA) 
biomarkers to establish relationships between dietary patterns, foods, and food 
components, such as FAs, and health outcomes. However, it is not clear which tissues may 
be optimal for assessing specific FAs as biomarkers for long-term dietary studies. 
 
4.1.2 Objective 
This study measured the content of unique diet-derived FAs from dairy, echium, 
and fish in a comprehensive panel of body tissues and fractions (adipose, muscle, liver, 
erythrocyte membranes, and plasma phospholipids, cholesterol esters, TGs, and FFAs) 
after long-term feeding in CD-1® mice. 
 
4.1.3 Methods 
Beginning at weaning, outbred mice (n=10-11/sex/diet) were fed one of four diets 
that only differed in FA composition: 1) control (CO) with 100% of fat reflecting the FA 
profile of the average U.S. American diet, or CO supplemented with 30% of 2) fish oil 
(FO), 3) dairy fat (BO), or 4) echium oil (EO). After 13 months, tissues were collected to 






As anticipated, the content of fish- and echium-derived FAs was generally 
enhanced in tissues of FO- and EO-fed mice, respectively. In contrast, the partitioning of 
dairy-derived FAs was highly dependent on tissue type in BO-fed mice. There was a 
profound influence of sex on the tissue-specific incorporation of diet-derived FAs. Diet-
derived FAs correlated with their content in adipose, muscle, and liver, but not blood. 
Intake of fish-derived FAs correlated strongly with their tissue content, while dairy- or 
echium-derived FAs were more variable in their incorporation. 
 
4.1.5 Conclusions 
Using an animal model, our study indicates that the distribution of dietary FAs is 
tissue- and sex-dependent. Accordingly, epidemiological and clinical studies using FA 
biomarker measurements to establish relationships between dietary patterns, diet 
conformance, and health outcomes should assess a combination of FA biomarkers to 
accurately validate patterns of FA intake and source. 
 
4.1.6 Key words 
Adipose tissue, Blood, Controlled dietary intervention, Dairy fat, Echium oil, Erythrocyte 
membranes, Fish oil, Liver tissue, Muscle tissue, Plasma 
 
4.1.7 Subject group  





 Investigation of the relationship between dietary patterns, foods, and food 
components, such as fat and FAs, and disease risk is a significant area of human nutrition 
research. Nutritional epidemiology has evolved to determine fat intake via measurement of 
FA biomarkers, an important indicator that aids in the understanding of dietary patterns 
and nutritional status estimated through FFQs, assessment of compliance, as well as 
differences in lipid metabolism of individuals (1). However, the body tissue used to 
measure FAs (e.g., adipose tissue, erythrocyte membranes, blood) varies significantly 
across studies, and there is currently no scientific consensus regarding the appropriate body 
tissue for measurement of FA biomarkers. 
Measurement of FAs in adipose tissue is considered the gold standard to assess 
long-term FA intake due to its stable storage of FAs as TGs (2–5). Importantly, adipose 
tissue collection for FA analysis is limited and often unfeasible, and thus, the use of blood 
is more common due to the relative ease of collection. Erythrocyte membranes appear to 
be a suitable blood lipid fraction to determine FA intake, as they are incapable of de novo 
FA synthesis due to their lack of metabolic machinery, particularly acetyl CoA carboxylase 
(5–7). Yet, the processing of erythrocyte membranes for FA analysis is rather labor 
intensive. In contrast, the FAs of plasma TGs generally reflect the previous meal consumed 
(5) and should only be used to assess short-term (i.e., day-to-day) changes in FA intake. 
FA analysis of plasma phospholipids (PLs), cholesterol esters (CEs) or FFAs, on the other 
hand, is thought to be suitable for the assessment of intermediate to long-term FA intake 
(5,8), respectively. However, each blood lipid fraction preferentially incorporates certain 




metabolic processes influence the partitioning of dietary FAs in each fraction is not fully 
understood.  
It is increasingly recognized that controlled feeding interventions are needed to 
better understand the reliability of dietary FAs as biomarkers of FA intake and food source 
in different body tissues (1). For this purpose, selection of FAs as biomarkers that are 
uniquely enriched in a food source is essential to clearly discern the relationship between 
FA intake and content in tissues without confounding the results due to endogenous FA 
synthesis. For example, fish oil, particularly derived from cold-water fatty fish consuming 
marine zooplankton and algae, is a rich source of long-chain n-3 FAs including 
eicosapentaenoic acid (20:5 c5,c8,c11,c14,c17; EPA), docosapentaenoic acid (22:5 
c7,c10,c13,c16,c19; DPA), and docosahexaenoic acid (22:6 c4,c7,c10,c13,c16,c19; DHA) 
(9). Moreover, synthesis of these FAs, especially DHA, from dietary a-linolenic acid (18:3 
c9,c12,c15; LNA) is limited in mammals (10), and thus, concentrations of these FAs in the 
body are primarily derived from the diet. Accordingly, one or a combination of these FAs 
has been nearly exclusively used to assess fish (oil) intake in previous research (11,12). 
Milk and dairy products also contain a diverse array of distinct FAs, due to metabolic 
processes in the rumen and mammary gland of ruminants, including odd- and branched-
chain FAs, trans-FAs, and conjugated linoleic acids (13,14). Typical FA biomarkers 
utilized to assess dairy fat intake are 15:0, 17:0, and 16:1 t9 (15–20), although Pranger et 
al. (21) recently also demonstrated that 18:1 t11 (vaccenic acid, VA) and 18:2 c9,t11 
(rumenic acid, RA), two metabolites of rumen microbial biohydrogenation, are potential 




intake (i.e., walnuts and linseed oil) supports that LNA can be a useful biomarker for plants 
rich in n-3 FAs (22). Other less studied plant-derived oils, such as seed oil from the plant 
Echium plantagineum (echium oil), is also rich in unsaturated FAs such as LNA (23), but 
echium oil stands out due to its unique content of stearidonic acid (18:4 c6,c9,c12,c15; 
SDA) and g-linolenic acid (18:3 c6,c9,c12; GLA). To our knowledge, no research has 
attempted to assess potential biomarker candidates of echium oil intake outside of 
intervention trials. 
The goal of our study was to evaluate specific diet-derived FAs as valid predictors 
of FA intake in a comprehensive panel of body tissues under a controlled, long-term 
feeding environment. We hypothesized that long-term consumption of unique FAs derived 
from fish oil, dairy fat, or echium oil would be reflected by a greater content of the 
respective FAs in body tissues of CD-1® mice. The primary objective of our study was to 
measure unique, dietary FAs that are considered fish-, dairy-, and echium-derived in 
adipose, muscle, liver tissues and blood fractions (erythrocyte membranes and plasma PLs, 
CEs, TGs, and FFAs) in male and female CD-1® mice. A secondary objective was to assess 
whether the content of these FAs in tissues varied due to the effect of sex.  
 
4.3 Methods 
4.3.1 Animals and experimental design 
 All protocols were approved and complied with guidelines and regulations of The 
University of Vermont Institutional Animal Care and Use Committee (#16-007). CD-1Ò mice 




specifically chosen as part of this study design to investigate the metabolic effects of dietary 
FA in a genetically-diverse population similar to humans. Forty-one male (29.3 ± 0.4 g) and 
40 female (22.4 ± 0.3 g) mice arrived three weeks after birth and were immediately randomized 
into same-sex cages in groups of two, with the exception of one group of three male cage 
mates. Mice were housed in ventilated racks (Thorens Caging Systems, Hazelton, PA, USA) 
and maintained on a 12-hr light:dark cycle at 23.6°C with 64% humidity. For one week, mice 
were acclimated to the new environment and were fed a standard laboratory chow diet (26% 
protein, 60% carbohydrate, and 14% fat; ProlabÒ Rat/Mouse/Hamster 3000, LabDiet, St. 
Louis, MO, USA). At four weeks of age, mice (n = 10 females, 10-11 males, each) were 
switched to one of four experimental high-fat diets (40% kcal/total energy), each with a distinct 
FA composition (Table 4.1; complete ingredient list in Table 4.S1). Mice were fed the 
designated experimental diet until 14 months of age. Mice were provided free access to food 
and water. Food was replaced weekly, and at this time, feed intake (per cage) was assessed. As 
part of animal health and growth monitoring, body weight was recorded on a weekly basis for 
the first three months, and subsequently on a monthly basis. 
 
4.3.2 Experimental diets 
 The four experimental diets were identical with the exception of the FA composition. 
Diets consisted of a basal diet mix (Research Diets, Inc., Brunswick, NJ, USA) supplemented 
with a fat blend comprised of either 100% U.S. fat blend (CO), representative of the dietary 
FA composition of the average U.S. American (24), 70% CO and 30% fish (menhaden) oil 




Experimental fat blends, except for the incorporation of fish oil into the U.S. fat blend, were 
prepared in our laboratory and the process has been reported previously (25). The FA 
composition of each experimental fat supplement is listed in Table 4.S2. Experimental fat 
blends were shipped to Research Diets, Inc. for diet formulation and pelleted diets were 
subsequently stored at 4°C until use. 
 
4.3.3 Tissue harvest 
 At the end of the experiment, mice were fasted for six hours (imitating an overnight fast in 
humans) before administration of isoflurane as an anesthetic agent. Mice were bled (~1 mL) 
via cardiac puncture for collection of blood into syringes with 0.129 M sodium citrate and 
subjected to a laparotomy to expose abdominal organs for tissue collection. The liver was 
immediately excised and homogenized before an aliquot was snap frozen. Because we 
collected adipose and skeletal muscle tissue for analysis of gene transcription activity, upon 
excision, gonadal fat pads and the quadriceps of the right leg were snap frozen in an aliquot of 
TRIzolTM . Cardiac blood was centrifuged at 9,500 g for 5 min at 4°C, and plasma supernatant 
was separated from the erythrocyte pellet. All collected tissues were stored at -80°C until 
subsequent FA analysis.  
 
4.3.4 Fat supplement and feed analysis 
Dietary fat supplements were transesterified via 0.5 M sodium methoxide as 
previously reported (23) and stored at -20ºC as a 1% final fatty acid methyl ester (FAME) 




according to Sukhija and Palmquist (26) using an internal standard of glyceryl tridecanoate 
(Nu-Check Prep, Elysian, MN, USA) per modifications described in Bainbridge et al. (23).  
 
4.3.5 Blood fraction analysis 
Erythrocyte membranes were first isolated and purified according to the methods 
described by Burton et al. (27). Erythrocyte membrane lipids were extracted using a 
mixture of chloroform:methanol (2:1, v:v) following the method of Bligh and Dyer (28). 
Subsequently, erythrocyte membrane lipids were derivatized as reported in Bainbridge et 
al. (23) with 0.5 N potassium hydroxide and 10% boron trifluoride in methanol.  
 For extraction of lipids from plasma, 0.5 M potassium phosphate solution, 
methanol, and chloroform were each added consecutively in a ratio of 1:1.5:2.5:7.5, 
respectively. After vortexing (10 min), samples were centrifuged at room temperature (520 
g for 7 min). The lower chloroform phase was extracted, filtered through sodium sulfate, 
and dried under N2 before reconstitution in 0.5 mL of n-hexane:tert-butyl methyl 
ether:acetic acid (100:3:0.3, v:v). Total plasma lipids were separated into lipid classes 
(TGs, PLs, CEs, and FFAs) by solid-phase extraction via aminopropyl cartridges as 
described by Bainbridge et al. (23). Subsequently, PLs and CEs were derivatized in a 
similar manner as erythrocyte membrane lipids using 0.5 N methanolic sodium hydroxide 
instead of 0.5 N potassium hydroxide. TGs were derivatized with 0.5 M sodium methoxide 
as previously reported (23). For FFAs, 1 mL each of n-hexane:tert-butyl methyl ester (1:1, 
v:v) and 2% sulfuric acid in methanol was added to dried (N2) samples. Samples were 




Following cooling, samples were vortexed with 0.25 mL 1 M sodium hydroxide and 2 mL 
n-hexane. Samples were centrifuged (520 g for 5 min), and the n-hexane layer was filtered 
through sodium sulfate into a clean tube. The extraction was repeated two additional times. 
Pooled FAME were dried via N2, reconstituted (0.2 mL n-hexane), and stored at -20ºC until 
GLC analysis. 
 
4.3.6 Tissue analysis 
For adipose and muscle tissue stored in Trizol, lipids were extracted following the 
methods detailed by Podechard et al. (29) with minor modifications. First, after the addition 
of chloroform (200 µL), samples were chilled at 4ºC for 15 min before centrifugation (520 
g) at room temperature for 15 min. In addition, isolated lipids suspended in the lower 
chloroform phase were filtered through sodium sulfate before being dried (N2) and 
reconstituted in 300 µL of toluene for storage (-20ºC) until methylation. Hepatic tissue (2-
3 g) was homogenized (ULTRA-TURRAX®) in 5 mL methanol. Chloroform (5 mL) was 
added and samples were sonicated in an ultrasonic water bath for 15 min before vortexing 
overnight. After addition of chloroform and 2% aqueous sodium chloride solution (5 mL 
each), samples were vortexed for 30 min, followed by centrifugation for 15 min (3,450 g 
at 8°C). The lower chloroform layer was extracted and processed for storage as described 
for other tissue lipids. 
FAME derivatization of lipids extracts of liver, muscle, and adipose tissues was 
performed using a base-catalyzed followed by acid-catalyzed method at 60°C as described 




min. FAMEs derived from liver, muscle, and adipose tissue were suspended in n-hexane 
(2, 0.2, and 1 mL, respectively) for storage (-20ºC) until GLC analysis.  
 
4.3.7 Gas-liquid chromatography analysis 
GLC analysis of FAMEs was performed as detailed in Unger et al. (14). Integration 
and determination for FAMEs ranging from 4:0-24:0 (experimental fat blends and 
formulated diets) and 12:0-24:0 (tissues) was also accomplished as described previously 
(14). Two additional single isomer standards, 21:5 n-3 and 20:3 n-9 (Larodan, Solna, 
Sweden), were additionally utilized for peak identification of FAMEs for tissues. FA 
composition was determined as g/100g of FAME identified (i.e., % of total FAMEs). FA 
content in experimental diets was determined based on the internal standard. 
 
4.3.8 Statistical Analysis 
Data were analyzed in JMP® Version 14 (SAS Institute Inc., NC, USA) via two-
way ANOVA to examine the main and interactive effects of diet and sex. To assess the fit 
of the data within the model, histograms of the residuals of each dependent variable were 
evaluated for normal distribution. If proper fit of the data was not met, one of the following 
transformations was applied as appropriate: log, square, square-root, or rank. Pairwise 
differences between diets and the interaction between diet and sex were determined using 
a post-hoc Tukey test. Significance was determined at P < 0.05. Correlations and their 






4.4.1 Intake and body weight measurements 
FA analysis of the experimental diets was used to calculate fat and FA intake 
(g/day) of mice at the time that tissue samples were collected (i.e., end of study, 14 months 
of age; Table 4.2). The experimental diets did not impact feed intake, however, as expected, 
males had a greater feed intake than females (3.4 ± 0.1 vs. 2.9 ± 0.1 g/day, respectively; P 
< 0.05), which corresponded with a greater intake of total fat (675 ± 14 vs. 565 ± 15 
mg/day, respectively P < 0.05). Similarly, body weight did not differ among diets, but body 
weight (60.8 ± 1.4 vs. 40.3 ± 2.3 g, respectively; P < 0.05) and weight gain (31.5 ± 1.3 vs. 
17.7 ± 2.2 g, respectively; P < 0.05) was greater in males than in females. Variation in the 
intake of FAs among diet groups reflected the FA composition of the respective dietary 
fats (P < 0.05).  
 
4.4.2 Content of diet-derived FAs in body tissues 
Content of diet-derived FAs among adipose, muscle, and liver tissues and blood fractions 
(i.e., erythrocyte membranes and plasma PLs/CEs/TGs/FFAs) of mice is summarized in 
Figure 4.1 and Tables 4.S3-10. 
 
Fish-derived FAs 
EPA content was consistently greatest in tissues and blood fractions of FO-fed 
mice, with a four-fold to 32-fold difference compared to CO-fed mice depending on the 




mice compared to CO-fed mice (0.39 ± 0.04 and 0.51 ± 0.07 vs. 0.16 ± 0.02 % of total 
FAMEs, respectively; P < 0.05), while no differences were found in DHA content among 
diet groups. Additionally, in plasma PLs, DHA content was not different between FO- and 
EO-fed mice (6.98 ± 0.43 vs. 5.99 ± 0.33 % of total FAMEs, respectively). Otherwise, DPA 
and DHA content was greatest in the tissues of FO-fed mice compared to other diet groups 
(three-fold to 12-fold difference and one-fold to nine-fold difference, respectively, when 
compared to CO-fed mice; P < 0.05). 
Spearman correlations were performed to evaluate the relationship between the 
intake (mg/day) and content of dairy-, echium-, and fish-derived FAs in blood fractions 
and tissues (Figures 2-4; Supplementary Figures 4.S1-11). EPA intake (mg/day) strongly 
correlated with its content in all tissues and blood fractions ($ = 0.67-0.76; P < 0.05; Figure 
4.4). This was also observed for DPA ($ = 0.55-0.69) and DHA ($ = 0.40-0.75) except for 
muscle tissue (P < 0.05).  
 
Dairy-derived FAs 
RA content was consistently greater (one-fold to six-fold difference) in tissues 
analyzed from BO-fed mice compared to CO-fed mice (P < 0.05; Figure 4.1). Similar 
results were observed for VA, however, VA was not detected in plasma CEs or erythrocyte 
membranes. Of note, other FAs typically considered biomarkers of dairy fat intake (15:0, 
16:1 t9, and 17:0) were often not found in body tissues as expected. For example, the 
content of 15:0, 16:1 t9, and 17:0 was similar in at least two types of body tissues in BO- 




Intake of specific dairy-derived FAs (15:0, 16:1 t9, VA, and RA) was strongly 
associated with their respective content in adipose, liver, and muscle tissues ($ = .47-.83; 
P < 0.05; Figure 4.2). Additionally, RA and 17:0 intake correlated strongest with their 
respective content in erythrocyte membranes in comparison to all other body tissues ($ = 
0.84 and 0.49, respectively; P < 0.05). Correlations between intake of dairy-derived FAs 
and their respective content in other blood fractions ranged from weak to strong ($ = 0.26-
0.63; P < 0.05). Moreover, intake of 16:1 t9 and 17:0 did not correlate with their respective 
content in plasma PLs or CEs. 
 
Echium-derived FAs 
FA biomarkers related to the EO-diet (LNA, GLA, and SDA) were greater in body 
tissues of EO-fed mice with a few exceptions. A greater proportion of GLA was found in 
adipose, muscle, and liver tissues of EO-fed mice compared to other diet groups (one-fold 
to 25-fold difference compared to CO-fed mice; P < 0.05). In addition, a greater proportion 
of GLA was found in all blood fractions of EO-fed mice compared to other diet groups 
(one-fold to five-fold difference compared to CO-fed mice; P < 0.05), except in plasma 
FFAs. Surprisingly, no diet differences were observed with SDA in plasma PLs or CEs of 
mice.  
A strong relationship was observed between intake of echium-derived LNA, GLA, 
and SDA and their respective content in tissues ($ = 0.57-0.84; P < 0.05; Figure 4.3), 
although GLA intake was observed to correlate only weakly with its content in the liver ($ 




membranes of GLA ($ = 0.59) and SDA ($ = 0.72), as well as intake and plasma TG 
content of LNA ($ = 0.55) and SDA ($ = 0.78, P < 0.05). 
 
Summary 
Taken together, these results suggest that the content of fish- (i.e., EPA, DPA, and 
DHA) and echium-derived (i.e., LNA, GLA, and SDA) FAs was greater in body tissues in 
response to consumption of fish oil or echium oil, respectively. However, with the 
exception of VA and RA, the content of dairy-derived FAs typically used as biomarkers 
for fat intake (i.e., 15:0, 16:1 t9, and 17:0) was not greater in all body tissues, particularly 
in blood fractions, of mice fed a diet supplemented with dairy fat. We also observed that 
intake of diet-derived FAs correlated more consistently with content in tissues compared 
to blood fractions. Lastly, intake of fish-derived FAs correlated strongly with their content 
in all body tissues, while correlations between intake of dairy- or echium-derived FAs and 
their respective content in tissues was much more variable. These results suggest that the 
distribution of diet-derived FAs is highly dependent on the body tissue. 
 
4.4.3 Effect of sex 
Sex differences were observed for certain FAs, yet, these differences were not 
uniform across all body tissues (Tables 4.S3-10). For example, there were minimal sex 
differences in the content of dairy-derived FAs in tissues and blood fractions; however, 
when differences were observed, the content of dairy-derived FAs in blood fractions of 




results were found for adipose, muscle, and liver tissues. Few differences were seen in the 
EPA and DHA content of tissues by sex, but the DPA content was up to one-fold greater 
in all blood fractions and in liver tissue (20-54 and 100%, respectively) of males compared 
to females (P < 0.05). In muscle tissue, the content of EPA, DPA, and DHA was greater in 
females compared to males (0.20 ± 0.04 vs. 0.11 ± 0.03, 0.41 ± 0.05 vs. 0.28 ± 0.03, and 
3.90 ± 0.46 vs. 1.73 ± 0.18 % of total FAMEs, respectively, P < 0.05). In adipose, muscle, 
and liver tissue, the content of GLA and SDA was moderately (less than one-fold) greater 
in females than in males (17-22% and 29-40% difference, respectively; P < 0.05). 
However, other than a 28% greater content of GLA in the plasma TGs of females (P < 
0.05), no other sex differences were observed for GLA and SDA in blood fractions. In sum, 
our findings indicate that the distribution of dietary FAs is sex-specific. 
 
4.5 Discussion 
A major sector of nutritional epidemiology centers on investigating the health 
effects of dietary fat consumption, with particular emphasis on specific FAs, FA 
composition, and dietary source (15–20,31–33). For these scientific efforts, the 
measurement of tissue-specific FA biomarkers serves as an important assessment tool to 
evaluate FA intake and understand the complex biology underlying dietary FA partitioning 
and metabolism. In our study, we evaluated the content of specific, dietary FAs in a 
comprehensive panel of body tissues in male and female CD-1® mice following long-term 




fats. Our goal was to appraise the suitability of each body tissue for identification of FA 
biomarkers in a controlled, long-term feeding intervention. 
The specific objective of our study was to measure unique, dietary FAs that are 
considered fish-, dairy-, and echium-derived in adipose, muscle, and liver tissue and blood 
fractions (erythrocyte membranes and plasma PLs, CEs, TGs, and FFAs) in male and 
female CD-1® mice. Specifically, we assessed i) EPA, DPA, and DHA (FO diet), ii) 15:0, 
16:1 t9, 17:0, VA, and RA (BO diet) and iii) LNA, GLA, and SDA (EO diet). Perhaps most 
strikingly, we found that the content of the majority of dairy-derived FAs was not greater 
in body tissues in response to dairy fat intake as expected. For example, FAs generally 
accepted as biomarkers of dairy fat intake (i.e., 15:0, 16:1 t9, and 17:0) were often greater 
in body tissues in response to fish oil and/or dairy fat intake, particularly in blood fractions 
but also tissues such as the muscle. Importantly,15:0, 16:1 t9, and 17:0, as well as VA and 
RA, are not unique to dairy products per se, but rather are bacteria-derived FAs, occurring 
in significant amounts in dairy products due to the microbial population colonizing the 
rumen of the ruminant species (13). Thus, fish, and in particular cold-water fatty fish 
consuming zooplankton and algae (9), are also commonly enriched in these bacterial FAs 
(34). Notably, the validity of these FA biomarkers as determinants of dairy fat intake has 
already been called into question (19,35,36), with research showing that 17:0 content in 
blood positively correlates with fish but not dairy intake. We also observed that 17:0 
content was greatest in the muscle tissue of mice fed fish oil. However, similarly to results 
reported in humans by Pranger et al. (21), we found that the content of VA and RA was 




suggesting that these FAs are better biomarkers of dairy fat consumption. Overall, this 
observation emphasizes the need to interpret FA intake data determined via biomarkers 
with caution, particularly when using bacteria-derived FAs that may be sourced from 
ruminant products (e.g., dairy or meat), fish, or other fermented products (37). Herein, we 
assert that the use of a combination of biomarkers, including VA and/or CLA, is necessary 
to more accurately determine dairy fat intake via FA biomarkers. 
As part of evaluating diet-derived FAs as biomarkers of long-term FA intake, we 
sought to assess the tissue-specific distribution of dietary FAs in mice. Adipose tissue is 
considered the most stable tissue for measurement of FA biomarkers as it serves as a 
storage depot of FAs (2–5), but adipose biopsies are often unfeasible, particularly for large-
scale epidemiological studies. Accordingly, many researchers opt to assess FA biomarkers 
in various blood lipid fractions (15–18,20,31–33). Research demonstrates accurate 
measurement of specific FA biomarkers via blood sampling (38–41), however other work 
suggests that blood lipid fractions are not an adequate alternative to adipose tissue (42). In 
particular, there is no agreement as to whether the FA composition of plasma FFAs, which 
are derived from adipose TGs but are subject to selective FA hydrolysis and release, 
reflects that of adipose tissue (39,40,42). Indeed, in our study, we found that echium- or 
fish-oil derived FAs in plasma FFAs were moderately to strongly correlated with FA intake 
(except for GLA), but this was not true for FAs derived from dairy. Our results align with 
previous studies showing that FA structure plays a significant role in the mobilization of 
FA from adipose tissue (43,44), with mobilization favoring essential FAs and their 




FFAs were generally a less reliable indicator of dairy- and echium-derived FAs than 
adipose tissue. The FA composition of erythrocyte membranes has been proposed as a 
suitable predictor of long-term FA intake because erythrocytes are incapable of de novo 
FA synthesis. Yet, for long-chain n-3 FAs, such as EPA, DPA, DHA, erratic or 
conservative detection of these FAs has been previously observed in studies where fish oil 
was supplemented to the diet (45,46). We found that fish-derived FAs in erythrocyte 
membranes correlated strongly with FA intake. Neither 16:1 t9 nor VA were detected in 
erythrocyte membranes, suggesting that this blood fraction is not ideal for the assessment 
of dairy fat intake depending on the FA biomarker selected. These inconsistencies in 
findings across the literature are likely a result of a combination of factors, including study 
population, experimental design, choice of FA biomarker, and differences in the FA 
analysis. Overall, our work supports that muscle, liver, and particularly adipose tissue were 
better than blood to evaluate content of diet-derived FAs as biomarkers of fat intake. 
Several factors other than diet have been identified to influence the FA profile of 
tissues and blood fractions, including genetics (47–50), age (51–54), and sex (51,53,54). 
As part of our secondary objective, we assessed the effect of sex on the tissue-specific 
partitioning of dietary FAs in mice and observed that dairy-, echium-, and fish-derived FAs 
differed between males and females depending on the body tissue evaluated. For example, 
in muscle tissue, EPA, DPA, and DHA content was greater in females than in males, but 
this sex difference was not observed in other body tissues. Research in rodents (55) and 
humans (56,57) shows that females exhibit a greater content of long-chain n-3 FAs in 




analysis by Lohner et al. (58) demonstrated that sex differences can dissipate with an 
increase in fish intake or age of an individual. This may explain why, in an aged (i.e., 
reproductively senescent) population, we did not see more pronounced sex differences in 
body tissue content of fish-derived FAs in response to fish oil intake. In future studies, it 
would be important to compare measurements of diet-derived FAs in tissues of a young 
and older population, with specific emphasis on the measurement of sex hormones, to gain 
a better understanding of the relationship between age, sex, and sex hormones in this 
context. Interestingly, we also observed that DPA was greater in males than females in the 
majority of the body tissues. This result cannot be explained by differences in FA intake 
between males and females, otherwise a greater tissue content of EPA, DPA, and DHA 
would have been consistently observed in one sex over the other. Thus, underlying sex 
differences in lipid metabolism are the most plausible explanation in this study. For 
example, past work supports that males may have an greater capacity for %-oxidation over 
females (59,60), and thus, it is possible that retroconversion of DHA to DPA via %-
oxidation occurs at a higher degree in males than females. It is clear future studies focused 
on this issue should include males and females within each cohort to carefully document 
the effect of sex on tissue-specific partitioning of dietary FAs. 
Certain limitations in our study design may influence the interpretation and 
generalization of our work. Firstly, our study was performed in mice rather than humans. 
Although the experimental diets were formulated to reflect a feasible dietary pattern of a 
human, and physiology between mice and humans is overall comparable (61), it is 




intake, digestion, and tissue-specific FA distribution. Nonetheless, it is reasonable to 
assume that any influence of coprophagy on the content of diet-derived FAs in body tissues 
is negligible, as it would similarly impact all mice regardless of diet. In regard to 
methodology, several studies have compared the utility of FA analysis from total plasma 
compared to plasma fractions, which we did not assess. From cardiac blood, approximately 
1 mL of whole blood can be feasibly collected, and thus we did not have a sufficient volume 
to measure FAs in both plasma fractions and total plasma. Still, the robust findings of our 
work stand out due to several strengths in our study design. For one, we performed a 
controlled long-term feeding study, which is essential to elucidate the validity of FA 
biomarkers in an array of tissues and blood fractions that are each affected by lipid 
metabolism in a distinct manner. We chose an outbred mouse stock, rather than an inbred 
strain, as our model organism to maximize applicability of our results to the human 
population with comparable genetic diversity. Furthermore, this study included male and 
female mice and assessed sex as a factor in the distribution of dietary FAs in body tissues, 
demonstrating that FA tissue content is differentially influenced by sex.  
Taken together, our work demonstrates that partitioning of dietary FAs in body 
tissues is tissue- and sex-dependent. Our results support that adipose tissue is superior to 
blood for analysis of specific, diet-derived FAs as biomarkers following long-term FA 
consumption. Should collection of adipose tissue not be possible, we recommend FA 
analysis be performed in more than one blood fraction to allow for a more complete 
interpretation of FA biomarkers. We also caution against the use of erythrocyte membranes 




assess a combination of FA biomarkers to accurately validate patterns of FA intake and 
source, particularly when measuring FA biomarkers that are dairy- and/or bacterial-
derived. 
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Table 4.1 Composition of experimental diets1 
Diet component CO FO BO EO 
 g/kg diet 
Basal diet mix2 790 790 790 790 
U.S. fat blend3 210 147 147 147 
Fish oil supplement4 - 63 - - 
Dairy fat supplement - - 63 - 
Echium oil supplement - - - 63 
 % of energy 
Protein 17 17 17 17 
Carbohydrate 43 43 43 43 
Fat 40 40 40 40 
1 Formulated by Research Diets Inc., BO, 70% CO supplemented with 
30% dairy (butter oil) fat. CO, 100% U.S. fat blend. EO: 70% CO 
supplemented with 30% echium oil. FO, 70% CO supplemented with 
30% of fish oil. 
2 Supplied and formulated by Research Diets Inc.  
3 U.S. fat blend consisted of lard, walnut oil, high-oleic sunflower oil, 
coconut oil, and palm oil in a ratio of 18.8:3.6:2.8:1.8:1.0.  







Table 4.2 Feed intake, fat intake, and fatty acid intake, body weight, and body weight gain for CD-1® mice at 14 months of age1-3 
 Diet
 Sex P value 
 CO FO BO EO Male Female Diet Sex Diet*Sex 
Feed intake, g/d 3.1 ± 0.1 3.3 ± 0.1 3.1 ± 0.2 3.2 ± 0.1 3.4 ± 0.1 2.9 ± 0.1 - <0.001 - 
Body weight, g 46.5 ± 2.7 55.4 ± 3.6 51.3 ± 4.2 50.1 ± 3.5 60.8 ± 1.4 40.3 ± 2.3 0.05 <0.001 - 
Total weight gain, g 20.5 ± 2.1 29.3 ± 3.1 25.1 ± 3.2 23.9 ± 2.9 31.5 ± 1.3 17.7 ± 2.2 0.06 <0.001 - 
          
Fat intake, mg/d 600 ± 22ab 590 ± 21b 607 ± 31ab 678 ± 20a 675 ± 14 565 ± 15 0.020 <0.001 - 
Fatty acid intake, mg/d  
15:0  0 ± 0c 1 ± 0b 2 ± 0a 0 ± 0c 1 ± 0 1 ± 0 <0.001 <0.001 0.017 
16:0 121 ± 4b 118 ± 4b 140 ± 7a 112 ± 3b 132 ± 3 112 ± 3 <0.001 <0.001 - 
16:1 t9 0 ± 0c 0 ± 0b 0 ± 0a 0 ± 0c 0 ± 0 0 ± 0 <0.001 <0.001 <0.006 
17:0 1 ± 0c 2 ± 0b 2 ± 0a 1 ± 0c 2 ± 0 2 ± 0 <0.001 <0.001 - 
18:0 58 ± 2ab 48 ± 2c 63 ± 3a 55 ± 2bc 60 ± 2 51 ± 2 <0.001 <0.001 - 
18:1 c9 224 ± 8a 162 ± 6b 202 ± 10a 214 ± 6a 218 ± 6 183 ± 6 <0.001 <0.001 - 
18:1 t11, VA 0 ± 0b 0 ± 0b 4 ± 0a 0 ± 0b 1 ± 0 1 ± 0 <0.001 0.005 0.004 
18:2 c9,t11, RA 0 ± 0b 0 ± 0b 2 ± 0a 0 ± 0b 1 ± 0 1 ± 0 <0.001 0.001 0.013 
18:2 c9,c12, LA 120 ± 4a 88 ± 3b 91 ± 5b 127 ± 4a 117 ± 4 97 ± 4 <0.001 <0.001 - 
18:3 c6,c9,c12, GLA  0 ± 0b 1 ± 0b 0 ± 0b 19 ± 1a 6 ± 2 4 ± 1 <0.001 <0.001 <0.001 
18:3 c9,c12,c15, LNA 11 ± 0b 11 ± 0b 9 ± 0b 70 ± 2a 31 ± 5 22 ± 4 <0.001 <0.001 <0.001 
18:4 c6,c9,c12,c15, SDA  0 ± 0c 4 ± 0b 0 ± 0c 23 ± 1a 9 ± 2 6 ± 1 <0.001 <0.001 <0.001 
20:4 c5,c8,c11,c14 1 ± 0b 3 ± 0a 1 ± 0b 1 ± 0b 1 ± 0 1 ± 0 <0.001 <0.001 0.003 
20:5 c5,c8,c11,c14,c17, EPA 0 ± 0b 24 ± 1a 0 ± 0b 0 ± 0b 6 ± 2 6 ± 2 <0.001 0.002 <0.001 






1 Values are expressed as mean ± SEM. Data presented as 0 mg/d signifies <0.5 mg/d. Means without a common letter (a-d) differ 
by diet (P < 0.05). BO, 70% CO supplemented with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. 
DPA, docosapentaenoic acid. EO, 70% CO supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO 
supplemented with 30% fish oil. GLA, !-linolenic acid. LA, linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, 
stearidonic acid. VA, vaccenic acid.  
2 U.S. fat blend (CO) consisted of lard, walnut oil, high-oleic sunflower oil, coconut oil, and palm oil in a ratio of 
18.8:3.6:2.8:1.8:1.0.  
3 Fish oil supplement was derived from menhaden and supplied by Research Diets Inc.  
22:6 c4,c7,c10,c13,c16,c19, DHA 0 ± 0b 17 ± 1a 0 ± 0b 0 ± 0b 4 ± 1 4 ± 1 <0.001 0.003 <0.001 
          
Fatty acid classes          
S SFAs 215 ± 8b 213 ± 7b 267 ± 13a 198 ± 6b 240 ± 7 204 ± 7 <0.001 <0.001 - 
S MUFAs 248 ± 9a 217 ± 8b 234 ± 12ab 237± 7ab 254 ± 5 214 ± 6 0.06 <0.001 - 
S PUFAs 136 ± 5c 157 ± 5b 106 ± 5d 243 ± 7a 181 ± 10 146 ± 8 <0.001 <0.001 0.042 
          
S n-6 FAs 124 ± 5b 96 ± 3c 94 ± 5c 148 ± 4a 128 ± 5 105 ± 4 <0.001 <0.001 - 





Table 4.S1 Components of experimental diets1 
 CO FO BO EO 
 % g of diet 
Protein 20 20 20 20 
Carbohydrate 50 50 50 50 
Fat 21 21 21 21 
     
Ingredients g/kg diet 
Casein 195 195 195 195 
DL-Methionine 3 3 3 3 
Cornstarch 391 391 391 391 
Maltodextrin 10 100 100 100 100 
Cellulose, BW200 50 50 50 50 
Ethoxyquin 0.04 0.04 0.04 0.04 
Mineral Mix S10001 35 35 35 35 
Calcium Carbonate 4 4 4 4 
Vitamin Mix V10001 10 10 10 10 
Choline Bitartrate 2 2 2 2 
Cholesterol 1.5 1.5 1.5 1.5 
     
FD&C Yellow Dye, #5 0.05 0 0 0.025 
FD&C Red Dye, #40 0 0.05 0 0 
FD&C Blue Dye, #1 0 0 0.05 0.025 
     
U.S. fat blend3 210 147 147 147 
Fish oil supplement4 - 63 - - 
Dairy fat supplement - - 63 - 
Echium oil supplement - - - 63 
     
Total (g) 1001.59 1001.59 1001.59 1001.59 
1 Formulated by Research Diets Inc. CO, 100% U.S. fat blend; FO, 70% CO supplemented 
with 30%; BO, 70% CO supplemented with 30% dairy (butter) fat; EO: 70% CO 




2 U.S. fat blend consisted of lard, walnut oil, high-oleic sunflower oil, coconut oil, and palm 
oil in a ratio of 18.8:3.6:2.8:1.8:1.0.  




Table 4.S2 Comprehensive fatty acid composition of experimental fat supplements for 
designated diets 1-3 
Fatty acid CO FO BO EO 
 % of total fatty acids 
4:0 0.00 0.00 3.10 0.00 
5:0 0.00 0.00 0.03 0.00 
6:0 0.05 0.00 2.01 0.00 
7:0 0.00 0.00 0.02 0.00 
8:0 0.59 0.00 1.20 0.00 
9:0 0.00 0.00 0.04 0.00 
10:0 0.49 0.00 2.81 0.00 
11:0 0.00 0.00 0.32 0.00 
11 cyclohexyl/11:0 0.00 0.00 0.04 0.00 
12:0 3.25 0.11 3.31 0.00 
13:0 0.00 0.05 0.21 0.00 
13:0 iso 0.00 0.01 0.02 0.00 
13:0 aiso 0.00 0.00 0.08 0.00 
14:0  2.08 8.40 10.72 0.03 
14:0 iso 0.00 0.06 0.10 0.00 
14:1 c9 0.00 0.04 0.89 0.00 
15:0 0.04 0.65 1.17 0.00 
15:0 iso 0.00 0.29 0.21 0.00 
15:0 aiso 0.00 0.13 0.44 0.00 
16:0 20.04 14.61 29.87 6.87 
16:0 iso 0.00 0.12 0.28 0.00 
16:1 c7 0.18 0.21 0.14 0.00 
16:1 c9 1.23 12.04 1.34 0.07 
16:1 t9 0.00 0.20 0.05 0.00 
16:1 c11 0.00 0.19 0.03 0.00 
16:1 isomer 0.00 0.00 0.04 0.00 
16:2 c9,c12 0.00 1.39 0.00 0.00 
16:3 c6,c9,c12 0.00 1.56 0.00 0.00 
17:0  0.24 0.46 0.60 0.10 
17:0 iso 0.00 0.00 0.32 0.00 
17:0 aiso 0.00 0.00 0.40 0.00 
17:1 c8 0.00 0.07 0.00 0.00 
17:1 c9 0.00 0.12 0.00 0.00 
17:1 t10 0.00 0.26 0.00 0.00 
18:0 10.30 2.49 10.44 3.52 
18:0 iso 0.00 0.27 0.07 0.00 
18:1 t4 0.00 0.00 0.04 0.00 
18:1 t5 0.00 0.00 0.02 0.00 
18:1 t6-8 0.00 0.00 0.29 0.00 




18:1 t9 0.00 0.00 0.25 0.00 
18:1 t10 0.00 0.00 0.45 0.00 
18:1 c11 1.64 2.44 0.66 0.47 
18:1 t11 0.00 0.00 1.20 0.00 
18:1 c12 0.00 0.00 0.46 0.00 
18:1 t12 0.00 0.00 0.45 0.00 
18:1 c13 0.05 0.05 0.11 0.00 
18:1 c14/t16 0.00 0.00 0.38 0.00 
18:1 t13/t14 0.00 0.00 0.78 0.00 
18:1 c15 0.00 0.79 0.06 0.00 
18:1 c16 0.00 0.00 0.08 0.00 
18:2 c9,t11 0.00 0.00 0.51 0.00 
18:2 c9,c12 19.51 1.28 2.48 14.15 
18:2 c9,t12 0.00 0.00 0.00 0.14 
18:2 c9,t13/t8,c12 0.00 0.00 0.21 0.00 
18:2 c9,t14 0.00 0.00 0.09 0.00 
18:2 t9,c12 0.00 0.00 0.00 0.02 
18:2 t10,t14 0.00 0.00 0.06 0.00 
18:2 t11,t13 0.00 0.00 0.00 0.00 
18:2 t,t isomer 0.00 0.00 0.00 0.00 
18:3 c6,c9,c12  0.00 0.32 0.00 10.01 
18:3 c9,c12,c15 1.89 1.29 0.39 32.71 
18:3 c9,t12,c15 0.00 0.00 0.00 0.06 
18:3 c9,t12,t15/c9,c12,t15 0.00 0.00 0.00 0.70 
18:3 t9,c12,c15 0.00 0.00 0.00 0.50 
18:4 c6,c9,c12,c15 0.00 2.57 0.00 13.38 
19:0 0.01 0.07 0.00 0.00 
20:0 0.24 0.14 0.15 0.10 
20:1 c9 0.00 0.42 0.10 0.00 
20:1 c11  0.42 0.00 0.03 0.74 
20:2 c11,c14 0.41 0.17 0.00 0.05 
20:3 c5,c8,c11 0.06 0.29 0.13 0.00 
20:3 c11,c14,c17 0.00 0.24 0.00 0.00 
20:4 c5,c8,c11,c14 0.14 1.36 0.16 0.00 
20:4 c8,c11,c14,c17 0.00 1.19 0.00 0.00 
20:5 c5,c8,c11,c14,c17 0.00 13.29 0.03 0.00 
22:0 0.05 0.15 0.06 0.05 
22:1 c13 0.05 0.00 0.00 0.39 
22:1 t13 0.00 0.00 0.00 0.05 
22:2 c13,c16 0.00 0.03 0.00 0.00 
23:0 0.00 0.05 0.00 0.00 
24:0 0.03 0.07 0.00 0.00 
24:1 c15   0.01 0.25 0.00 0.11 




22:5 c4,c7,c10,c13,c16 0.00 0.54 0.00 0.00 
22:5 c7,c10,c13,c16,c19 0.00 2.02 0.00 0.00 
22:6 c4,c7,c10,c13,c16,c19 0.00 10.33 0.00 0.00 
1 BO, 70% CO supplemented with 30% dairy (butter) fat. CO, 100% U.S. fat blend. EO: 
70% CO supplemented with 30% echium oil. FO, 70% CO supplemented with 30%.  
2 U.S. fat blend consisted of lard, walnut oil, high-oleic sunflower oil, coconut oil, and 
palm oil in a ratio of 18.8:3.6:2.8:1.8:1.0.  





Table 4.S3 Fatty acid composition (percent of total FAME) of plasma phospholipids in CD-1 mice1 
 Diet
 Sex P value 
Fatty acid CO FO BO EO Male Female Diet Sex Diet*Sex 
15:0 0.07 ± 0.02b 0.14 ± 0.03ab 0.22 ± 0.05a 0.15 ± 0.03ab 0.11 ± 0.01 0.18 ± 0.03 0.021 0.020 - 
16:0 23.59 ± 0.64b 26.07 ± 0.88ab 24.03 ± 0.67ab 26.36 ± 0.55a 24.76 ± 0.48 25.52 ± 0.56 0.013 - - 
16:1 t9 0.05 ± 0.01 0.05 ± 0.00 0.07 ± 0.01 0.04 ± 0.01 0.04 ±  0.00 0.06 ± 0.01 - 0.001 - 
17:0 0.95 ± 0.11 0.89 ± 0.10 0.99 ± 0.11 0.74 ± 0.07 0.79 ± 0.06 0.96 ± 0.07 - - - 
18:0 18.96 ± 0.58 18.89 ± 0.69 17.89 ± 0.43 19.56 ± 0.53 18.85 ± 0.38 18.91 ± 0.44 - - - 
18:1 c9 (n-9) 8.66 ± 0.44 9.10 ± 0.58 9.86 ± 0.50 8.97 ± 0.49 8.85 ± 0.30 9.38 ± 0.40 - - - 
18:1 t11, VA 0.15 ± 0.03b 0.18 ± 0.03b 0.35 ± 0.03a 0.21 ± 0.03b 0.19 ± 0.02 0.24 ± 0.03 <0.001 0.09 - 
18:2 c9,t11, RA 0.01 ± 0.00b 0.03 ± 0.01ab 0.06 ± 0.01a 0.00 ± 0.00b 0.02 ± 0.01 0.03 ± 0.01 <0.001 - - 
18:2 c9,c12 (n-6), LA 18.78 ± 1.13 17.33 ± 0.88 18.92 ± 0.75 17.30 ± 0.74 19.60 ± 0.57 16.56 ± 0.56 - <0.001 - 
18:3 c6,c9,c12 (n-6), GLA  0.12 ± 0.01b 0.09 ± 0.02b 0.09 ± 0.02b 0.26 ± 0.03a 0.15 ± 0.03 0.12 ± 0.02 <0.001 - - 
18:3 c9,c12,c15 (n-3), LNA 0.10 ± 0.03b 0.09 ± 0.02b 0.07 ± 0.02b 0.21 ± 0.02a 0.13 ± 0.02 0.13 ± 0.02 <0.001 - 0.039 
18:4 c6,c9,c12,c15 (n-3), SDA  0.05 ± 0.04 0.12 ± 0.04 0.09 ± 0.03 0.16 ± 0.04 0.09 ± 0.02 0.13 ± 0.03 - - - 
20:4 c5,c8,c11,c14 (n-6) 9.91 ± 0.79a 3.99 ± 0.36c 9.00 ± 0.52a 7.18 ± 0.47b 8.14 ± 0.55 6.62 ± 0.50 <0.001 0.003 - 
20:5 c5,c8,c11,c14,c17 (n-3), EPA 0.12 ± 0.02c 2.60 ± 0.27a 0.21 ± 0.05c 0.94 ± 0.13b 1.10 ± 0.22 0.99 ± 0.20 <0.001 - - 
22:5 c7,c10,c13,c16,c19 (n-3), DPA 0.19 ± 0.02c 0.67 ± 0.05a 0.26 ± 0.04c 0.52 ± 0.04b 0.49 ± 0.05 0.38 ± 0.04 <0.001 0.038 - 
22:6 c4,c7,c10,c13,c16,c19 (n-3), DHA 4.84 ± 0.34b 6.98 ± 0.43a 5.20 ± 0.29b 5.99 ± 0.33ab 6.05 ± 0.28 5.62 ± 0.29 <0.001 - - 
          
Fatty acid classes          
S SFAs 48.88 ± 0.87b 51.22 ± 0.73a 47.83 ± 0.69b 50.78 ± 0.70a 47.96 ± 0.43 51.57 ± 0.51 <0.001 <0.001 - 
S MUFAs 12.95 ± 0.68 13.30 ± 0.93 14.74 ± 0.65 12.73 ± 0.73 12.53 ± 0.47 14.13 ± 0.58 - - - 
S PUFAs 38.47 ± 1.22 35.86 ± 1.21 37.42 ± 0.89 36.48 ± 1.20 39.51 ± 0.62 34.55 ± 0.77 - <0.001 - 





1 Values are expressed as mean ± SEM. Means without a common letter (a-d) differ by diet (P < 0.05). BO, 70% CO supplemented 
with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EO: 70% CO 
supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO supplemented with 30%. GLA, !-linolenic acid. LA, 
linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, stearidonic acid. VA, vaccenic acid. 
S n-6 FAs 31.00 ± 1.71a 23.42 ± 1.24c 30.73 ± 0.92ab 27.73 ± 1.18bc 30.93 ± 0.85 25.34 ± 0.96 <0.001 <0.001 - 
S n-3 FAs 5.46 ± 0.33c 10.81 ± 0.59a 6.00 ± 0.34c 8.15 ± 0.33b 8.07 ± 0.50 7.53 ± 0.44 <0.001 - - 





Table 4.S4 Fatty acid composition (percent of total FAME) of plasma cholesterol esters in CD-1 mice1 
 Diet
 Sex P value 
Fatty acid CO FO BO EO Male Female Diet Sex Diet*Sex 
15:0 0.24 ± 0.05 0.29 ± 0.04 0.24 ± 0.03 0.21 ± 0.04 0.18 ± 0.02 0.31 ± 0.03 - .0001 - 
16:0 4.54 ± 0.29 5.10 ± 0.33 4.58 ± 0.25 4.44 ± 0.24 3.88 ±  0.13 5.35 ± 0.17 - <0.001 - 
16:1 t9 0.11 ± 0.02 0.10 ± 0.01 0.10 ± 0.01 0.11 ± 0.02 0.07 ± 0.01 0.14 ± 0.01 - <0.001 - 
17:0 0.51 ± 0.13 0.58 ± 0.12 0.50 ± 0.08 0.46 ± 0.08 0.24 ± 0.03 0.75 ± 0.07 - <0.001 - 
18:0 1.06 ± 0.17 1.09 ± 0.14 0.97 ± 0.17 0.95 ± 0.14 0.60 ± 0.06 1.38 ± 0.09 - <0.001 - 
18:1 c9 (n-9) 9.35 ± 0.85ab 7.46 ± 0.41bc 9.99 ± 0.75a 6.33 ± 0.42c 6.57 ± 0.26 9.46 ± 0.50 <0.001 <0.001 0.07 
18:1 t11, VA - - - - - - - - - 
18:2 c9,t11, RA 0.05 ± 0.01b 0.04 ± 0.01b 0.10 ± 0.02a 0.02 ± 0.01b 0.03 ± 0.01 0.07 ± 0.01 <0.001 0.002 - 
18:2 c9,c12 (n-6), LA 29.84 ± 1.40 29.84 ± 1.31 32.17 ± 1.24 32.02 ± 1.09 34.15 ± 0.73 28.20 ± 0.72 - <0.001 - 
18:3 c6,c9,c12 (n-6), GLA  0.40 ± 0.04b 0.44 ± 0.13b 0.59 ±  0.18b 2.53 ±  0.20a 1.28 ± 0.24 0.84 ± 0.15 <0.001 - - 
18:3 c9,c12,c15 (n-3), LNA 0.23 ± 0.02b 0.33 ± 0.05b 0.23 ± 0.03b 0.78 ± 0.11a 0.40 ± 0.06 0.43 ± 0.07 <0.001 - - 
18:4 c6,c9,c12,c15 (n-3), SDA  0.27 ± 0.11 0.26 ± 0.10 0.18 ± 0.10 0.35 ± 0.11 0.23 ± 0.06 0.30 ± 0.08 - - - 
20:4 c5,c8,c11,c14 (n-6) 33.81 ± 2.65a 16.03 ± 1.01c 31.38 ± 1.67ab 28.12 ± 1.32b 30.04 ± 1.92 24.00 ± 1.36 <0.001 <0.001 - 
20:5 c5,c8,c11,c14,c17 (n-3), EPA 0.45 ± 0.03c 15.05 ± 1.02a 0.82 ± 0.24c 4.21 ± 0.64b 5.82 ± 1.30 5.44 ± 1.07 <0.001 - - 
22:5 c7,c10,c13,c16,c19 (n-3), DPA 0.05 ± 0.01c 0.24 ± 0.02a 0.08 ± 0.02c 0.15 ± 0.02b 0.16 ± 0.02 0.11 ± 0.02 <0.001 0.007 - 
22:6 c4,c7,c10,c13,c16,c19 (n-3), DHA 3.47 ± 0.21c 6.34 ± 0.36a 3.88 ±  0.18c 5.08 ± 0.26b 5.11 ± 0.31 4.54 ± 0.24 <0.001 - - 
          
Fatty acid classes          
S SFAs 10.43 ± 1.24 12.08 ± 1.25 10.96 ± 0.79 10.17 ± 0.79 7.72 ± 0.30 13.83 ± 0.60 - <0.001 - 
S MUFAs 13.87 ± 0.99ab 14.23 ± 0.71a 15.80 ± 0.95a 11.43 ± 0.73b 11.17 ± 0.46 15.95 ± 0.49 <0.001 <0.001 - 
S PUFAs 74.83 ± 2.45ab 72.33 ± 2.13b 73.00 ± 1.59ab 78.19 ± 1.45a 80.95 ± 0.68 69.13 ± 1.08 0.038 <0.001 - 





1 Values are expressed as mean ± SEM. Means without a common letter (a-d) differ by diet (P < 0.05). BO, 70% CO supplemented 
with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EO: 70% CO 
supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO supplemented with 30%. GLA, !-linolenic acid. LA, 
linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, stearidonic acid. VA, vaccenic acid.  
  
S n-6 FAs 67.38 ± 2.99a 47.54 ± 1.94b 65.52 ± 1.95a 64.70 ±  1.90a 67.24 ± 1.81 54.81 ± 1.80 <0.001 <0.001 - 
S n-3 FAs 5.54 ± 0.42c 23.80 ± 0.90a 6.08 ± 0.62c 11.29 ± 0.41b 12.60 ± 1.59 11.75 ± 1.26 <0.001 - 0.003 





Table 4.S5 Fatty acid composition (percent of total FAME) of plasma TGs in CD-1 mice1 
 Diet
 Sex P value 
Fatty acid CO FO BO EO Male Female Diet Sex Diet*Sex 
15:0 0.25 ± 0.05 0.29 ± 0.05 0.31 ± 0.03 0.21 ± 0.02 0.23 ± 0.02 0.29 ± 0.03 0.07 - - 
16:0 20.49 ± 0.41
a 19.62 ± 0.64ab 19.99 ± 0.40a 18.07 ± 0.45b 18.50 ± 0.33 20.32 ± 0.35 0.001 <0.001 0.011 
16:1 t9 0.01 ± 0.00b 0.02 ± 0.01ab 0.04 ± 0.01a 0.03 ± 0.01ab 0.03 ± 0.01 0.03 ± 0.00 0.016 - 0.001 
17:0 0.22 ± 0.01ab 0.26 ± 0.02ab 0.28 ± 0.02a 0.20 ± 0.02b 0.23 ± 0.01 0.25 ± 0.01 0.007 - - 
18:0 4.48 ± 0.30 3.97 ± 0.34 4.28 ± 0.28 4.02 ± 0.23 4.00 ± 0.21 4.32 ± 0.20 - - 0.08 
18:1 c9 (n-9) 37.57 ± 0.52a 27.90 ± 0.77b 36.09 ± 0.95a 29.04 ± 0.65b 32.47 ± 0.98 32.33 ± 0.86 <0.001 - - 
18:1 t11, VA 0.08 ± 0.01b 0.12 ± 0.02b 0.27 ± 0.02a 0.14 ± 0.03b 0.14 ± 0.02 0.16 ± 0.02 <0.001 - - 
18:2 c9,t11, RA 0.05 ± 0.01b 0.06 ± 0.02b 0.31 ± 0.04a 0.08 ± 0.02b 0.10 ± 0.02 0.14 ± 0.03 <0.001 0.048 - 
18:2 c9,c12 (n-6), LA 19.02 ± 0.48ab 16.15 ± 0.48c 16.56 ± 0.66bc 18.82 ± 0.53a 17.50 ± 0.54 17.77 ± 0.35 <0.001 - - 
18:3 c6,c9,c12 (n-6), GLA  0.37 ± 0.07b 0.22 ± 0.06b 0.38 ± 0.11b 1.16 ± 0.12a 0.47 ± 0.09 0.60 ± 0.10 <0.001 0.018 0.07 
18:3 c9,c12,c15 (n-3), LNA 2.04 ± 0.10b 2.17 ± 0.26b 2.72 ± 0.35b 5.51 ± 0.47a 3.64 ± 0.39 2.75 ± 0.30 <0.001 0.017 - 
18:4 c6,c9,c12,c15 (n-3), SDA  0.12 ± 0.02b 0.31 ± 0.05b 0.26 ± 0.12b 1.15 ± 0.13a 0.45 ± 0.08 0.50 ± 0.11 <0.001 - - 
20:4 c5,c8,c11,c14 (n-6) 2.45 ± 0.19a 1.16 ± 0.08b 2.48 ± 0.16a 2.11 ± 0.13a 1.96 ± 0.14 2.06 ± 0.14 <0.001 - - 
20:5 c5,c8,c11,c14,c17 (n-3), EPA 0.23 ± 0.02c 6.80 ± 0.50a 0.67 ± 0.33c 3.38 ± 0.48b 3.18 ± 0.63 2.69 ± 0.48 <0.001 - - 
22:5 c7,c10,c13,c16,c19 (n-3), DPA 0.20 ± 0.02c 2.08 ± 0.19a 0.32 ± 0.08c 1.31 ± 0.18b 1.24 ± 0.20 0.84 ± 0.13 <0.001 0.018 0.034 
22:6 c4,c7,c10,c13,c16,c19 (n-3), DHA 1.62 ± 0.12c 8.47 ± 0.61a 2.01 ± 0.17c 3.80 ± 0.44b 4.70 ± 0.72 3.51 ± 0.42 <0.001 0.001 <0.001 
          
Fatty acid classes          
S SFAs 27.38 ± 0.38a 26.38 ± 1.25bc 26.89 ± 0.66ab 24.46 ± 0.67c 24.69 ± 0.50 27.44 ± 0.58 <0.001 <0.001 0.07 
S MUFAs 44.29 ± 0.61a 34.97 ± 0.92b 44.55 ± 1.25a 35.36 ± 0.84b 39.62 ± 1.20 39.41± 0.93 <0.001 - - 
S PUFAs 27.96 ± 0.59b 38.64 ± 1.44a 26.89 ± 0.72b 39.87 ± 1.28a 35.40 ± 1.52 32.46 ± 1.10 <0.001 0.019 0.035 





1 Values are expressed as mean ± SEM. Means without a common letter (a-d) differ by diet (P < 0.05). BO, 70% CO supplemented 
with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EO: 70% CO 
supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO supplemented with 30%. GLA, !-linolenic acid. LA, 
linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, stearidonic acid. VA, vaccenic acid.  
  
S n-6 FAs 23.03 ± 0.54ab 18.25 ± 0.57c 20.65 ± 0.70b 23.14 ± 0.60a 21.21 ± 0.63 21.25 ± 0.50 <0.001 - 0.09 
S n-3 FAs 4.44 ± 0.17c 19.91 ± 1.21a 6.44 ± 0.94c 16.12 ± 1.22b 13.61 ± 1.53 10.89 ± 1.18 <0.001 0.038 - 





Table 4.S6 Fatty acid composition (percent of total FAME) of plasma FFAs in CD-1 mice1 
 Diet
 Sex P value 
Fatty acid CO FO BO EO Male Female Diet Sex Diet*Sex 
15:0 0.60 ± 0.30b 0.47 ± 0.07a 0.63 ± 0.13a 0.45 ± 0.10ab 0.49 ± 0.08 0.57 ± 0.15 <0.001 - - 
16:0 29.33 ± 0.59b 32.04 ± 0.76a 30.76 ± 0.75ab 30.00 ± 0.59ab 29.37 ± 0.40 31.54 ± 0.51 0.031 <0.001 - 
16:1 t9 0.03 ± 0.01b 0.04 ± 0.01b 0.08 ± 0.01a 0.03 ± 0.01b 0.04 ± 0.01 0.05 ± 0.01 <0.001 - - 
17:0 0.35 ± 0.03b 0.46 ± 0.03a 0.43 ± 0.02ab 0.42 ± 0.03ab 0.44 ± 0.02 0.39 ± 0.02 0.034 0.07 - 
18:0 15.10 ± 0.71 16.64 ± 0.48 15.25 ± 0.65 15.96 ± 0.71 15.94 ± 0.38 15.55 ± 0.53 - - - 
18:1 c9 (n-9) 20.26 ± 0.89a 13.97 ± 0.43c 17.66 ± 1.02ab 15.50 ± 0.77bc 16.70 ± 0.68 16.97 ± 0.72 <0.001 - - 
18:1 t11, VA 0.07 ± 0.01b 0.11 ± 0.02b 0.23 ± 0.03a 0.10 ± 0.02b 0.13 ± 0.02 0.12 ± 0.02 <0.001 - - 
18:2 c9,t11, RA 0.03 ± 0.01b 0.03 ± 0.01b 0.12 ± 0.03a 0.04 ± 0.01b 0.05 ± 0.01 0.06 ± 0.01 <0.001 - - 
18:2 c9,c12 (n-6), LA 13.07 ± 0.49a 10.44 ± 0.49b 11.04 ± 0.74ab 11.51 ± 0.62ab 12.21 ± 0.48 10.85 ± 0.39 0.011 0.011 - 
18:3 c6,c9,c12 (n-6), GLA  0.26 ± 0.07b 0.22 ± 0.08b 0.25 ± 0.07ab 0.61 ± 0.09a 0.36 ± 0.06 0.33 ± 0.06 0.002 - - 
18:3 c9,c12,c15 (n-3), LNA 1.09 ± 0.08b 1.03 ± 0.18b 1.21 ± 0.31b 3.06 ± 0.31a 2.02 ± 0.27 1.32 ± 0.17 <0.001 0.011 - 
18:4 c6,c9,c12,c15 (n-3), SDA  0.13 ± 0.08c 0.43 ± 0.14ab 0.84 ± 0.30b 1.12 ± 0.25a 0.78 ± 0.21 0.52 ± 0.11 <0.001 - - 
20:4 c5,c8,c11,c14 (n-6) 5.86 ± 0.40a 2.48 ± 0.35c 4.82 ± 0.43ab 4.09 ± 0.35b 4.41 ± 0.33 4.25 ± 0.35 <0.001 - - 
20:5 c5,c8,c11,c14,c17 (n-3), EPA 0.19 ± 0.01c 4.38 ± 0.43a 0.33 ± 0.14c 1.55 ± 0.22b 1.70 ± 0.36 1.48 ± 0.32 <0.001 - - 
22:5 c7,c10,c13,c16,c19 (n-3), DPA 0.13 ± 0.01c 0.68 ± 0.08a 0.15 ± 0.03c 0.36 ± 0.05b 0.40 ± 0.06 0.26 ± 0.04 <0.001 0.006 0.007 
22:6 c4,c7,c10,c13,c16,c19 (n-3), DHA 2.52 ± 0.16b 5.14 ± 0.37a 2.51 ± 0.20b 3.18 ± 0.29b 3.34 ± 0.30 3.29 ± 0.22 <0.001 - 0.038 
          
Fatty acid classes          
S SFAs 48.19 ± 1.01 53.32 ± 1.49 50.89 ± 1.51 50.25 ± 1.42 49.30 ± 0.90 52.41 ± 1.01 - 0.027 - 
S MUFAs 26.29 ± 0.99a 20.19 ± 0.51b 25.29 ± 1.05a 21.60 ± 0.81b 23.07 ± 0.72 23.53 ± 0.78 <0.001 - - 
S PUFAs 25.52 ± 0.71ab 26.49 ± 1.27ab 23.82 ± 0.93b 28.15 ± 1.03a 27.63 ± 0.74 24.64 ± 0.67 0.010 0.003 0.032 





1 Values are expressed as mean ± SEM. Means without a common letter (a-d) differ by diet (P < 0.05). BO, 70% CO supplemented 
with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EO: 70% CO 
supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO supplemented with 30%. GLA, !-linolenic acid. LA, 
linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, stearidonic acid. VA, vaccenic acid. 
  
S n-6 FAs 20.61 ± 0.73a 13.90 ± 0.76c 17.20 ± 1.03bc 17.54 ± 0.83b 18.22 ± 0.68 16.58 ± 0.73 <0.001 0.050 - 
S n-3 FAs 4.68 ± 0.13c 12.35 ± 0.72a 5.32 ± 0.50c 10.12 ± 0.50b 8.88 ± 0.76 7.58 ± 0.57 <0.001 0.07 0.012 





 Table 4.S7 Fatty acid composition (percent of total FAME) of erythrocyte membranes in CD-1 mice1 
 Diet
 Sex P value 
Fatty acid CO FO BO EO Male Female Diet Sex Diet*Sex 
15:0 0.38 ± 0.05ab 0.37 ± 0.02a 0.47 ± 0.04a 0.29 ± 0.03b 0.32 ± 0.02 0.42 ± 0.03 <0.001 0.08 - 
16:0 28.00 0.33c 31.56 ± 0.36a 28.69 ± 0.31bc 29.67 ± 0.43b 29.89 ± 0.37 29.26 ± 0.32 <0.001 - - 
16:1 t9 - - - - - - - - - 
17:0 0.40 ± 0.01b 0.49 ± 0.01a 0.50 ± 0.02a 0.41 ± 0.01b 0.45 ± 0.01 0.44 ± 0.01 <0.001 - - 
18:0 16.08 ± 0.18ab 15.87 ± 0.20b 15.38 ± 0.16b 16.81 ± 0.25a 16.27 ± 0.18 15.89 ± 0.16 <0.001 - 0.081 
18:1 c9 (n-9) 12.52 ± 0.22 12.38 ± 0.24 12.27 ± 0.17 12.19 ± 0.18 11.96 ± 0.09 12.68 ± 0.15 - <0.001 - 
18:1 t11, VA - - - - - - - - - 
18:2 c9,t11, RA 0.00 ± 0.00b 0.00 ± 0.00b 0.03 ± 0.00a 0.00 ± 0.00b 0.01 ± 0.00 0.01 ± 0.00 <0.001 - - 
18:2 c9,c12 (n-6), LA 8.24 ± 0.24ab 7.96 ± 0.18ab 7.63 ± 0.17b 8.69 ± 0.25a 8.43 ± 0.20 7.89 ± 0.12 0.011 0.06 - 
18:3 c6,c9,c12 (n-6), GLA 0.07 ± 0.01b 0.05 ± 0.01b 0.07 ± 0.01b 0.34 ±0.02a 0.15 ± 0.02 0.13 ± 0.02 <0.001 - - 
18:3 c9,c12,c15 (n-3), LNA 0.21 ± 0.03b 0.12 ± 0.02c 0.15 ± 0.03bc 0.35 ± 0.03a 0.18 ± 0.02 0.24 ± 0.03 <0.001 0.012 - 
18:4 c6,c9,c12,c15 (n-3), SDA 0.00 ± 0.00b 0.00 ± 0.00b 0.00 ± 0.00b 0.05 ± 0.01a 0.01 ± 0.00 0.02 ± 0.01 <0.001 - - 
20:4 c5,c8,c11,c14 (n-6) 17.68 ± 0.49a 7.81 ± 0.17c 17.66 ± 0.44a 14.30 ± 0.23b 14.04 ± 0.74 14.01 ± 0.74 <0.001 - - 
20:5 c5,c8,c11,c14,c17 (n-3), EPA 1.01 ± 0.08c 5.34 ± 0.13a 1.05 ± 0.09c 1.72 ± 0.10b 2.23 ± 0.30 2.53 ± 0.34 <0.001 0.003 - 
22:5 c7,c10,c13,c16,c19 (n-3), DPA 0.54 ± 0.04c 2.18 ± 0.06a 0.70 ± 0.04c 1.90 ± 0.07b 1.52 ± 0.13 1.27 ± 0.13 <0.001 0.001 - 
22:6 c4,c7,c10,c13,c16,c19 (n-3), DHA 3.81 ± 0.15c 7.40 ± 0.18a 4.13 ± 0.11c 4.96 ± 0.16b 5.25 ± 0.28 5.08 ± 0.26 <0.001 - - 
          
Fatty acid classes          
S SFAs 46.59 ± 0.34c 49.70 ± 0.36a 46.55 ± 0.29c 48.21 ± 0.36b 48.11 ± 0.38 47.64 ± 0.28 <0.001 - 0.08 
S MUFAs 18.91 ± 0.61a 17.95 ± 0.49a 18.66 ± 0.52a 16.53 ± 0.21b 17.15 ± 0.24 18.70 ± 0.41 <0.001 0.001 0.031 
S PUFAs 34.46 ± 0.81a 32.35 ± 0.40b 34.77 ± 0.58a 35.24 ± 0.30a 34.73 ± 0.30 33.64 ± 0.49 <0.001 - - 





1 Values are expressed as mean ± SEM. Means without a common letter (a-d) differ by diet (P < 0.05). BO, 70% CO supplemented 
with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EO: 70% CO 
supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO supplemented with 30%. GLA, !-linolenic acid. LA, 
linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, stearidonic acid. VA, vaccenic acid. 
S n-6 FAs 29.41 ± 0.60a 17.30 ± 0.26c 28.70 ± 0.48a 26.24 ± 0.24b 25.51 ± 0.87 24.60 ± 0.90 <0.001 0.012 - 
S n-3 FAs 5.57 ± 0.14c 15.04 ± 0.25a 6.03 ± 0.16c 9.01 ± 0.16b 9.21 ± 0.67 9.14 ± 0.67 <0.001 - - 





Table 4.S8 Fatty acid composition (percent of total FAME) of adipose tissue in CD-1 mice1 
 Diet
 Sex P value 
Fatty acid CO FO BO EO Male Female Diet Sex Diet*Sex 
15:0 0.08 ± 0.00c 0.21 ± 0.01b 0.26 ± 0.01a 0.10 ± 0.01c 0.15 ± 0.01 0.17 ± 0.02 <0.001 0.011 0.004 
16:0 15.56 ± 0.55b 18.07 ± 0.83a 16.02 ± 0.70ab 14.66 ± 0.50b 14.18 ± 0.28 17.79 ± 0.49 <0.001 <0.001 - 
16:1 t9 0.02 ± 0.00c 0.03 ± 0.01ab 0.04 ± 0.00a 0.02  ± 0.00bc 0.03 ± 0.00 0.02 ± 0.00 <0.001 0.023 - 
17:0 0.16 ± 0.01b 0.25 ± 0.01a 0.21 ± 0.01a 0.15 ± 0.01b 0.17 ± 0.01 0.20 ± 0.01 <0.001 0.012 - 
18:0 2.81 ± 0.26 3.11 ± 0.31 2.57 ± 0.25 2.59 ± 0.26 2.05 ± 0.08 3.44 ± 0.20 - <0.001 - 
18:1 c9 (n-9) 50.98 ± 0.76a 44.42 ± 0.87b 50.49 ± 0.91a 46.78 ± 0.75b 50.34 ± 0.58 45.99 ± 0.68 <0.001 <0.001 - 
18:1 t11, VA 0.05 ± 0.00b 0.07 ± 0.01b 0.33 ± 0.03a 0.04 ± 0.01b 0.09 ± 0.02 0.15 ± 0.03 <0.001 <0.001 <0.001 
18:2 c9,t11, RA 0.07 ± 0.00b 0.06 ± 0.00b 0.52 ± 0.03a 0.06 ± 0.00b 0.13 ± 0.02 0.20 ± 0.04 <0.001 <0.001 <0.001 
18:2 c9,c12 (n-6), LA 17.24 ± 0.41ab 16.16 ± 0.53b 14.15 ± 0.29c 18.49 ± 0.44a 17.72 ± 0.40 15.50 ± 0.32 <0.001 <0.001 - 
18:3 c6,c9,c12 (n-6), GLA  0.03 ± 0.00c 0.14 ± 0.05b 0.03 ± 0.00c 0.78 ± 0.08a 0.23 ± 0.05 0.28 ± 0.07 <0.001 0.007 - 
18:3 c9,c12,c15 (n-3), LNA 0.81 ± 0.05bc 1.20 ± 0.20b 0.71 ± 0.05c 3.61 ± 0.26a 1.57 ± 0.23 1.69 ± 0.25 <0.001 0.006 - 
18:4 c6,c9,c12,c15 (n-3), SDA  0.03 ± 0.01c 0.25 ± 0.04b 0.06 ± 0.02c 0.58 ± 0.07a 0.20 ± 0.04 0.28 ± 0.06 <0.001 0.008 - 
20:4 c5,c8,c11,c14 (n-6) 0.14 ± 0.01 0.12 ± 0.01 0.14 ± 0.01 0.11 ± 0.01 0.11 ± 0.01 0.14 ± 0.01 - 0.003 - 
20:5 c5,c8,c11,c14,c17 (n-3), EPA 0.00 ± 0.00c 0.31 ± 0.04a 0.01 ± 0.00c 0.06 ± 0.01b 0.07 ± 0.02 0.12 ± 0.03 <0.001 - - 
22:5 c7,c10,c13,c16,c19 (n-3), DPA 0.01 ± 0.00c 0.13 ± 0.02a 0.01 ± 0.00c 0.05 ± 0.00b 0.05 ± 0.01 0.05 ± 0.01 <0.001 - 0.07 
22:6 c4,c7,c10,c13,c16,c19 (n-3), DHA 0.03 ± 0.00c 0.31 ± 0.04a 0.03 ± 0.00c 0.08 ± 0.01b 0.09 ± 0.02 0.14 ± 0.03 <0.001 - 0.016 
          
Fatty acid classes          
S SFAs 21.05 ± 0.98b 24.86 ± 1.37a 22.38 ± 1.23ab 19.58 ± 0.87b 18.52 ± 0.39 25.09 ± 0.80 0.001 <0.001 - 
S MUFAs 60.15 ± 0.85a 55.95 ± 0.96b 61.49 ± 1.17a 56.14 ± 0.85b 60.89 ± 0.60 55.99 ± 0.72 <0.001 <0.001 - 
S PUFAs 18.79 ± 0.41b 19.19 ± 0.71b 16.13 ± 0.26c 24.28 ± 0.52a 20.59 ± 0.64 18.93 ± 0.57 <0.001 0.005 - 





1 Values are expressed as mean ± SEM. Means without a common letter (a-d) differ by diet (P < 0.05). BO, 70% CO supplemented 
with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EO: 70% CO 
supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO supplemented with 30%. GLA, !-linolenic acid. LA, 
linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, stearidonic acid. VA, vaccenic acid.
S n-6 FAs 17.67 ± 0.40b 16.66 ± 0.57b 14.50 ± 0.28c 19.66 ± 0.41a 18.27 ± 0.44 16.19 ± 0.36 <0.001 <0.001 - 
S n-3 FAs 0.91 ± 0.05c 2.29 ± 0.22b 0.85 ± 0.06c 4.45 ± 0.31a 2.02 ± 0.27 2.35 ± 0.30 <0.001 0.012 0.037 





Table 4.S9 Fatty acid composition (percent of total FAME) of muscle tissue in CD-1 mice1 
 Diet
 Sex P value 
Fatty acid CO FO BO EO Male Female Diet Sex Diet*Sex 
15:0 0.08 ± 0.00c 0.19 ± 0.00b 0.22 ± 0.00a 0.09 ± 0.00c 0.13 ± 0.01 0.16 ± 0.01 <0.001 0.005 0.004 
16:0 16.88 ± 0.53b 20.36 ± 0.54a 17.44 ± 0.76b 16.55 ± 0.51b 16.69 ± 0.37 18.96 ± 0.51 <0.001 <0.001 - 
16:1 t9 0.02 ± 0.00b 0.02 ± 0.00b 0.05 ± 0.00a 0.02 ± 0.00b 0.02 ± 0.00 0.03 ± 0.00 <0.001 - - 
17:0 0.14 ± 0.01c 0.23 ± 0.01a 0.18 ± 0.01b 0.16 ± 0.01bc 0.18 ± 0.01 0.18 ± 0.01 <0.001 - 0.047 
18:0 3.67 ± 0.35 4.13 ± 0.33 4.00 ± 0.48 4.40 ± 0.52 3.24 ± 0.14 4.93 ± 0.36 - <0.001 - 
18:1 c9 (n-9) 47.67 ± 1.02a 41.14 ± 1.09b 44.99 ± 1.86ab 42.13 ± 1.38b 47.13 ± 0.60 40.40 ± 1.11 <0.001 <0.001 0.07 
18:1 t11, VA 0.03 ± 0.00b 0.05 ± 0.01b 0.22 ± 0.01a 0.03 ± 0.00b 0.07 ± 0.01 0.10 ± 0.02 <0.001 0.001 <0.001 
18:2 c9,t11, RA 0.07 ± 0.01b 0.05 ± 0.00b 0.35 ± 0.01a 0.06 ± 0.01b 0.11 ± 0.02 0.15 ± 0.02 <0.001 <0.001 0.016 
18:2 c9,c12 (n-6), LA 15.14 ± 0.22b 13.96 ± 0.44b 12.19 ± 0.32c 16.46 ± 0.47a 15.64 ± 0.34 13.34 ± 0.33 <0.001 <0.001 - 
18:3 c6,c9,c12 (n-6), GLA  0.04 ± 0.00b 0.07 ± 0.02b 0.04 ± 0.01b 0.57 ± 0.04a 0.18 ±0.04 0.21 ± 0.05 <0.001 0.022 <0.001 
18:3 c9,c12,c15 (n-3), LNA 0.57 ± 0.02b 0.81 ± 0.14b 0.44 ± 0.02b 3.25 ± 0.18a 1.45 ± 0.23 1.26 ± 0.20 <0.001 - - 
18:4 c6,c9,c12,c15 (n-3), SDA  0.05 ± 0.01c 0.17 ± 0.01b  0.08 ± 0.01c 0.41 ± 0.03a 0.17 ± 0.02 0.22 ± 0.03 <0.001 0.005 - 
20:4 c5,c8,c11,c14 (n-6) 1.35 ± 0.15ab 0.55 ± 0.13c 2.00 ± 0.35a 1.14 ± 0.21b 0.77 ± 0.07 1.73 ± 0.22 <0.001 <0.001 0.001 
20:5 c5,c8,c11,c14,c17 (n-3), EPA 0.02 ± 0.00c 0.41 ± 0.05a 0.03 ± 0.01c 0.15 ± 0.03b 0.11 ± 0.03 0.20 ± 0.04 <0.001 <0.001 - 
22:5 c7,c10,c13,c16,c19 (n-3), DPA 0.16 ± 0.02c 0.39 ± 0.04ab 0.29 ± 0.05bc 0.51 ± 0.07a 0.28 ± 0.03 0.41 ± 0.05 <0.001 0.014 0.028 
22:6 c4,c7,c10,c13,c16,c19 (n-3), DHA 1.94 ± 0.32 2.64 ± 0.44 3.24 ± 0.67 3.21 ± 0.62 1.73 ± 0.18 3.90 ± 0.46 - <0.001 0.037 
          
Fatty acid classes          
S SFAs 22.64 ± 0.84b 27.66 ± 0.90a 24.54 ± 1.30ab 22.92 ± 1.04b 22.11 ± 0.50 26.84 ± 0.85 0.002 <0.001 - 
S MUFAs 57.12 ± 1.17a 51.77 ± 1.26ab 55.58 ± 2.15a 50.24 ± 1.58b 56.63 ± 0.74 50.20 ± 1.34 0.001 <0.001 0.06 
S PUFAs 20.25 ± 0.44b 20.05 ± 0.59b 19.88 ± 0.91b 26.85 ± 0.71a 21.26 ± 0.62 22.77 ± 0.79 <0.001 0.006 0.006 





1 Values are expressed as mean ± SEM. Means without a common letter (a-d) differ by diet (P < 0.05). BO, 70% CO supplemented 
with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EO: 70% CO 
supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO supplemented with 30%. GLA, !-linolenic acid. LA, 
linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, stearidonic acid. VA, vaccenic acid.
S n-6 FAs 17.04 ± 0.17b 14.88 ± 0.36c 14.81 ± 0.20c 18.69 ± 0.33a 16.98 ± 0.36 15.85 ± 0.30 <0.001 0.003 0.009 
S n-3 FAs 3.05 ± 0.36b 4.91 ± 0.55b 4.55 ± 0.75b 8.04 ± 0.70a 4.09 ± 0.35 6.56 ± 0.62 <0.001 <0.001 0.023 





Table 4.S10 Fatty acid composition (percent of total FAME) of liver tissue in CD-1 mice1 
 Diet
 Sex P value 
Fatty acid CO FO BO EO Male Female Diet Sex Diet*Sex 
15:0 0.07 ± 0.01b 0.12 ± 0.01a 0.14 ± 0.01a 0.08 ± 0.01b 0.11 ± 0.01 0.10 ± 0.01 <0.001 0.002 - 
16:0 22.55 ± 0.59b 25.73 ± 0.48a 22.40 ± 0.67b 22.46 ± 0.34b 22.33 ± 0.40 24.24 ± 0.42 <0.001 <0.001 - 
16:1 t9 0.01 ± 0.00b 0.01 ± 0.00b 0.03 ± 0.00a 0.01 ± 0.00b 0.01 ± 0.00 0.01 ± 0.00 <0.001 - - 
17:0 0.16 ± 0.01a 0.18 ± 0.01a 0.19 ± 0.01a 0.16 ± 0.01a 0.17 ± 0.01 0.17 ± 0.01 0.027 - - 
18:0 4.01 ± 0.32b 5.54 ± 0.49ab 4.40 ± 0.52ab 6.08 ± 0.68a 4.43 ± 0.31 5.53 ± 0.42 0.007 0.016 - 
18:1 c9 (n-9) 42.66 ± 1.28a 30.61 ± 1.60b 41.60 ± 1.75a 29.26 ± 1.74b 35.69 ± 1.59 36.23 ± 1.50 <0.001 - - 
18:1 t11, VA 0.03 ± 0.01b 0.02 ± 0.00b 0.12 ± 0.01a 0.02 ± 0.00b 0.05 ± 0.01 0.04 ± 0.01 <0.001 0.007 - 
18:2 c9,t11, RA 0.05 ± 0.02b 0.03 ± 0.00b 0.24 ± 0.02a 0.03 ± 0.00b 0.07 ± 0.02 0.09 ± 0.02 <0.001 - - 
18:2 c9,c12 (n-6), LA 16.51 ± 0.71ab 14.72 ± 0.50b 14.71 ± 0.83b 18.36 ± 0.63a 16.77 ± 0.56 15.49 ± 0.49 0.001 - - 
18:3 c6,c9,c12 (n-6), GLA  0.22 ± 0.02b 0.13 ± 0.02b 0.17 ± 0.01b 0.52 ± 0.05a 0.24 ± 0.03 0.28 ± 0.04 <0.001 0.013 0.030 
18:3 c9,c12,c15 (n-3), LNA 0.44 ± 0.02b 0.86 ± 0.17b 0.37 ± 0.03b 3.25 ± 0.29a 1.39 ± 0.25 1.10 ± 0.22 <0.001 - - 
18:4 c6,c9,c12,c15 (n-3), SDA  0.04 ± 0.01b 0.10 ± 0.01b 0.04 ± 0.01b 0.43 ± 0.06a 0.13 ± 0.03 0.18 ± 0.04 <0.001 0.003 <0.001 
20:4 c5,c8,c11,c14 (n-6) 3.73 ± 0.36ab 2.82 ± 0.31b 4.24 ± 0.60ab 5.10 ± 0.68a 3.78 ± 0.38 4.13 ± 0.38 0.019 - - 
20:5 c5,c8,c11,c14,c17 (n-3), EPA 0.08 ± 0.01c 2.61 ± 0.23a 0.11 ± 0.01c 1.22 ± 0.14b 1.08 ± 0.20 0.95 ± 0.21 <0.001 - - 
22:5 c7,c10,c13,c16,c19 (n-3), DPA 0.16 ± 0.02c 1.54 ± 0.19a 0.18 ± 0.03c 1.06 ± 0.14b 1.01 ± 0.15 0.49 ± 0.10 <0.001 <0.001 0.005 
22:6 c4,c7,c10,c13,c16,c19 (n-3), DHA 2.10 ± 0.22c 7.71 ± 0.76a 2.48 ± 0.34c 5.36 ± 0.59b 4.76 ± 0.62 4.13 ± 0.45 <0.001 - - 
          
Fatty acid classes          
S SFAs 27.51 ± 0.78b 32.34 ± 0.70a 28.11 ± 1.03b 29.76 ± 0.90ab 28.05 ± 0.62 30.80 ± 0.64 <0.001 <0.001 - 
S MUFAs 48.06 ± 1.56a 36.04 ± 1.92b 48.09 ± 2.15a 33.32 ± 1.97b 41.11 ± 1.85 41.43 ± 1.70 <0.001 - - 
S PUFAs 24.44 ± 1.20c 31.62 ± 1.62b 23.80 ± 1.47c 36.93 ± 1.34a 30.84 ± 1.44 27.77 ± 1.24 <0.001 - - 





1 Values are expressed as mean ± SEM. Means without a common letter (a-d) differ by diet (P < 0.05). BO, 70% CO supplemented 
with 30% dairy (butter) fat. CO, 100% U.S. fat blend. DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EO: 70% CO 
supplemented with 30% echium oil. EPA, eicosapentaenoic acid. FO, 70% CO supplemented with 30%. GLA, !-linolenic acid. LA, 
linoleic acid. LNA, "-linolenic acid. RA, rumenic acid. SDA, stearidonic acid. VA, vaccenic acid.
S n-6 FAs 21.41 ± 1.01b 18.48 ± 0.76b 20.14 ± 1.19b 25.42 ± 0.92a 22.17 ± 0.82 20.65 ± 0.78 <0.001 - - 
S n-3 FAs 2.84 ± 0.23c 14.11 ± 0.84a 3.19 ± 0.36c 11.41 ± 0.63b 8.53 ± 1.07 7.03 ± 0.82 <0.001 0.06 0.018 







Figure 4.1 Summary of diet-derived fatty acid content from fish oil, dairy fat, or echium oil in tissues and blood lipid fractions of CD-
1® mice at 14 months of age. All mice were fed a high-fat diet (40% of total energy) for 13 months comprised of 70% background fat 
(representative of the average U.S. American dietary fatty acid composition) and supplemented with 30% of either fish oil, dairy fat, or 
echium oil (signified by an icon of a fish, cow, or plant, respectively). Presence of an icon signifies that either 1) the respective diet 

























18:3 c6,c9,c12 (n-6), GLA
18:3 c9,c12,c15 (n-3), LNA
18:4 c6,c9,c12,c15 (n-3), SDA
Fish-derived
20:5 c5,c8,c11,c14,c17 (n-3), EPA
22:5 c7,c10,c13,c16,c19 (n-3), DPA





differentiated from the diet group with the greatest content of a fatty acid for the respective body tissue analyzed (as determined by two-
way ANOVA and post-hoc Tukey test). DHA, docosahexaenoic acid. DPA, docosapentaenoic acid. EPA, eicosapentaenoic acid. GLA, 
























Figure 4.2 Spearman correlation matrix of fish-derived fatty acid intake and content in 
tissues and blood fractions (% of total FAMEs): 20:5 c5,c8,c11,c14,c17 (A), 22:5 



























































































































































































































































































































































































































































































































signifies a significant (P < 0.05) positive correlation, and a larger circle signifies a stronger 






Figure 4.3 Spearman correlation matrix of dairy-derived fatty acid intake and content in 
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(D), and 18:2 c9,t11 (E). Presence of a white circle signifies a significant (P < 0.05) positive 






Figure 4.4 Spearman correlation matrix of echium-derived fatty acid intake and content in 

































































































































































































































































































































































































































































































































and 18:4 c6,c9,c12,c15 (C). Presence of a white circle signifies a significant (P < 0.05) 
positive correlation, and a larger circle signifies a stronger (i.e., closer to 1) correlation. 
 
Figure 4.S1 Spearman correlation matrix of 20:5 c5,c8,c11,c14,c17 n-3 intake and content 
in tissues and blood fractions (percent of total FAMEs). A positive correlation (closer to 1) 
is signified by a darker shade of blue; a negative correlation (closer to −1) is signified by a 
darker shade of red (P < 0.05). 
  















































































































































Figure 4.S2 Spearman correlation matrix of 22:5 c7,c10,c13,c16,c19 n-3 intake and 
content in tissues and blood fractions (percent of total FAMEs). A positive correlation 
(closer to 1) is signified by a darker shade of blue; a negative correlation (closer to −1) is 
signified by a darker shade of red (P < 0.05). 
  















































































































































Figure 4.S3 Spearman correlation matrix of 22:6 c4,c7,c10,c13,c16,c19 n-3 intake and 
content in tissues and blood fractions (percent of total FAMEs). A positive correlation 
(closer to 1) is signified by a darker shade of blue; a negative correlation (closer to −1) is 
signified by a darker shade of red (P < 0.05).
















































































































































Figure 4.S4 Spearman correlation matrix of 15:0 intake and content in tissues and blood 
fractions (percent of total FAMEs). A positive correlation (closer to 1) is signified by a 
darker shade of blue; a negative correlation (closer to −1) is signified by a darker shade of 
red (P < 0.05).
















































































































































Figure 4.S5 Spearman correlation matrix of 16:1 t9 intake and content in tissues and blood 
fractions (percent of total FAMEs). A positive correlation (closer to 1) is signified by a 
darker shade of blue; a negative correlation (closer to −1) is signified by a darker shade of 
red (P < 0.05).



























































































































Figure 4.S6 Spearman correlation matrix of 17:0 intake and content in tissues and blood 
fractions (percent of total FAMEs). A positive correlation (closer to 1) is signified by a 
darker shade of blue; a negative correlation (closer to −1) is signified by a darker shade of 
red (P < 0.05).















































































































































Figure 4.S7 Spearman correlation matrix of 18:1 t11 intake and content in tissues and 
blood fractions (percent of total FAMEs). A positive correlation (closer to 1) is signified 
by a darker shade of blue; a negative correlation (closer to −1) is signified by a darker shade 
of red (P < 0.05). 





































































































Figure 4.S8 Spearman correlation matrix of 18:2 c9,t11 intake and content in tissues and 
blood fractions (percent of total FAMEs). A positive correlation (closer to 1) is signified 
by a darker shade of blue; a negative correlation (closer to −1) is signified by a darker shade 
of red (P < 0.05).















































































































































Figure 4.S9 Spearman correlation matrix of 18:3 c9,c12,c15 n-3 intake and content in 
tissues and blood fractions (percent of total FAMEs). A positive correlation (closer to 1) is 
signified by a darker shade of blue; a negative correlation (closer to −1) is signified by a 
darker shade of red (P < 0.05).















































































































































Figure 4.S10 Spearman correlation matrix of 18:3 c6,c9,c12 n-6 intake and content in 
tissues and blood fractions (percent of total FAMEs). A positive correlation (closer to 1) is 
signified by a darker shade of blue; a negative correlation (closer to −1) is signified by a 
darker shade of red (P < 0.05). 















































































































































Figure 4.S11 Spearman correlation matrix of 18:4 c6,c9,c12,c15 n-3 intake and content in 
tissues and blood fractions (percent of total FAMEs). A positive correlation (closer to 1) is 
signified by a darker shade of blue; a negative correlation (closer to −1) is signified by a 
darker shade of red (P < 0.05).














































































































































CHAPTER 5: COLONIC BACTERIAL COMPOSITION IS SEX-
SPECIFIC IN AGED CD-1 MICE FED DIETS VARYING IN 
FAT QUALITY 
  
Allison L. Unger1, Korin Eckstrom2, Thomas L.  Jetton3, Jana Kraft1,3*  
 
1 Department of Animal and Veterinary Sciences, The University of Vermont, 
Burlington, VT, USA 
2 Department of Microbiology and Molecular Genetics, The University of Vermont, 
Burlington, VT, USA 
3 Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, The 
University of Vermont, Colchester, VT, USA 
 
* Corresponding author 






Evidence suggests that sex influences the effect of diet on the gut bacterial 
composition, yet, no studies have been performed assessing dietary fatty acid composition 
(i.e., fat quality) in this context. This study examined the effect of dietary fat quality on 
colonic bacterial composition in an aged, genetically-diverse mouse population. CD-1 mice 
were fed isoenergetic diets consisting of (1) control fat (CO; “Western-style” fat blend), 
(2) CO supplemented with 30% fish oil, (3) CO supplemented with 30% dairy fat, or (4) 
CO supplemented with 30% echium oil. Fecal samples were collected at mid-life and aged 
(reproductively senescent) time points. Overall, the abundance of Bacteroidetes was 
greater in mice fed echium oil compared to mice fed the control fat. Examination of colonic 
bacterial relative abundance also revealed sex differences, with 73 bacterial taxa being 
differentially expressed in males and females. Notably, results showed a strong interactive 
effect among the diet, sex, and age of mice which influenced colonic bacterial relative 
abundance and alpha diversity. In males, supplementation of the diet with dairy fat or 
echium oil caused the abundance of Bacteroidetes and Bacteroides to change with age. 
Additionally, supplementation of the diet with fish oil induced sex-dependent changes in 
the alpha diversity of aged mice compared to mid-life. This work supports that sex is a 
critical factor in colonic bacterial composition of an aged, genetically-heterogenous 
population. Moreover, this study establishes that the effectiveness of dietary interventions 
for health maintenance and disease prevention via direct or indirect manipulation of the gut 






The gut harbors a dynamic and complex bacterial community that plays a critical 
role in disease prevention and pathogenesis [1–3]. Compared to the number of the host’s 
cells in the body, the gut bacteria comprise a comparable cell number and contribute to as 
much as 0.3% of an individual’s body weight [4]. Yet, the number of bacterial genes is 
100-fold greater than that of the human host [5] and, consequently, they influence systemic 
host metabolism and immunity [3,6]. Conversely, many host-related factors, including age, 
diet, and genetic makeup, shape the gut bacterial community structure and hence their 
functional and metabolic characteristics [2,7,8]. 
The composition of the gut bacteria changes throughout an individual’s lifetime 
[9]. An infant has a highly variable gut bacterial population that rapidly develops until 
approximately the age of three [10]. During adulthood, the gut bacterial composition is 
relatively stable and dominated by the phyla Firmicutes and Bacteroidetes [11]. However, 
the gut bacteria population undergoes dramatic changes during the aging process. For 
instance, aging has been associated with a general decrease in bacterial diversity and 
increased prevalence of Bacteroidetes [12]. Changes in the gut bacterial composition have 
been correlated with inflammation, frailty, and several comorbidities [13,14]. While it is 
thought that the gut bacteria are key drivers of chronic low-grade inflammation, termed 
“inflammaging” [15] or immunosenescence [16], the underlying mechanisms are 
unknown. Yet, as the number of elderly individuals (65 years and older) is increasing 




to lifestyle patterns (e.g., diet preference) in an aged population is of critical importance 
for health maintenance and disease prevention.  
The “Western-style” diet, generally considered to be a dietary pattern high in 
saturated fatty acids (SFA) and simple carbohydrates while low in dietary fiber, has been 
shown to negatively impact the gut bacterial community structure, characterized by an 
increased ratio of Firmicutes to Bacteroidetes and a loss of bacterial diversity [18–22]. In 
addition, shifts in gut bacterial composition in response to a “Western-style” diet have been 
linked to metabolic risk factors such as obesity [23–27], inflammation [21,28,29], and 
altered energy homeostasis [22,23,29,30]. Nevertheless, the effect of dietary fatty acid 
(FA) composition on the gut bacterial community structure is not well established. Recent 
evidence in mouse studies demonstrated that diets comprising of oils rich in 
monounsaturated FA (MUFA, e.g., olive oil) or cold-water fatty fish rich in long-chain 
polyunsaturated FA (PUFA) have a range of effects on the gut bacterial composition 
compared to diets high in SFA [21,22,28]. However, it is important to note that these 
studies involved short-term diet manipulations, ranging from 4-11 weeks. 
A recent review [31] highlighted a striking sexual dimorphism in mammalian 
phenotypes and identified both a sex-bias and/or a lack of analysis by sex in medical 
research. Sex has been shown to play a key role in shaping the gut bacterial composition 
[32–34]. Although the mechanisms are not fully understood, the relationship between sex 
and the gut bacterial community structure is thought to be driven by differences in 
circulating sex hormones [35]. Although data are accumulating indicating that diet may 




are only a few mouse studies examining the interaction between the gut microbiota and 
diet have incorporated both sexes into the experimental design. 
It is also not known whether there are sex-specific physiological effects of a long-
term dietary intervention varying in fat quality in an aged population. Our study sought to 
compare the impact of three diets with different fat quality (i.e., FA composition) to the fat 
quality of a “Western-style” diet on the density, abundance, and diversity of colonic 
bacteria in a genetically heterogeneous, aged mouse population. Specifically, we 
supplemented diets with one of three dietary sources of unique FA conferring a distinct FA 
composition to each diet: fish oil (FO), rich in eicosapentaenoic acid and docosahexaenoic 
acid; dairy (butter) fat (BO), rich in short-, odd-, branched-chain FA, vaccenic acid, and 
conjugated linoleic acids; or echium oil (EO), rich in !- and "-linolenic acids and 
stearidonic acid. We hypothesized that a diet supplemented with dietary fats rich in unique 
FA (i.e., fish oil, dairy fat, and echium oil) lowers the ratio of Firmicutes to Bacteroidetes 
and enhances the diversity of colonic bacteria compared to a control fat reflecting the FA 
profile of a typical U.S. American diet [39] (i.e., Western-style diet) at mid-life and aged 
life stages. The objectives were to i) identify and quantify the composition of colonic 
bacteria, ii) classify the colonic bacteria at the phylum, genus, and operational taxonomic 
unit (OTU) level via 16S rRNA gene sequencing, and iii) analyze differences in abundance 






5.3.1 Metabolic parameters 
Body weight, feed intake, and feed efficiency were not different among diet groups 
(Table 5.S1). As expected, feed efficiency declined with age in both sexes (P < 0.001), and 
males had a greater body weight (P < 0.001) and feed efficiency (P < 0.001; Fig 5.1) than 
females (Table 5.1). Metabolic parameters of mice for all diet groups are shown in Table 
5.S1. 
 
5.3.2 Colonic bacterial density and abundance 
As obesity has been previously linked to changes in gut bacterial community 
structure [20,23–27,40], we sought to investigate the effect of animal weight on the colonic 
bacterial composition in aged mice. Surprisingly, when included as a covariate in the 
statistical model, body weight was found to have no effect on colonic bacterial density or 
abundance at the phylum level. As a covariate, body weight affected the abundance of 
several genera including Allobaculum, Anaerostipes, Blautia, and Lachnoclostridium (P < 
0.05).  
Age impacted the colonic bacterial density; mice at 13.5 months of age had a greater 
bacterial density than at 10.5 months of age (14.3 versus 13.9 log copies/µg fecal pellet, P 
< 0.001; Fig 5.2). Colonic bacterial density for diet groups, collapsed by sex and age, is 
shown in Table 5.S2.  
At the phylum level, abundance by counts of Bacteroidetes was 100% greater in 




in Fig 5.3A; P < 0.05). No differences among diet groups were observed in the abundance 
of other phyla. The abundance of Bacteroidetes (Table 5.2; relative abundance displayed 
in Fig 5.3B) was 17% greater and the ratio of Firmicutes to Bacteroidetes (Fig 5.3C) was 
59% lower in females than in males (P < 0.05). Notably, an interaction between diet, sex, 
and age (Table 5.2; P < 0.001) revealed that colonic bacterial abundance of Bacteroidetes 
changed inversely as aging occurred in BO-fed males vs. BO-fed females, and in EO-fed 
males vs. females (P < 0.01; relative abundance displayed in Fig 5.3D). Furthermore, at 
13.5 compared to 10.5 months of age, BO-fed males had a greater abundance of 
Bacteroidetes (10715 versus 3145, respectively P < 0.01), while EO-fed males had a lower 
abundance of Bacteroidetes (4360 versus 11954; P < 0.01). The abundance of colonic 
bacteria at the phylum level for diet groups, collapsed by sex and age, is shown in Table 
5.S2, while the relative abundance of bacteria at the phylum level for diet groups, 
segregated by sex and age, is shown in Figure 5.S1. 
At the genus level, colonic bacterial abundance did not differ among diet groups 
(Table 5.S3). Roseburia was over 20% more abundant in females than males (Table 5.3; 
relative abundance displayed in Figure 5.S2; P < 0.05). Compared to 10.5 months of age, 
abundance, by counts, of Barnesiella (315 versus 1406; P < 0.001), Bilophila (185 versus 
515; P < 0.01), Ruminococcus (319 versus 951; P < 0.01), and Turicibacter (323 versus 
1329; P < 0.01) was greater at 13.5 months of age compared to 10.5 months of age in 
females. The abundance by counts of Alistipes changed from 1468 to 237 in CO-fed males 
and from 331 to 1141 counts in CO-fed females (10.5 versus 13.5 months of age, 




abundance of Bacteroides changed from 1484 to 7314 counts in BO-fed males but from 
8643 to 3108 counts in EO-fed males (10.5 versus 13.5 months of age, respectively; relative 
abundance displayed in Figure 5.S3; P < 0.05). The abundance of colonic bacteria at the 
genus level for diet groups, collapsed by sex and age, is shown in Table 5.S3. The relative 
abundance of colonic bacteria at the genus level for diet groups, segregated by sex and age, 
is shown in Figure 5.S3. These data suggest that sex is an important factor in the effect of 
dietary fat quality on colonic bacterial composition in aged mice.  
To elucidate the observed sex differences in colonic bacterial composition of aged 
mice, analysis of colonic bacteria at the OTU level was performed. Core microbiome 
analysis of the average abundance of OTUs per sample showed that four colonic bacterial 
OTUs were specific to females, and seven colonic bacterial OTUs were specific to females; 
however, 66.5% of colonic bacterial abundance within individuals was not sex-specific 
(Fig 5.4A). A redundancy analysis constrained by sex further demonstrated a high 
variability in colonic bacterial relative abundance within and between samples with 
minimal overlap; sex contributed 6.3% of the variance (Fig 5.4B). However, an M-A plot 
illustrating the log-fold change of differentially abundant OTUs revealed that 73 OTUs 
were differentially abundant between males and females (false discovery rate < 0.05; Fig 
5.4C). The differentially abundant OTUs, mapped to the species level, are included in 
Table 5.S4. A heat map of percent read abundance of the top 20 bacterial OTUs in CD-1 
mice, segregated by diet, sex, and age is shown in Figure 5.S4. Overall, our data indicate 




distinct FA compositions may be influenced by a limited number of differentially abundant 
bacterial taxa. 
 
5.3.3 Colonic bacterial diversity 
 As a covariate, body weight had no effect on colonic bacterial diversity. We 
detected an interactive effect between sex and age on the number of observed genera in 
CD-1 mice (P < 0.001); in females, the number of observed genera changed from 66 to 74 
(10.5 and 13.5 months of age, respectively; P < 0.01). In addition, an interaction between 
diet, sex, and age (P < 0.05) revealed that the alpha diversity (Shannon’s Diversity Index) 
changed from 2.7 to 3.0 in FO-fed females, but changed from 2.6 to 2.3 in FO-fed males 
(10.5 versus 13.5 months of age, respectively). The colonic bacterial alpha diversity 
measurements for diet groups, collapsed by sex and age, are shown in Table 5.S5. Beta 
diversity (i.e., Bray-Curtis) was greater in males compared to females (P < 0.05; Fig 5.5). 
Taken together, these results provide evidence that aged males and females exhibit 
differences in colonic bacterial diversity. 
 
5.4 Discussion 
The purpose of this study was to examine if there is a sex-dependent effect of a 
long-term dietary intervention with distinct FA constituents on the colonic bacteria in an 
aged, outbred mouse population. In mice, it has been reported that a high-fat “Western-
style” diet increases the relative abundance of Firmicutes and decreases the relative 




with several metabolic abnormalities [21–24,38,41]. We found that mice consuming a diet 
supplemented with echium oil had a greater abundance of Bacteroidetes than mice fed a 
“Western-style” control fat. While there are only limited studies on the role of dietary fat 
quality in gut bacterial composition, de Wit et al. [22] demonstrated that mice fed a 45% 
fat (of total energy) diet of safflower oil rich in PUFA had a greater abundance of 
Bacteroidetes compared to mice fed palm oil. Byerley et al. [42] found that male rats fed a 
diet containing walnuts (18% of total energy), a dietary source rich in the PUFA !-linolenic 
acid (~14% of total FA) [43], exhibited a reduced the abundance of Bacteroidetes 
compared to rats fed a control diet without walnuts; yet, whether these changes were due 
to !-linolenic or another component of walnuts is unclear. Our study is the first to 
characterize the effects of echium oil, a unique plant (seed) oil, on colonic microbiota 
structure. Echium oil contains a significant proportion of PUFA, including !-linolenic acid, 
stearidonic acid, and "-linolenic acid (S6 Table). Although no studies have yet been 
conducted, it is conceivable that intake of these unique FA constituents may directly or 
indirectly modulate gut bacterial composition (e.g., changes in bile acid metabolism).  
In humans, we have previously demonstrated that a diet supplemented with dairy 
fat reduced the ratio of Firmicutes to Bacteroidetes compared to a control diet lacking dairy 
fat [44]. In the current study, we did not detect differences in the Firmicutes to 
Bacteroidetes ratio among the different diet groups. However, we observed an interaction 
between the effects of diet, sex, and age whereby in BO- and EO-fed mice, the abundance 
of Bacteroidetes, as well as the genus Bacteroides, changed inversely in males and females 




this pattern can likely be attributed to different study designs. In this study, the dietary fat 
sources of interest (fish oil, dairy fat, or echium oil, respectively) were supplemented at 
30% of total fat content, while other studies used 80-100% of an experimental fat source 
[21,22,28]. Although the experimental fat blends were intentionally formulated to reflect 
realistic human dietary patterns, this relatively conservative supplementation may have 
attenuated the potential impact of these dietary fat sources to induce colonic bacterial shifts. 
Additionally, other studies utilized inbred strains of mice, while this study intentionally 
employed an outbred stock to reflect human genetic variation. Hence, genetic diversity 
may be the reason why dietary fat quality did not have a pronounced effect on the colonic 
bacterial composition in this study. Another potential factor contributing to the 
inconsistency between results from other studies may be variability in resident colonic 
bacteria present among different animal husbandry facilities [45].    
We also hypothesized that a high-fat diet supplemented with unique FA would 
enrich the diversity of colonic bacteria compared to a “Western-style” control fat. Greater 
bacterial diversity is considered to be beneficial to host health by rendering the host more 
resilient to gastrointestinal insults and disease [46]. Thus far, results from mouse models 
suggest that diets higher in total SFA may reduce bacterial diversity [22], while studies in 
both mice and humans have indicated that diets rich in PUFA enhance bacterial diversity 
[22,47]. Specifically, supplementation of the diet with fish oil, rich in PUFA such as 
eicosapentaenoic acid and docosahexaenoic acid, has been shown to enhance alpha 
diversity in mice [48]. In our study, we also found that alpha diversity (Shannon’s Diversity 




oil (consisting of 40% PUFA; Table 5.4). Yet, no differences in alpha diversity of colonic 
bacteria were observed in mice fed a diet supplemented with echium oil (consisting of 72% 
PUFA; Table 5.4). Although there is limited research to distinguish the effects of dietary 
fats with different PUFA compositions on gut bacterial composition, these results suggest 
the possibility that consumption of very long-chain n-3 PUFA (e.g., docosahexaenoic acid) 
may have a more potent influence on colonic bacterial diversity than consumption of 
shorter chain n-3 PUFA (e.g., !-linolenic acid), either directly or indirectly. 
Studies have shown that, in general, a greater dietary diversity enriches gut bacterial 
diversity, likely due to enhanced substrate utilization and opportunity of cross-feeding 
among bacteria [49]. Moreover, it has been postulated that an increase in dietary FA 
diversity would also induce an enrichment of bacterial diversity [49]. This may also explain 
in part why the FO diet, comprising a greater FA diversity, increased colonic bacterial 
diversity compared to the CO diet. For this reason, we hypothesized that the BO diet, 
despite its high SFA content, would also lead to a greater colonic bacterial diversity due to 
the greater FA diversity (i.e., short-, odd-, and branched-chain FA; vaccenic acid; 
conjugated linoleic acids; Table 5.4). Yet, BO-fed mice did not exhibit an enhanced 
bacterial diversity compared to CO-fed mice. Despite the unique FA diversity of the BO 
diet, the concentration of these FA in the diet may have been too low to counterbalance the 
prevailing influence of the SFA in the BO diet to maintain bacterial diversity. The BO diet 
contained almost twice the SFA content compared to the CO diet (67% SFA compared to 




that no detectable changes in bacterial diversity were could be observed due to the high 
content of SFA in the BO diet.  
Similar to other studies, our study specifically investigated the relationship between 
body weight and colonic bacterial community structure. Because mice are coprophagous, 
and when caged in pairs, we expected for cage mates to be similar in gut bacterial 
community structure. As several studies suggest that body weight is intimately associated 
with gut bacterial composition [20,23–27,40], by extension, this indicates that mice housed 
together under the same dietary regime should also be similar in weight. However, our data 
revealed that body weight had limited effect colonic bacteria at the genus level. Moreover, 
neither the abundance of at the phylum level nor diversity of colonic bacteria were 
associated with body weight, despite considerable variation in the weight of cage mates. 
Thus, these observations point to the alternative hypothesis that obesity development may 
be independent of gut bacterial composition [19,50,51]. As we studied outbred CD-1 mice, 
a genetically heterogeneous stock, it is possible that other inherent factors, such as genetic 
diversity, contributed to the differences in body weight. In addition, a limitation of our 
study is that we were only able to measure feed intake on a cage basis; hence, feed intake 
may have varied between cage mates.  
Aging has been identified as a contributing factor in shaping the composition of gut 
bacteria, but only few longitudinal studies have been performed. Observational studies in 
humans revealed an increase in relative abundance of Bacteroidetes [12,52,53] and loss in 
bacterial diversity [54] following the transition to the geriatric age. However, confounding 




medical history) result in lack of a consistent pattern. Mouse studies have also reported 
conflicting results of age-related changes in the gut microbiota. Fransen et al. [15] reported 
a decreased ratio of Firmicutes to Bacteroidetes in aged mice (18 months old) compared 
to young mice (3 months old). Another study found no differences in the relative abundance 
of Firmicutes or Bacteroidetes but an increased alpha diversity and a variable beta diversity 
in aged mice (19 months old) compared to young mice (3 months old) [55]. While there 
were no changes in beta diversity in mice at a mid-life compared to an aged life stage in 
our study, alpha diversity (i.e., number of observed genera) increased in female mice with 
age. This study did not examine the colonic bacteria of frank geriatric mice (considered to 
be 18 months of age) due to advanced morbidity in our CD-1 mouse population 
investigated; however, our data further demonstrate that sex may, at least in part, influence 
the gut microbiota community structure in aged mice. More research is warranted to 
determine whether sex may play a role in modulating the effects of dietary fat quality on 
the colonic bacterial community structure in the frank geriatric population. 
Recent evidence implicates sex playing a role in gut bacterial composition [32–34], 
although the underlying mechanisms are not fully understood. Yurkovetskiy et al. [56] 
examined i) male, female, and castrated male NOD mice at pre- and post-pubescent ages, 
and ii) specific pathogen-free versus germ-free NOD mice, and concluded that androgens 
and the gut microbiota contribute equally to host health in the context of autoimmune 
diabetes. Org et al. [35] utilized gonadectomized mice and determined that the difference 
in circulating androgens between males and females contributed to microbiota changes. In 




been reported in humans [57,58]. Although our study did not incorporate gonadectomized 
mice, we also verified that sex is a key determinant of the colonic bacterial community 
structure in aged mice. In our study, sex was observed to affect bacterial diversity as aging 
progressed. In addition, we found that 73 colonic bacterial OTUs were differentially 
abundant in males versus females. This suggests that the greater abundance of 
Bacteroidetes and a lower ratio of Firmicutes to Bacteroidetes observed in females 
compared to males, respectively, may have been driven by a select number of colonic 
bacteria at the OTU level. In our study, there was a high level of variability between and 
within colonic bacterial samples as highlighted by redundancy analysis (Fig 5.4B). This 
variability, likely stemming from the genetic diversity inherent in the CD-1 mouse stock, 
is the probable underlying factor that prevented more pronounced differences in colonic 
bacterial composition between males and females.  Sampling a larger population may have 
elucidated more profound sex-specific differences in these heterogenous, aged mice. 
Overall, these results further emphasize the effect that sex of the host and, by inference, 
the sex hormone milieu, can exert on the gut bacterial community structure.  
The manner in which dietary patterns influence the gut bacteria is increasingly 
gaining interest, as the gut bacterial composition is now known to significantly contribute 
to an individual’s health status. Our work with the outbred CD-1 mouse model supports 
the hypothesis that sex is an important variable in colonic bacterial composition in an aged, 
genetically diverse population. Moreover, results from this study demonstrate a strong 
interactive effect between the diet, sex, and age of mice on the colonic bacterial community 




individual’s sex, age, and genetic background that collectively factors into the 
susceptibility of the gut bacteria to undergo population changes in response to diet. While 
our study solely assessed modifications to the colonic bacterial composition, such changes 
are indicative of its derived metabolites that affect the systemic metabolism of the host. 
Accordingly, this study has important implications for the development of nutritional 
strategies to maintain health and, by extension, mitigate risk of disease in humans. Moving 
forward, further research is needed to ascertain whether dietary fat quality shapes the gut 
bacterial composition in a direct or indirect manner, and whether and to what degree host 
factors facilitate the interaction pathways. 
 
5.5 Methods 
5.5.1 Animals and experimental design 
 All procedures were approved by and performed in accordance with guidelines and 
regulations of The University of Vermont Institutional Animal Care and Use Committee 
(#16-007). Eighty-one male and female outbred mice (CD-1® IGS #022) were purchased 
from Charles River (Raleigh, NC, USA), an ideal aging rodent model with a genetic 
variability comparable to the human population compared to other inbred strains [59–61]. 
At the age of three weeks, mice arrived in two shipping boxes, segregated by sex, and were 
immediately randomized into cages. Mice were housed in ventilated racks (Thorens Caging 
Systems, Hazelton, PA, USA) in same-sex pairs, with the exception of one group of three, 
on a 12-hour light/dark cycle at 23.6°C with 64% humidity. Mice were adjusted to their 
new environment for one week; during this time mice were fed a laboratory chow diet 




3000, LabDiet, St. Louis, MO, USA). After acclimatization, mice (n=10-11/group) were 
fed one of the following high-fat (40% kcal) diets for 13 months: i) CO: 100% control fat 
(U.S. fat blend), ii) FO: 70% CO + 30% fish (menhaden) oil, iii) BO: 70% CO + 30% dairy 
(butter) fat, or iv) EO: 70% CO + 30% echium oil; Table 5.4).  
 Mice were provided with feed and water ad libitum for the entirety of the study. 
Body weight was recorded weekly until three months of age, and thereafter every four 
weeks for the remainder of the study. Feed intake was determined on a cage basis at weekly 
intervals. 
 
5.5.2 Experimental diets 
Diets were identical with the exception of the FA composition. All fat blends, 
except for the addition of fish oil, were prepared in-house. The U.S. fat blend was designed 
of lard, walnut oil, high-oleic sunflower oil, coconut oil, and palm oil in a ratio of 
18.8:3.6:2.8:1.8:1.0 to reflect the FA profile of an average U.S. American diet [39] (Table 
5.4). Pure butter fat was separated from water through gentle heating of butter into a liquid 
phase and subsequent centrifugation at 3,434 g at 4°C for 60 min (Sorvall Legend RT 
Centrifuge, ThermoFisher Scientific, Waltham, MA, USA) to yield a solid supernatant of 
pure butter fat. Echium oil was procured from Technology Crops International (Winston-
Salem, NC, USA). Dairy fat and echium oil replaced 30% (by weight) of U.S. fat blend to 
produce BO and EO fat blends, respectively. Fat blends were sent to Research Diets, Inc. 
(Brunswick, NJ, USA) to be incorporated into the diets (pelleted form). In the case of the 




the U.S. fat blend on-site at Research Diets, Inc. All experimental diets were isoenergetic 
and consisted of 17% protein, 43% carbohydrates, and 40% fat (Table 5.4). The complete 
FA composition of the experimental fat supplements is shown in S6 Table. 
 
5.5.3 Fatty acid analysis of experimental fat blends 
Experimental fat blends were prepared as FA methyl esters and analyzed via gas-
liquid chromatography analysis following the method described by Bainbridge et al. [62].  
 
5.5.4 Fecal collection and DNA extraction 
 Fecal collection was carried out at 10.5 and 13.5 months of age to represent the 
colonic bacterial community structure at mid-life (adult) and aged (reproductively 
senescent) life stages, respectively. Due to logistical reasons (e.g., number of metabolism 
cages), two cages (cage mates in sets of two or three; n=4-5/sex/diet group) were selected 
for analysis of the colonic bacteria. Morbidity of one CO-fed male and poor DNA quality 
after isolation from a fecal sample of another CO-fed male caused two rather than four 
samples to be analyzed at 10.5 months of age. At 13.5 months of age, fecal samples were 
collected from an additional nine mice fed dairy fat (n = 8-9/sex/BO diet). Our secondary 
objective was to examine the effect of body weight on the colonic bacterial composition; 
obesity has previously been associated with changes in gut microbiota community structure 
[20,23–26,40]. Accordingly, mice that were selected for analysis of colonic bacterial 





 Fecal samples were collected in 70% ethanol over a 24-hour period via individual 
metabolism cages (Techniplast, West Chester, PA, USA) and stored at 4°C for subsequent 
DNA extraction. Total microbial DNA was extracted via QIAmp DNA Stool Mini Kit 
(Qiagen, Germantown, MD, USA) following the method of Yu and Morrison [63]. 
Modifications described in Cersosimo et al. [64] were followed with an additional 
modification of using 50% more InhibitEx per sample. The DNA extract was verified for 
adequate concentration and purity via Nanodrop 2000c Spectrophotometer (ThermoFisher 
Scientific, Waltham, MA, USA) and stored at -20°C until PCR amplification.  
 
5.5.5 PCR amplification 
 The V1-V3 region of the 16S rRNA gene was amplified using the bacteria-specific 
primer pair 27F and 519R (Integrated DNA Technologies, Skokie, IL, USA) on the 
GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA, USA). Each PCR 
reaction contained 50 μL total volume with 2 μL of extracted DNA (diluted to 10 ng/μL). 
The PCR program consisted of the following: hot start at 98°C held for 3 min; 30 cycles of 
98°C for 30 sec, 56°C for 30 sec, 72°C for 45 sec; an extension at 72°C for 3 min; then 
held at 8°C. A positive control of Bacteroides vulgatus (American Type Culture Collection, 
Manassas, VA, USA) and a negative control of RT-PCR Grade Water (ThermoFisher 
Scientific, Waltham, MA, USA) were used with all reactions. The PCR products were 
verified for appropriate amplicon length via gel electrophoresis and for adequate 




USA). Amplicons were stored at -20°C before shipment to Molecular Research DNA 
(Shallowater, TX, USA) for sequencing and bioinformatics analysis.  
 
5.5.6 Real-Time PCR amplification  
 Real-time PCR was performed in triplicate via BioRad C1000 Touch Thermocycler 
(BioRad, Hercules, CA, USA) to determine bacterial density. Each PCR reaction 
contained: 12.5 μL of iQ SYBR Green Super Mix (BioRad, Hercules, CA, USA), 6.5 μL 
of RT-PCR Grade Water (ThermoFisher Scientific, Waltham, MA, USA), 2.5 μL of primer 
pair 1114F and 1275R (Integrated DNA Technologies, Skokie, IL, USA) for the 16S rRNA 
gene [65], and 1 μL of sample DNA. The PCR program was as follows: hot start of 98°C 
for 3 min; 40 cycles of 95°C for 10 sec and 60°C for 30 sec; a final melting curve analysis 
of the fluorescence performed between 55°C and 95°C, with increments of 0.5°C every 5 
sec. Positive controls and standards of Bacteroides vulgatus (American Type Culture 
Collection, Manassas, VA, USA) in serial dilution (10 ng μL−1) and negative controls of 
RT-PCR Grade Water (ThermoFisher Scientific, Waltham, MA, USA) were used with all 
reactions. Only reaction plates with a serial dilution of standards that yielded an R2 value 
greater than or equal to 0.997 were included in analysis.  
 Determination of bacterial density did not account for variation in potential number 
of 16S rRNA-encoding genes per bacterium. Mean individual bacterial densities were 
calculated as bacterial copies per µg wet fecal pellet, under the assumption of one 16S 





5.5.7 Sequencing and bioinformatics analysis 
 At Molecular Research DNA (Shallowater, TX, USA), amplicons were prepared 
for sequencing with the addition of barcodes to forward primers of amplicons via PCR. 
PCR products were checked via gel electrophoresis. Samples were pooled and purified 
using Ampure XP beads (Agencourt Bioscience Corporation, MA, USA). Library 
preparation then ligated adapter sequences to the samples. Amplicons were sequenced via 
Illumina Miseq (v.3) following manufacturer's guidelines and sequences were processed 
using the MRDNA analysis pipeline. Briefly, paired-end sequences were combined and 
depleted of barcodes using usearch with an average length of 550 base pairs and non-
overlapping reads were removed; sequences were trimmed with a quality score cut-off of 
25; any sequences with <200 base pairs or with ambiguous base calls were excluded. 
Sequences were denoised, OTUs were generated based on 97% similarity using usearch, 
and chimeras were detected and removed using uchime. The mean sequencing depth was 
27,536 reads, with a minimum of 9,953 and a maximum of 76,590 reads. OTUs were 
taxonomically classified using BLASTn top hit and compiled into text files by raw counts.  
 In-house, colonic bacterial abundance and diversity analyses were conducted in R 
version 3.5.1 using the packages phyloseq [67] and ampvis2 [68] and differential OTU 
abundance via the package edgeR [69]. Normalization and transformations were conducted 
by normalizing to the total sequences per sample to calculate read abundance (library size) 
and transformed via TMM (differential OTU analysis) or Hellinger transformations for 




Sequencing files are available via the Sequence Read Archive (SRA) under the accession 
number PRJNA484010.   
 
5.5.8 Statistical analysis 
 Body weight, feed intake, feed efficiency, colonic bacterial density and alpha 
diversity, and the ratio of Firmicutes to Bacteroidetes were analyzed with PROC MIXED 
in SAS 9.4 (SAS Institute, Cary, NC). Colonic bacterial counts (i.e., abundance) at the 
phylum and genus level were analyzed with PROC GLIMMIX in SAS 9.4 (SAS Institute, 
Cary, NC). Poisson or negative binomial distribution was assumed to provide the best fit 
for each dependent variable, determined by whether or not there was over-dispersion. Both 
models included the fixed effects of diet, sex, and age and the random effect of cage with 
body weight as a covariate. Post hoc contrast statements were chosen to determine 
unadjusted pairwise differences due to the quantity of interactions present in the statistical 
model. Feed efficiency, colonic bacterial density, the ratio of Firmicutes to Bacteroidetes, 
and the colonic bacterial relative abundance were graphed in GraphPad Prism version 7.00 
(GraphPad Software, La Jolla, CA, USA). Differences in beta diversity (Bray-Curtis) were 
determined in the R package vegan [70] and included the factors of diet, sex, and age.  
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Table 5.S5 Colonic bacterial alpha diversity measurements of male and female CD-
1 mice collapsed by sex and age. Values are expressed as mean ± standard error of the 
mean. *P < 0.05; ***P < 0.001. 
Table 5.S6 Fatty acid composition of fat supplements. 
Figure 5.S1(A) Relative abundance of bacteria at the phylum level of male and 
female CD-1 mice fed “Western-style” control fat (CO) at 10.5 and 13.5 months of age. 
(B) Relative abundance of bacteria at the phylum level of male and female CD-1 mice fed 
CO supplemented with 30% fish oil (FO) at 10.5 and 13.5 months of age. (C) Relative 
abundance of bacteria at the phylum level of male and female CD-1 mice fed CO 
supplemented with 30% dairy fat (BO) at 10.5 and 13.5 months of age. (D) Relative 
abundance of bacteria at the phylum level of male and female CD-1 mice fed CO 
supplemented with 30% echium oil (EO) at 10.5 and 13.5 months of age.  
Figure 5.S2 Relative abundance of bacteria at the genus level of male and female 
CD-1 mice collapsed by diet group and age.   
Figure 5.S3 (A) Relative abundance of bacteria at the genus level of male and 
female CD-1 mice fed “Western-style” control fat (CO) at 10.5 and 13.5 months of age. 
(B) Relative abundance of bacteria at the genus level of male and female CD-1 mice fed 
CO supplemented with 30% fish oil (FO) at 10.5 and 13.5 months of age. (C) Relative 
abundance of bacteria at the genus level of male and female CD-1 mice fed CO 
supplemented with 30% dairy fat (BO) at 10.5 and 13.5 months of age. (D) Relative 
abundance of bacteria at the genus level of male and female CD-1 mice fed CO 




Figure 5.S4 Heat map of read abundance of the 20 most abundant colonic bacterial 





Table 5.1 Body weight, feed intake, and feed efficiency of male and female CD-1 mice 
collapsed by diet group and age. Values are expressed as mean ± standard error of the 
mean. *P < 0.05; **P < 0.01; ***P < 0.001. 
          P value 
Parameter Male SEM Female SEM D1 S2 A3 DxS DxA SxA DxSxA 
Body weight (g) 62.1 1.5 40.2 2.4 - *** * - - - - 
Feed intake (g/day) 3.6 0.1 3.1 0.1 - - ** - ** - - 
Feed efficiency4 0.006 0.000 0.004 0.001 - *** *** - - *** - 






Table 5.2 Colonic bacterial abundance by counts at the phylum level1 of male and female 
CD-1 mice collapsed by diet group and age. Values are expressed as mean ± standard error 
of the mean. *P < 0.05; ***P < 0.001. 
  
    P value 
Phylum Male SEM Female SEM D2 S3 A4 DxS DxA SxA DxSxA 
Bacteroidetes 6583 1115 7722 887 * * - - - - *** 
Firmicutes 22838 2935 15219 1565 - - - - - * - 
Proteobacteria 312 82 843 452 - - - - - - - 
Verrucomicrobia 590 279 614 233 - - - - - - - 





Table 5.3 Colonic bacterial abundance by counts at the genus level1 of male and female 
CD-1 mice collapsed by diet group and age. Values are expressed as mean ± standard error 
of the mean. *P < 0.05; **P < 0.01; ***P < 0.001. 
   P value 
Genus Male SEM Female SEM D2 S3 A4 DxS DxA SxA DxSxA 
Akkermansia 590 279 614 233 - - - - - - - 
Alistipes 799 109 1608 211 - - - - - *** * 
Allobaculum 3151 880 997 571 - - - - - - - 
Anaerostipes 323 51 371 82 - - - - - - - 
Bacteroides 4469 908 4085 698 - - - - - - * 
Barnesiella 326 57 934 204 - - *** - - ** - 
Bilophila 216 44 373 77 - - * - - * - 
Blautia 448 43 553 84 - - - - - - - 
Clostridium 7167 981 6325 660 - - - - - - - 
Eubacterium 210 43 363 60 - - - - - - - 
Lachnoclostridium 338 31 350 45 - - - - - - - 
Lactobacillus 7716 1734 2372 507 - - - - - - - 
Oscillospira 813 105 784 72 - - - - - - - 
Parabacteroides 904 210 1023 175 - - - - - - - 
Roseburia 380 55 494 58 - * - - - - - 
Ruminococcus 269 53 678 320 - - - - - * - 
Turicibacter 723 179 894 260 - - ** - - * - 





Table 5.4 Composition of experimental diets. 
 
 Diet 
Diet component CO FO BO EO 
 g/kg diet 
Basal diet mix1 790 790 790 790 
Fiber 50 50 50 50 
U.S. fat blend2 210 147 147 147 
Fish oil supplement3 - 63 - - 
Dairy fat supplement - - 63 - 
Echium oil supplement - - - 63 
 % of energy 
Protein 17 17 17 17 
Carbohydrate 43 43 43 43 
Fat 40 40 40 40 
Fatty acid composition g/100g total fatty acids 
Σ SFA4 37.32 33.51 67.05 10.29 
Σ MUFA5 39.69 21.98 26.66 15.77 
Σ PUFA6 22.82 39.93 4.52 71.88 
Key fatty acids     
Σ SCFA7 0.57 0.00 6.16 0.00 
Σ OBCFA8 0.29 1.92 4.17 0.10 
18:1 t11 0.03 0.00 1.84 0.00 
Σ CLA9 0.07 0.03 0.87 0.00 
Σ n-3 2.36 31.17 0.99 48.28 
18:3 c9,c12,c15 2.27 1.77 0.81 34.48 
18:4 c6,c9,c12,c15 0.00 2.16 0.00 13.39 
20:4 c8,c11,c14,c17 0.00 1.08 0.04 0.00 
20:5 c5,c8,c11,c14,c17 0.00 14.80 0.06 0.00 
22:5 c7,c10,c13,c16,c19 0.03 2.63 0.10 0.00 
22:6 c4,c7,c10,c13,c16,c19 0.00 9.56 0.00 0.00 
Σ n-6 20.31 3.96 1.82 23.58 
18:2 c9,c12 19.66 1.18 1.61 13.86 
18:3 c6,c9,c12 0.01 0.29 0.02 9.65 
20:4 c5,c8,c11,c14 0.14 1.32 0.10 0.00 
n-6/n-3 ratio 8.6 0.1 1.8 0.5 
1Supplied and formulated by Research Diets Inc. 2U.S. fat blend consisted of lard, walnut 
oil, high-oleic sunflower oil, coconut oil, and palm oil in a ratio of 18.8:3.6:2.8:1.8:1.0. 




monounsaturated fatty acids. 6PUFA: polyunsaturated fatty acids. 7SCFA: short-chain fatty 
acids (4:0-8:0). 8OBCFA: odd- and branched-chain fatty acids (5:0; 7:0; 9:0; 11:0; 13:0; 
13:0 iso; 13:0 aiso; 14:0 iso; 15:0; 15:0 iso; 15:0 aiso; 15:0; 16:0 iso; 17:0; 17:0 iso; 17:0 
aiso; 18:0 iso; 17:1 c8; 17:1 c9; 17:1 t10; 19:0; 21:0; 23:0). 9CLA: conjugated linoleic 
acids (18:2 t7/t9/t10,t12; 18:2 c8,c10; 18:2 t8,c10/t7,c9; 18:2 c9,c11; 18:2 c9,t11; 18:2 





Table 5.S1 Body weight, feed intake, and feed efficiency of CD-1 mice collapsed by sex and age. Values are expressed as mean ± 
standard error of the mean. *P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001. 
                            P value 
Parameter  CO1 SEM  FO2 SEM  BO3 SEM  EO4 SEM  D5 S6 A7 D*S D*A S*A D*S*A 
Body weight (g)  44.1 2.7 
 56.7 4.9  50.9 3.5  51.2 3.6  - *** * - - - - 
Feed intake (g/day)  3.1 0.2 
 3.6 0.1  3.3 0.1  3.4 0.0  - - ** - ** - - 
Feed efficiency8 
 
0.005 0.000  0.006 0.001  0.005 0.001  0.005 0.001  - *** *** - - *** - 
1CO: CD-1 mice fed a “Western-style” control fat. 2FO: CD-1 mice fed CO supplemented with 30% fish oil. 3BO: CD-1 mice 
fed CO supplemented with 30% dairy fat. 4EO: CD-1 mice fed CO supplemented with 30% echium oil. 5D: Diet. 6S: Sex. 7A: 




Table 5.S2 Colonic bacterial density and abundance by counts at the phylum level1 of CD-1 mice collapsed by sex and age. Values 
are expressed as mean ± standard error of the mean. *P < 0.05; ***P < 0.001. 
                            P value 
  CO2 SEM  FO3 SEM  BO4 SEM  EO5 SEM  D6 S7 A8 D*S D*A S*A D*S*A 
Density9  14.0 0.1  14.1 0.1  14.2 0.1  14.1 0.1  - - *** - - - - 
Phylum                     
     Bacteroidetes  4613 594  5234 657  8316 1444  9248 1767 
 * * - - - - *** 
     Firmicutes  17979 3098  22701 4832  16337 2274  20108 3744 
 - - - - - * - 
     Proteobacteria  255 65  499 130  1096 670  192 58 
 - - - - - - - 
     Verrucomicrobia 
 
173 68  128 66  1193 423  536 388  - - - - - - - 
     Firmicutes:Bacteroidetes                    
     ratio 
 
5.7 1.7  6.3 1.9  4.3 1.0  5.5 2.0  - * - - - - - 
1Mean relative abundance > 1%. 2CO: CD-1 mice fed a “Western-style” control fat. 3FO: CD-1 mice fed CO supplemented with 30% 
fish oil. 4BO: CD-1 mice fed CO supplemented with 30% dairy fat. 5EO: CD-1 mice fed CO supplemented with 30% echium oil. 6D: 




Table 5.S3 Colonic bacterial abundance by counts at the genus level1 of CD-1 mice collapsed by sex and age. Values are expressed 
as mean ± standard error of the mean. *P < 0.05; ∗∗P < 0.01; ***P < 0.001. 
              P value 
Genus  CO2 SEM  FO3 SEM  BO4 SEM  EO5 SEM  D6 S7 A8 D*S D*A S*A D*S*A 
Akkermansia  173 68  128 66  1193 423  536 388  - - - - - - - 
Alistipes  698 215  933 198  1207 134  1855 385  - - - - - *** * 
Allobaculum  2491 1761  3351 1492  1457 516  1414 789  - - - - - - - 
Anaerostipes  397 179  313 104  308 50  392 85  - - - - - - - 
Bacteroides  2558 381  3111 421  5307 1256  5210 1363  - - - - - - * 
Barnesiella  534 184  672 197  486 145  885 345  - - *** - - ** - 
Bilophila  231 69  493 129  286 82  182 58  - - * - - * - 
Blautia  590 178  353 58  458 48  624 104  - - - - - - - 
Clostridium  6751 1324  6749 1302  5805 743  8023 1509  - - - - - - - 
Eubacterium  489 141  268 61  177 35  302 68  - - - - - - - 
Lachnoclostridium  377 96  269 46  325 35  412 51  - - - - - - - 
Lactobacillus  3687 1130  8663 3110  3916 1356  4300 1533  - - - - - - - 
Oscillospira  760 139  710 145  789 106  920 130  - - - - - - - 
Parabacteroides  784 201  474 72  1281 283  1099 327  - - - - - - - 
Roseburia  466 118  366 68  394 47  541 102  - * - - - - - 
Ruminococcus  571 189  167 36  241 70  1003 639  - - - - - * - 
Turicibacter  302 122  632 202  1195 349  826 350  - - ** - - * - 
1Mean relative abundance > 1%. 2CO: CD-1 mice fed a “Western-style” control fat. 3FO: CD-1 mice fed CO supplemented with 30% 
fish oil. 4BO: CD-1 mice fed CO supplemented with 30% dairy fat. 5EO: CD-1 mice fed CO supplemented with 30% echium oil. 6D: 




Table 5.S4 M-A plot results of differentially abundant (P < 0.05) colonic bacterial OTUs in males (positive logFC) versus in females 
(negative logFC) collapsed by diet group and age. 
OTU logFC logCPM PValue FDR Kingdom Phylum Class Order Family Genus Specdddsssies 
OTU_726 4.0286 7.0152 3.37E-08 0.0003 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_10053 -2.9683 8.5972 3.55E-08 0.0003 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides intestinalis 
OTU_30306 5.6427 9.8907 3.85E-08 0.0003 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__anaerostipes s__anaerostipes sp. 
OTU_13058 3.981 10.1621 5.28E-08 0.0003 k__bacteria p__firmicutes c__bacilli o__lactobacillales f__lactobacillaceae g__lactobacillus s__lactobacillus johnsonii 
OTU_23 -5.2661 11.2058 6.13E-08 0.0003 k__bacteria p__firmicutes c__bacilli o__lactobacillales f__lactobacillaceae g__lactobacillus s__lactobacillus intestinalis 
OTU_48 -3.8029 9.1853 3.36E-07 0.0014 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__rikenellaceae g__alistipes s__alistipes spp. 
OTU_744 2.9377 6.9317 1.40E-06 0.005 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__blautia s__blautia producta 
OTU_7056 3.4295 6.7281 1.63E-06 0.0051 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_693 -2.3706 7.1657 1.97E-06 0.0052 k__bacteria p__firmicutes c__clostridia o__clostridiales f__peptococcaceae g__peptococcus s__peptococcus sp. 
OTU_33634 2.7641 6.763 2.10E-06 0.0052 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium spp. 
OTU_21622 2.8848 6.6709 2.32E-06 0.0053 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_892 -3.4932 7.1671 2.78E-06 0.0058 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__roseburia s__roseburia sp. 
OTU_8833 -2.7467 8.1946 3.00E-06 0.0058 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__porphyromonadaceae g__parabacteroides s__parabacteroides distasonis 
OTU_346 3.5347 7.0826 3.35E-06 0.006 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__coprococcus s__coprococcus eutactus 
OTU_42 2.1281 11.1603 4.16E-06 0.0067 k__bacteria p__firmicutes c__clostridia o__clostridiales f__peptostreptococcaceae g__romboutsia s__romboutsia ilealis 
OTU_543 -3.0785 6.7998 4.25E-06 0.0067 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__porphyromonadaceae g__barnesiella s__barnesiella spp. 
OTU_297 3.2933 8.6448 5.35E-06 0.0076 k__bacteria p__firmicutes c__bacilli o__lactobacillales f__lactobacillaceae g__lactobacillus s__lactobacillus johnsonii 
OTU_5618 -3.1468 6.741 5.65E-06 0.0076 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__blautia s__blautia producta 
OTU_28116 3.6925 7.6365 5.75E-06 0.0076 k__bacteria p__firmicutes c__bacilli o__lactobacillales f__lactobacillaceae g__lactobacillus s__lactobacillus johnsonii 
OTU_103 2.2417 10.6225 6.48E-06 0.0081 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium spp. 




OTU_962 3.2739 7.4751 9.14E-06 0.01 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_2113 2.8725 6.6062 9.19E-06 0.01 k__bacteria p__actinobacteria c__actinobacteria o__bifidobacteriales f__bifidobacteriaceae g__bifidobacterium s__bifidobacterium pseudolongum 
OTU_459 -2.4735 7.5697 1.07E-05 0.0111 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides stercorirosoris 
OTU_1331 -2.0863 8.2877 1.32E-05 0.013 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides uniformis 
OTU_33606 2.4848 6.8385 1.35E-05 0.013 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiales g__intestinimonas s__intestinimonas butyriciproducens 
OTU_384 -5.1027 7.5597 1.43E-05 0.0133 k__bacteria p__firmicutes c__clostridia o__clostridiales f__eubacteriaceae g__eubacterium s__eubacterium coprostanoligenes 
OTU_2410 2.8758 6.6644 1.65E-05 0.0147 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_134 3.6881 8.7057 2.21E-05 0.0191 k__bacteria p__firmicutes c__bacilli o__lactobacillales f__lactobacillaceae g__lactobacillus s__lactobacillus reuteri 
OTU_1271 3.7348 6.9942 2.74E-05 0.0229 k__bacteria p__firmicutes c__erysipelotrichia o__erysipelotrichales f__erysipelotrichaceae g__allobaculum s__allobaculum sp 
OTU_108 3.3155 8.0349 2.95E-05 0.0231 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_1152 -2.4918 7.1491 2.96E-05 0.0231 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides intestinalis 
OTU_32542 2.46 6.8697 3.09E-05 0.0234 k__bacteria p__firmicutes c__erysipelotrichia o__erysipelotrichales f__erysipelotrichaceae g__allobaculum s__allobaculum sp 
OTU_4226 2.1555 11.7558 3.32E-05 0.0239 k__bacteria p__firmicutes c__bacilli o__lactobacillales f__lactobacillaceae g__lactobacillus s__lactobacillus johnsonii 
OTU_4573 -2.3463 7.0551 3.34E-05 0.0239 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides uniformis 
OTU_162 1.7875 8.5221 4.10E-05 0.0285 k__bacteria p__firmicutes c__clostridia o__clostridiales f__ruminococcaceae g__oscillospira s__oscillospira spp. 
OTU_2770 3.2417 7.3033 4.26E-05 0.0288 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_9674 3.136 6.9772 4.75E-05 0.0301 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_25339 3.2011 6.6724 4.77E-05 0.0301 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_29658 -2.6141 7.2803 4.90E-05 0.0301 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides intestinalis 
OTU_1701 -2.3449 6.5762 4.93E-05 0.0301 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__porphyromonadaceae g__barnesiella s__barnesiella spp. 
OTU_288 -2.1835 8.5786 5.21E-05 0.031 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__porphyromonadaceae g__parabacteroides s__parabacteroides distasonis 
OTU_5723 -2.2407 7.2747 5.42E-05 0.0316 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__rikenellaceae g__alistipes s__alistipes senegalensis 
OTU_4682 3.0689 6.7041 5.58E-05 0.0317 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_7282 2.4407 6.534 5.86E-05 0.0326 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__roseburia s__roseburia faecis 
OTU_174 -3.0049 8.617 6.29E-05 0.0335 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__roseburia s__roseburia sp. 




OTU_941 2.2498 6.7731 6.43E-05 0.0335 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides xylanolyticus 
OTU_10407 2.7349 7.0029 6.58E-05 0.0336 k__bacteria p__firmicutes c__erysipelotrichia o__erysipelotrichales f__erysipelotrichaceae g__allobaculum s__allobaculum sp 
OTU_30843 2.099 10.2323 6.84E-05 0.0343 k__bacteria p__firmicutes c__bacilli o__lactobacillales f__lactobacillaceae g__lactobacillus s__lactobacillus johnsonii 
OTU_27415 5.1202 7.6456 7.27E-05 0.0353 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__roseburia s__roseburia faecis 
OTU_1 2.1564 16.8102 7.36E-05 0.0353 k__bacteria p__firmicutes c__bacilli o__lactobacillales f__lactobacillaceae g__lactobacillus s__lactobacillus johnsonii 
OTU_19915 3.3749 8.0894 7.55E-05 0.0353 k__bacteria p__firmicutes c__erysipelotrichia o__erysipelotrichales f__erysipelotrichaceae g__allobaculum s__allobaculum sp 
OTU_7464 2.5908 6.5547 7.60E-05 0.0353 k__bacteria p__firmicutes c__erysipelotrichia o__erysipelotrichales f__erysipelotrichaceae g__holdemanella s__eubacterium biforme 
OTU_11209 2.2315 6.5039 7.96E-05 0.0357 k__bacteria p__firmicutes c__erysipelotrichia o__erysipelotrichales f__erysipelotrichaceae g__holdemanella s__eubacterium biforme 
OTU_7257 2.5055 6.6961 8.07E-05 0.0357 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_861 -2.195 7.4927 8.12E-05 0.0357 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides uniformis 
OTU_1138 2.5135 6.8576 9.13E-05 0.0394 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__blautia s__ruminococcus gnavus 
OTU_1244 -2.0344 6.848 9.70E-05 0.0412 k__bacteria p__firmicutes c__clostridia o__clostridiales f__eubacteriaceae g__eubacterium s__eubacterium sp. 
OTU_22656 2.7408 7.4909 9.92E-05 0.0414 k__bacteria p__firmicutes c__clostridia o__clostridiales f__clostridiaceae g__clostridium s__clostridium sp. 
OTU_32868 -2.4065 6.7432 0.000100806 0.0414 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__porphyromonadaceae g__barnesiella s__barnesiella spp. 
OTU_2183 -2.1601 8.0625 0.000102685 0.0415 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__porphyromonadaceae g__parabacteroides s__parabacteroides distasonis 
OTU_16362 2.8495 7.4857 0.000104827 0.0417 k__bacteria p__firmicutes c__erysipelotrichia o__erysipelotrichales f__erysipelotrichaceae g__allobaculum s__allobaculum sp 
OTU_7833 -2.6376 6.5693 0.000110637 0.0431 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__porphyromonadaceae g__barnesiella s__barnesiella spp. 
OTU_2156 -2.4272 7.3923 0.000111981 0.0431 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__bacteroidaceae g__bacteroides s__bacteroides intestinalis 
OTU_3921 -2.5394 7.1084 0.000127099 0.0473 k__bacteria p__bacteroidetes c__bacteroidia o__bacteroidales f__porphyromonadaceae g__parabacteroides s__parabacteroides distasonis 
OTU_11236 -3.0406 6.7178 0.000127273 0.0473 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__blautia s__ruminococcus gnavus 
OTU_1101 2.878 6.9012 0.000129817 0.0473 k__bacteria p__firmicutes c__clostridia o__clostridiales f__ruminococcaceae g__oscillospira s__oscillospira spp. 
OTU_19165 -3.3179 6.8879 0.000130478 0.0473 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__anaerostipes s__anaerostipes caccae 
OTU_30215 -2.087 7.0923 0.000135834 0.0486 k__bacteria p__firmicutes c__clostridia o__clostridiales f__ruminococcaceae g__ruminococcus s__ruminococcus sp. 
OTU_5156 -1.9801 7.0353 0.000138679 0.0489 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__anaerostipes s__anaerostipes caccae 
OTU_1468 5.0093 7.4823 0.000142141 0.0494 k__bacteria p__firmicutes c__clostridia o__clostridiales f__lachnospiraceae g__roseburia s__roseburia faecis 





Table 5.S5 Colonic bacterial alpha diversity measurements of male and female CD-1 mice collapsed by sex and age. Values are 
expressed as mean ± standard error of the mean. *P < 0.05; ∗∗∗P < 0.001. 
                            P value 
Alpha diversity measurement  CO
1 SEM  FO2 SEM  BO3 SEM  EO4 SEM  D5 S6 A7 D*S D*A S*A D*S*A 
Number of observed genera  66 3  68 2  70 2  78 3  - - - - - *** - 
Shannon’s Diversity Index  2.6 0.1  2.6 0.1  2.7 0.1  2.7 0.1  - - - - - * * 
1CO: CD-1 mice fed a “Western-style” control fat. 2FO: CD-1 mice fed CO supplemented with 30% fish oil. 3BO: CD-1 mice fed CO 




Table 5.S6 Fatty acid composition of fat supplements. 
 
 Fat supplement 
Fatty acid CO1 FO BO EO 
 g/100g fatty acids  
4:0 0.00 0.00 3.10 0.00 
5:0 0.00 0.00 0.03 0.00 
6:0 0.05 0.00 2.01 0.00 
7:0 0.00 0.00 0.02 0.00 
8:0 0.59 0.00 1.20 0.00 
9:0 0.00 0.00 0.04 0.00 
10:0 0.49 0.00 2.81 0.00 
11:0 0.00 0.00 0.32 0.00 
11 cyclohexyl/11:0 0.00 0.00 0.04 0.00 
12:0 3.25 0.11 3.31 0.00 
13:0 0.00 0.05 0.21 0.00 
13:0 iso 0.00 0.01 0.02 0.00 
13:0 aiso 0.00 0.00 0.08 0.00 
14:0  2.08 8.40 10.72 0.03 
14:0 iso 0.00 0.06 0.10 0.00 
14:1 c9 0.00 0.04 0.89 0.00 
15:0 0.04 0.65 1.17 0.00 
15:0 iso 0.00 0.29 0.21 0.00 
15:0 aiso 0.00 0.13 0.44 0.00 
16:0 20.04 14.61 29.87 6.87 
16:0 iso 0.00 0.12 0.28 0.00 
16:1 c7 0.18 0.21 0.14 0.00 
16:1 c9 1.23 12.04 1.34 0.07 
16:1 t9 0.00 0.20 0.05 0.00 
16:1 c11 0.00 0.19 0.03 0.00 
16:1 isomer 0.00 0.00 0.04 0.00 
16:2 c9,c12 0.00 1.39 0.00 0.00 
16:3 c6,c9,c12 0.00 1.56 0.00 0.00 
17:0  0.24 0.46 0.60 0.10 
17:0 iso 0.00 0.00 0.32 0.00 
17:0 aiso 0.00 0.00 0.40 0.00 
17:1 c8 0.00 0.07 0.00 0.00 
17:1 c9 0.00 0.12 0.00 0.00 
17:1 t10 0.00 0.26 0.00 0.00 
18:0 10.30 2.49 10.44 3.52 
18:0 iso 0.00 0.27 0.07 0.00 
18:1 t4 0.00 0.00 0.04 0.00 
18:1 t5 0.00 0.00 0.02 0.00 
18:1 t6-8 0.00 0.00 0.29 0.00 




18:1 c9 36.93 3.58 19.67 14.89 
18:1 t9 0.00 0.00 0.25 0.00 
18:1 t10 0.00 0.00 0.45 0.00 
18:1 c11 1.64 2.44 0.66 0.47 
18:1 t11 0.00 0.00 1.20 0.00 
18:1 c12 0.00 0.00 0.46 0.00 
18:1 t12 0.00 0.00 0.45 0.00 
18:1 c13 0.05 0.05 0.11 0.00 
18:1 c14/t16 0.00 0.00 0.38 0.00 
18:1 t13/t14 0.00 0.00 0.78 0.00 
18:1 c15 0.00 0.79 0.06 0.00 
18:1 c16 0.00 0.00 0.08 0.00 
18:2 c9,t11 0.00 0.00 0.51 0.00 
18:2 c9,c12 19.51 1.28 2.48 14.15 
18:2 c9,t12 0.00 0.00 0.00 0.14 
18:2 c9,t13/t8,c12 0.00 0.00 0.21 0.00 
18:2 c9,t14 0.00 0.00 0.09 0.00 
18:2 t9,c12 0.00 0.00 0.00 0.02 
18:2 t10,t14 0.00 0.00 0.06 0.00 
18:2 t11,t13 0.00 0.00 0.00 0.00 
18:2 t,t isomer 0.00 0.00 0.00 0.00 
18:3 c6,c9,c12  0.00 0.32 0.00 10.01 
18:3 c9,c12,c15 1.89 1.29 0.39 32.71 
18:3 c9,t12,c15 0.00 0.00 0.00 0.06 
18:3 c9,t12,t15/c9,c12,t15 0.00 0.00 0.00 0.70 
18:3 t9,c12,c15 0.00 0.00 0.00 0.50 
18:4 c6,c9,c12,c15 0.00 2.57 0.00 13.38 
19:0 0.01 0.07 0.00 0.00 
20:0 0.24 0.14 0.15 0.10 
20:1 c9 0.00 0.42 0.10 0.00 
20:1 c11  0.42 0.00 0.03 0.74 
20:2 c11,c14 0.41 0.17 0.00 0.05 
20:3 c5,c8,c11 0.06 0.29 0.13 0.00 
20:3 c11,c14,c17 0.00 0.24 0.00 0.00 
20:4 c5,c8,c11,c14 0.14 1.36 0.16 0.00 
20:4 c8,c11,c14,c17 0.00 1.19 0.00 0.00 
20:5 c5,c8,c11,c14,c17 0.00 13.29 0.03 0.00 
22:0 0.05 0.15 0.06 0.05 
22:1 c13 0.05 0.00 0.00 0.39 
22:1 t13 0.00 0.00 0.00 0.05 
22:2 c13,c16 0.00 0.03 0.00 0.00 
23:0 0.00 0.05 0.00 0.00 
24:0 0.03 0.07 0.00 0.00 
24:1 c15   0.01 0.25 0.00 0.11 




22:4 c7,c10,c13,c16 0.07 0.21 0.00 0.00 
22:5 c4,c7,c10,c13,c16 0.00 0.54 0.00 0.00 
22:5 c7,c10,c13,c16,c19 0.00 2.02 0.00 0.00 
22:6 c4,c7,c10,c13,c16,c19 0.00 10.33 0.00 0.00 
Unknown 0.00 3.12 0.43 0.89 
1CO: U.S. fat blend consisted of lard, walnut oil, high-oleic sunflower oil, coconut oil, and 







Figure 5.1 Feed efficiency (final body weight (g) – initial body weight (g) / total feed 
(kcal) consumed) during the study of male and female CD-1 mice collapsed by diet group. 
Male CD-1 mice exhibited a higher feed efficiency compared to female CD-1 mice (P < 
0.05). 
  



































Figure 5.2 Colonic bacterial density (log copies/µg fecal pellet) of CD-1 mice at 10.5 and 
13.5 months of age collapsed by diet group and sex. Values are expressed as mean ± 
standard error of the mean. *P < 0.001. 
  

































Figure 5.3 (A) Relative abundance of colonic bacteria at the phylum level of male and 
female CD-1 mice collapsed by sex and age. CO: CD-1 mice fed a “Western-style” control 
fat. FO: CD-1 mice fed CO supplemented with 30% fish oil. BO: CD-1 mice fed CO 
supplemented with 30% dairy fat. EO: CD-1 mice fed CO supplemented with 30% echium 
oil. Abundance by counts of Bacteroidetes was greater in EO-fed mice compared to all 
other diet groups (P < 0.05). (B) Relative abundance of colonic bacteria at the phylum level 
of male and female CD-1 mice collapsed by diet group and age. Abundance by counts of 
Bacteroidetes was greater in females compared to males (P < 0.05). (C) Ratio of Firmicutes 
to Bacteroidetes of male and female CD-1 mice collapsed by diet group and age. (D) Shifts 
in relative abundance of the colonic Bacteroidetes of BO-fed male and female CD-1 mice 
at 10.5 and 13.5 months of age. Shifts in relative abundance of the colonic Bacteroidetes 
of EO-fed male and female CD-1 mice at 10.5 and 13.5 months of age. In BO-fed males, 
abundance by counts of Bacteroidetes was greater at 13.5 months of age compared to 10.5 
months of age (P < 0.01). In EO-fed males, abundance by counts of Bacteroidetes was 
lower at 13.5 months of age compared to 10.5 months of age (P < 0.01). Values are 
expressed as mean ± standard error of the mean. *P < 0.05; **P < 0.01. 
  
















































































































Figure 5.4 (A) Core microbiome analysis at the operational taxonomic unit (OTU) level  










Non-core: 28337 (66.5%) 
 
 


























































of the colonic bacteria in male and female CD-1 mice collapsed by diet group and age. (B) 
Redundancy analysis at the OTU level constrained by sex of colonic bacteria in CD-1 mice 
collapsed by age. CO: CD-1 mice fed “Western-style” control fat (CO). FO: CD-1 mice 
fed CO supplemented with 30% fish oil. BO: CD-1 mice fed CO supplemented with 30% 
dairy fat. EO: CD-1 mice fed CO supplemented with 30% echium oil. (C) M-A plot of 
colonic bacteria at the OTU level that were differentially abundant in males (positive y-






Figure 5.5 Principal coordinate analysis of beta diversity (Bray-Curtis) of male and female 






Figure 5.S1 (A) Relative abundance of bacteria at the phylum level of male and female 
CD-1 mice fed “Western-style” control fat (CO) at 10.5 and 13.5 months of age. (B) 
Relative abundance of bacteria at the phylum level of male and female CD-1 mice fed CO 
supplemented with 30% fish oil (FO) at 10.5 and 13.5 months of age. (C) Relative 
abundance of bacteria at the phylum level of male and female CD-1 mice fed CO 
supplemented with 30% dairy fat (BO) at 10.5 and 13.5 months of age. In males, abundance 
by counts of Bacteroidetes was greater at 13.5 months of age compared to 10.5 months of 
age (P < 0.01). (D) Relative abundance of bacteria at the phylum level of male and female 
CD-1 mice fed CO supplemented with 30% echium oil (EO) at 10.5 and 13.5 months of 
age. In males, abundance by counts of Bacteroidetes was lower at 13.5 months of age 
compared to 10.5 months of age (P < 0.01). Values are expressed as mean ± standard error 
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S1 Fig. (A) Relative abundance of bacteria at the phylum level of male and female CD-1 mice fed “Western-
style” control fat (CO) at 10.5 and 13.5 months of age. (B) Relative abundance of bacteria at the phylum 
level of male and female CD-1 mice fed CO supplemented with 30% fish oil (FO) at 10.5 and 13.5 months 
of age. (C) Relative abundance of bacteria at the phylum level of male and female CD-1 mice fed CO 
supplemented with 30% dairy fat (BO) at 10.5 and 13.5 months of age. In males, abundance by counts of 
Bacteroidetes was greater at 13.5 months of age compared to 10.5 months of age (P < 0.01). (D) Relative 
abundance of bacteria at the phylum level of male and female CD-1 mice fed CO supplemented with 30% 
echium oil (EO) at 10.5 and 13.5 months of age. In males, abundance by counts of Bacteroidetes was lower 
at 13.5 months of age compared to 10.5 months of age (P < 0.01). Values are expressed as mean ± 











Figure 5.S2 Relative abundance of bacteria at the genus level of male and female CD-1 
mice collapsed by diet group and age. Colonic abundance by counts of Roseburia was more 
abundant in females than males. 
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Figure 5.S3 (A) Relative abundance of bacteria at the genus level of male and female CD-
1 mice fed “Western-style” control fat (CO) at 10.5 and 13.5 months of age. In males, the 
abundance by counts of Alistipes was lower at 13.5 months of age compared to 10.5 months 
of age (P < 0.01), but in females, the abundance by counts of Alistipes was greater at 13.5 
months of age compared to 10.5 months of age (P < 0.01). (B) Relative abundance of 
bacteria at the genus level of male and female CD-1 mice fed CO supplemented with 30% 
fish oil (FO) at 10.5 and 13.5 months of age. In females, the abundance by counts of 
Alistipes was greater at 13.5 months of age compared to 10.5 months of age (P < 0.05). (C) 
Relative abundance of bacteria at the genus level of male and female CD-1 mice fed CO 
supplemented with 30% dairy fat (BO) at 10.5 and 13.5 months of age. In males, abundance 
by counts of Bacteroides was greater at 13.5 months of age compared to 10.5 months of 
age (P < 0.05). (D) Relative abundance of bacteria at the genus level of male and female 
CD-1 mice fed CO supplemented with 30% echium oil (EO) at 10.5 and 13.5 months of 
age. In males, the abundance by counts of Bacteroides was lower at 13.5 months of age 
compared to 10.5 months of age (P < 0.05). Values are expressed as mean ± standard error 
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S3 Fig. (A) Relative abundance of bacteria at the genus level of male and female CD-1 mice fed “Western-style” control 
fat (CO) at 10.5 and 13.5 months of age. In males, the abundance by counts of Alistipes was lower at 13.5 months of age 
compared to 10.5 months of age (P < 0.01), but in females, the abundance by counts of Alistipes was greater at 13.5 
months of age compared to 10.5 months of age (P < 0.01). (B) Relative abundance of bacteria at the genus level of male 
and female CD-1 mice fed CO supplemented with 30% fish oil (FO) at 10.5 and 13.5 months of age. In females, the 
abundance by counts of Alistipes was greater at 13.5 months of age compared to 10.5 months of age (P < 0.05). (C) 
Relative abu dance of bacteria at the genus level of mal  and female CD-1 mice ed CO supplemented with 30% dairy 
fat (BO) at 10.5 and 13.5 months of age. In males, abundance by counts of Bacteroides was greater at 13.5 months of 










Figure 5.S4 Heat map of read abundance of the 20 most abundant colonic bacterial OTUs 
in CD-1 mice separated by diet, sex, and age. BO: Male (M) and female (F) CD-1 mice fed 
“Western-style” control fat (CO) supplemented with 30% dairy fat (BO) at 10.5 and 13.5 
months of age. CO: Male (M) and female (F) CD-1 mice fed “Western-style” control fat 
(CO) at 10.5 and 13.5 months of age. EO: Male (M) and female (F) CD-1 mice fed CO 
supplemented with 30% echium oil (EO) at 10.5 and 13.5 months of age. FO: Male (M) 
and female (F) CD-1 mice fed CO supplemented with 30% fish oil (FO) at 10.5 and 13.5 






CHAPTER 6: SUMMARY, LIMITATIONS, AND GENERAL 
CONCLUSIONS 
6.1 Summary 
The overall objective of this dissertation research was to investigate whether life-
long consumption of unique dietary sources of fatty acids (FAs), with a particular focus on 
dairy fat, attenuated age-related metabolic impairments and disease risk. This overarching 
research goal was evaluated accordingly through the work discussed in Chapters 2-5. 
My first research objective (Chapter 2) was to investigate whether, and to what 
degree, retail whole milk from conventional and organic milk production systems differ in 
fat quality and its potential implications for human nutrition. This work secondarily 
assessed the impact of season on milk fat quality. The fatty acid (FA) content of retail 
conventional, organic, and n-3 FA-fortified milk brands available in the Northeast U.S. 
was analyzed for an entire year to evaluate the differences in the FA content among these 
retail milk brands based on a serving of whole milk. Findings from this study demonstrate 
that organic milk contained a greater content of unique bioactive FAs, including short-
chain FAs, odd- and branched-chain FAs, vaccenic acid, and conjugated linoleic acids per 
serving, particularly during the warm season. In addition, organic and n-3-FA fortified milk 
contained a similar content of total n-3 FAs per serving. Thus, these results indicate that 
organic milk has a unique and more healthful FA profile which stands out compared to 
conventional and n-3-FA fortified milk (graphic summary shown in Figure 6.1). 




dairy systems significantly increases the content of n-3 FAs and conjugated linoleic acids 
in whole milk.  
For the next research objective (Chapter 3), I assessed how long-term 
supplementation of various sources of FAs to a control diet comprised of the FA 
composition consumed by the average U.S. American influenced markers of metabolic 
disease risk throughout aging in an outbred CD-1® mouse population. Mice were fed 
experimental diets supplemented with dairy (butter) fat, echium oil, or fish oil from 
weaning to 14 months of age. Parameters of glucose homeostasis (i.e., glucose tolerance 
and insulin sensitivity) were assessed every three months. Results from this work revealed 
a strong sexual divergence in the metabolic responses of mice to diets as aging progressed. 
Over the course of the 13-month dietary intervention, glucose tolerance improved only in 
males consuming a diet supplemented with fish oil or echium oil compared to males fed 
the control diet. Females on the other hand were more metabolically resilient across all age 
groups. Correlation analyses revealed that the sex-specific metabolic outcomes observed 
were associated with specific diet-derived FAs found in the body tissues. In particular, the 
content of fish-derived FA in liver, muscle, and adipose tissue was associated with 
improved glucose tolerance in males. In female mice, however, this relationship was only 
observed in the muscle tissue. Additional correlation analyses revealed that alpha diversity 
of colonic bacteria was associated with insulin sensitivity in males, but not females. In sum, 
this research provides evidence that long-term consumption of unique, diet-derived FAs 
influences metabolic health during aging in a sex-dependent manner, with either a direct 




Research discussed in Chapters 4 and 5 was performed to more closely evaluate the 
role of dietary FA tissue content and colonic bacterial composition on glucose homeostasis 
as observed in Chapter 3. First, in Chapter 4, FA composition of adipose, muscle, and liver 
tissue as well as blood fractions (plasma phospholipids, cholesterol esters, triacylglycerols, 
and free FAs) from mice at 14 months of age was determined via gas-liquid 
chromatography. Content of fish- and echium-derived FAs in adipose, muscle, liver, and 
blood was greater in response to fish oil and echium oil intake, respectively, with minor 
exceptions. However, dairy-derived FA content in tissues was more variable, particularly 
in blood, in response to dairy fat intake. In addition, sex was found to influence the tissue-
specific partitioning of diet-derived FAs. In Chapter 5, colonic bacterial composition was 
evaluated at middle age versus old age to examine whether the diet modified the gut 
microbial composition and if the observed changes could be associated to the various 
outcome measures investigated. Results showed that dietary fat quality affected colonic 
bacterial composition differently in males and females over time. Most notably, in males 
only, dietary dairy fat or echium oil caused the abundance of Bacteroidetes and Bacteroides 
to change with age. Additionally, dietary fish oil induced sex-dependent changes in the 
alpha diversity of aged mice compared to middle age. These results suggest that 
consumption of fats with distinct FA profiles can significantly influence the colonic 
bacterial composition, and thus disease risk, during aging. In summary, Chapters 4 and 5 
indicate that dietary fat quality impacts tissue FA and colonic bacteria in aged mice 
specifically in a sex-specific fashion. Taken together, my research provides evidence that 
long-term consumption of unique bioactive FAs influences metabolic health and disease 





6.2 Research Limitations and Future Perspectives 
In Chapter 2, sample size (i.e., the number of milk samples included for FA 
analysis) was limited. For one, on a monthly basis, one sample of each milk brand was 
collected for analysis. However, each milk brand was collected for a consecutive year, and 
analyzed grouped by retail label to strengthen statistical power. Additionally, only three n-
3-FA fortified milk brands were available for purchase in the Northeast U.S., and thus, 
only three could be included in our analysis as opposed to six and eight milk brands 
included for analysis of organic and conventional milk brands, respectively. The inclusion 
of more milk brands for FA analysis in future studies would therefore expand on the 
findings of our research. 
Another potential limitation of Chapter 2 was the use of a gas-liquid chromatograph 
equipped with a 100m SP-2560 column for milk FA analysis. While this methodology is 
regarded for its high-quality separation of major FAs in milk, nevertheless the use of gas-
liquid chromatography for FA analysis has certain drawbacks. Specifically, the use of gas-
liquid chromatography relies on a single temperature program, which is not capable of 
eluting all individual FA within a milk sample. However, it is noteworthy that, while 
complementary analyses exist which can resolve the proportion of every single minor FA 
isomer, such additional analysis would not impact the main findings of Chapter 2.  
To confirm and enhance understanding of the results reported in Chapter 2, more 
research analyzing the FA composition and content of retail whole milk is needed. For 
example, the FA analysis of other types of retail milk, particularly “grass-fed” milk, is 




composition.  Future work could also expand milk sampling of retail brands across 
different U.S. regions. Such analyses would add insight into milk FA composition and 
content by assessing another important factor (i.e., geographic region) potentially 
impacting the FA content of retail milk.  
For Chapters 3-5, a key limitation is that mice are an imperfect model organism to 
study a human population. However, the utilization of a murine model allowed us to 
characterize the impact of dietary fat quality on metabolic across multiple life stages. 
Moreover, the utilization of an outbred CD-1 mouse model replicated the genetic 
heterogeneity of a human population, thus enhancing the translatability of our findings to 
humans relative to other research via inbred mouse strains. 
Sex was consistently the most pronounced effect observed on parameters of glucose 
homeostasis (Chapter 3) and colonic bacterial composition (Chapter 5). In addition, sex 
was found to significantly affect the tissue-specific content of dietary FAs (Chapter 4). Yet, 
due to logistical reasons (e.g., cost and labor), this research (Chapters 3-5) did not assess 
the role of sex hormones underlying these observed sex differences in mice. Therefore, this 
limitation curtails the understanding of how sex and sex hormones influence the 
relationship between dietary fat quality and metabolic health during aging. More research 
with a study designed to examine the role of sex hormones (e.g., intact vs. gonadectomized 
mice) is critical to fully understand sex differences in glucose homeostasis, partitioning of 
diet-derived FAs in tissues, and colonic bacterial composition (as discussed in Chapters 3, 
4, and 5, respectively). 
Due to an unexpectedly relatively high incidence of morbidity and mortality in our 




Therefore, we were unable to study the metabolic effects of long-term dietary fat quality 
in a reproductively senescent, frank elderly population (approximately 18 months of age). 
Nonetheless, our long-term study spanned over multiple life stages of mice, from weaning 
until 14 months of age (an age when female mice are transitioning into reproductive 
senescence), and thus, the main goals of our work was achieved. Future work should focus 
on the impact of long-term dietary fat quality in an elderly (over 65 years of age) 
population.  
In Chapters 3 and 5, sample size was a notable limitation in analyses of colonic 
bacterial composition, as fecal samples were selected from a subset of mice 
(n=4/diet/sex/time point) for colonic bacterial analysis. This number of animals was 
justified due to cost and logistical considerations (i.e., number of metabolism cages 
available). However, the perhaps insufficient sample size may have to contributed to the 
modest effect of diet on colonic bacterial composition observed, as colonic bacterial 
composition among individuals is often accompanied by a large variation. This is an 
especially relevant consideration in our research, as we utilized the genetically outbred CD-
1® mouse stock for this research. Hence, more pronounced changes may have been detected 
in a larger number of mice. Furthermore, our study solely assessed dietary modifications 
to the colonic bacterial composition via 16S rRNA amplicon sequencing. As a result, this 
research measured broad changes to colonic bacterial composition (i.e., genus level), and 
could not assess changes in metabolites produced that may have affected the systemic 
metabolism of the mice. Accordingly, any diet-induced changes in the production of 
metabolites by colonic bacteria or in the gut milieu could not be characterized. Despite 




dietary fat quality differentially influences colonic bacterial composition during aging in 
males and females. For future work, it would be valuable to utilize metagenomics and 
metatranscriptomics to precisely characterize the role of gut bacteria and derived 
metabolites on the mechanisms underlying the effectiveness of a dietary strategy to 
mitigate disease risk. 
Moving forward, randomized clinical trials enrolling males and females across 
multiple age groups are essential to understand the effects of dietary fat quality metabolic 
health and disease risk. Future work designed to clearly evaluate the additional factors of 
food matrix and fat source will be also instrumental for progress in this field of nutritional 
research.  
 
6.3 General Conclusions 
The research presented in this dissertation indicates that long-term intake of dietary 
fat with a unique FA composition influences metabolic health later in life. Yet, this research 
also demonstrates the complexity and challenges in designing nutritional strategies to 
protect metabolic health. For example, the examination of the fat quality of retail whole 
milk suggested that whole milk is a rich source of unique, beneficial FAs and that three 
servings of whole milk daily can fit into current dietary guidelines of recommended fat 
intake. Yet, when dairy (butter) fat was supplemented into the diet in a controlled feeding 
study, neutral effects on glucose homeostasis were observed. In contrast, dietary 
supplementation with fish oil or echium oil significantly attenuated age-related glucose 
intolerance in a sex-specific manner. Thus, this work underscores that there are important 




effectiveness of a dietary strategy to mitigate metabolic disease risk. Moving forward, to 
address these questions, large-scale randomized clinical trials with multiple age groups, 
utilizing a strictly controlled dietary regimen but supplementing different food sources of 
unique FAs, are critically needed. Specifically, assessing the role of an individual’s sex 
and age, as well the interaction of their genetic makeup and gut microbiome, on metabolic 
health is necessary to design clear and accurate (i.e., personalized) dietary 






Figure 6.1 Summary of key differences in fatty acid content (mg/serving) among retail whole milk (3.25% fat) labeled as 












































Figure 6.2 Summary of key factors (i.e., diet, sex, age, and underlying biological mechanisms) assessed in this dissertation that attenuate 
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Utilization of murine models remains a valuable tool in biomedical research, yet, 
disease phenotype of mice across studies can vary considerably. With advances in next 
generation sequencing, it is increasingly recognized that inconsistencies in host phenotype 
can be attributed, at least in part, to differences in gut bacterial composition. Research with 
inbred murine strains demonstrates that housing conditions play a significant role in 
variations of gut bacterial composition, however, few studies have assessed whether 
observed variation influences host phenotype in response to an intervention. Our study 
initially sought to examine the effects of a long-term (9-months) dietary intervention (i.e., 
diets with distinct fatty acid compositions) on the metabolic health, in particular glucose 
homeostasis, of genetically-outbred male and female CD-1 mice. Yet, mice were shipped 
from two different husbandry facilities of the same commercial vendor (Cohort A and B, 
respectively), and we observed throughout the study that diet, sex, and aging differentially 
influenced the metabolic phenotype of mice depending on their husbandry facility of 
origin. Examination of the colonic bacteria of mice revealed distinct bacterial 
compositions, including 23 differentially abundant genera and an enhanced alpha diversity 
in mice of Cohort B compared to Cohort A. We also observed that a distinct metabolic 
phenotype was linked with these differentially abundant bacteria and indices of alpha 
diversity. Our findings support that metabolic phenotypic variation of mice of the same 
strain but shipped from different husbandry facilities may be influenced by their colonic 
bacterial community structure. Our work is an important precautionary note for future 
research of metabolic diseases via mouse models, particularly those that seek to examine 





Microbiome structure and composition within the gastrointestinal tract have been 
identified as an important determinant of host disease development and severity [1–5]. 
Accordingly, defining the underlying mechanisms involved in the relationship between gut 
microbiota and host metabolic function has become an essential focus of biomedical 
research. Of particular interest are the bacteria, which dominate the colonization of the 
gastrointestinal tract compared to eukarya and archaea [6]. Yet, the role of host-related 
factors such as genetic background, sex, age, and lifestyle (e.g., diet) on gut bacterial 
composition and, thus, disease risk remains poorly understood. 
The utilization of murine models is ideal to characterize the dynamics of gut 
bacteria and their host while minimizing the influence of confounding factors. Yet, while 
there are many benefits to murine models in biomedical research, reproducibility of results 
and variation in phenotype remains a concern [7]. Recently, it has been theorized that the 
observed heterogeneity in disease phenotype of mice across studies is, at least, in part due 
to pervasive differences in gut bacterial composition [8]. Indeed, evidence shows that the 
gut bacteria of mice, even within the same strain, can vary due to factors such as 
commercial vendor [8–12], facility [10,11,13,14], room [15], and cage [16,17]. 
Importantly, few studies which reported variability among the gut bacteria of mice from 
different vendors or facilities further assessed whether, and to what degree, these 
differences influenced host disease phenotype in response to an intervention. Moreover, to 
our knowledge, these studies have only been performed in inbred strains [8,10–13,15–17], 
while none have examined this phenomenon in the context of a genetically-heterogenous 




We originally designed an experiment to examine the effect of long-term 
consumption of diets varying in fat quality on metabolic health during aging. Accordingly, 
four experimental diets with distinct fatty acid (FA) compositions were formulated for 
long-term feeding: a control fat blend, based on the diet of the average U.S. American, or 
the control fat blend supplemented with fish oil, butter oil, or echium oil. Inadvertently, the 
vendor shipped outbred CD-1 mice from two different husbandry facilities two weeks 
apart. During the course of the study, we observed that the metabolic phenotype varied 
among mice from the different husbandry facilities. We hypothesized that differences in 
the colonic bacterial composition of mice between facilities was a contributory factor to 
the metabolic phenotype observed in response to the dietary intervention. To test this 
hypothesis, our objectives were to 1) evaluate the metabolic response to a long-term dietary 
intervention of male and female mice derived from different husbandry facilities, 2) 
evaluate variations in colonic bacterial composition of male and female mice from these 
facilities, and 3) assess the influence of colonic bacterial composition on the metabolic 
phenotype of mice from each facility. 
 
A.3 Methods 
A.3.1 Animals and experimental design 
All animal procedures were approved by and conformed to the guidelines and 
regulations of The University of Vermont Institutional Animal Care and Use Committee. 
A total of 162 CD-1 mice were used (IGS #022, Charles River, Wilmington, MA, USA) 




husbandry facility (n=10-11/cohort/sex/diet). At three weeks of age mice arrived from each 
facility two weeks apart. Upon arrival, mice were randomly paired (same sex) in ventilated 
cages (Thorens Caging Systems, Hazelton, PA, USA). For the duration of the study, mice 
were housed at a temperature of 23.6°C with 64% humidity on a 12 hr light-dark cycle. 
During the one-week acclimation period, mice had free access to water and a standard chow 
of 26% protein, 60% carbohydrate, and 14% fat (Prolab® Rat/Mouse/Hamster 3000, 
LabDiet, St. Louis, MO, USA). Mice were then fed one of four experimental high-fat (40% 
of total energy) diets from one until 10 months of age: 1) CO: 100% control fat; 2) FO: 
70% CO supplemented with 30% fish oil; 3) BO: 70% CO supplemented with 30% butter 
oil; or 4) EO: 70% CO supplemented with 30% echium oil. Oil derived from fish, butter, 
and echium were chosen to create experimental diets with distinct fatty acid profiles (FO, 
BO, and EO, respectively) from one another and the CO diet. In particular, the CO diet was 
marked by the combination of its high content of saturated fatty acids and its high n-6/n-3 
fatty acid ratio; the FO diet by its high content of long-chain n-3 fatty acids, the BO diet 
by its high content of short-, medium-, odd-chain, and branched-chain fatty acids; and the 
EO diet by its high content of n-3 fatty acids and γ-linolenic acid (n-6 fatty acid). A detailed 
description of the experimental diets has been previously published by Unger et al. [18]. 
 As expected with a long-term study, there were a few (5 in total) mice that died or 
were euthanized before the projected completion of the study due to one of the following 
reasons: spinal injury (n = 1), atrial thrombosis (n = 1), fatal fight wounds (n = 2), and an 





A.3.2 Measurement of metabolic parameters 
 Feed intake per cage was measured weekly. Body weight was recorded weekly for 
the initial three months and then monthly for the remaining duration of the study. On a 
monthly basis, mice were tail-nicked to measure glucose during the fed state (~9:00 AM) 
from whole blood with a glucose meter (Free Style Lite, Abbott, Abbott Park, IL, USA). 
Whole blood was collected in heparinized microhematocrit capillary tubes (Fisher 
Scientific, Waltham, MA, USA) and centrifuged (Sorvall® Biofuge Fresco, Kendro 
Laboratory Products, Asheville, NC, USA) at 9,500 g for 5 min at 4°C; plasma was stored 
at -20°C until measurement of insulin concentration with a commercially available kit 
(Mouse Ultrasensitive Insulin ELISA, Alpco, Salem, NH, USA).   
Every three months, parameters of glucose homeostasis were assessed via 
intraperitoneal (IP) glucose tolerance test and insulin tolerance test (GTT and ITT, 
respectively). IP administration of glucose and insulin was chosen over oral administration, 
as it is a highly reproducible method with relatively stress-free administration and is more 
practical for large animal cohorts. On the day of the GTT, mice were fasted for six hours 
before IP administration of glucose (2 g/kg; Sigma-Aldrich, St. Louis, MO, USA), and 
glucose from whole blood was measured at 0, 15, 30, 60, 90, and 120 min. Whole blood 
was also collected via tail nick at 0 and 30 min and processed as described above for 
determination of glucose-induced insulin secretion. Insulin resistance was assessed via the 
homeostatic model assessment of insulin resistance (HOMA-IR), calculated as glucose0 
min*insulin0 min)/405 [19]. b-cell function was evaluated via the insulinogenic index 
(Δinsulin1-30 min)/(Δglucose1-30 min) [20]. Two weeks after the GTT, ITT was performed. 




0.75 U/kg; Eli Lilly and Company, Indianapolis, IN, USA). Over a time-course of one 
hour, glucose was measured at 0, 15, 30, and 60 min. Fasting insulin was measured from 
plasma processed from whole blood as described above.  
 
A.3.3 Analysis of colonic bacteria 
 Sample collection and analysis of colonic bacteria has been described previously 
[18]. At approximately ten months of age, following the final GTT and ITT, 24-hour fecal 
collection (n = 2-5/diet/sex, n=28-31/cohort) was executed via individual metabolism 
cages (Techniplast, West Chester, PA, USA). Total microbial DNA was extracted and the 
V1-3 region of the bacterial 16S rRNA was amplified on the GeneAmp PCR System 9700 
(Applied Biosystems, Foster City, CA, USA) using the primer pair 27F and 519R 
(Integrated DNA Technologies, Skokie, IL, USA). Amplicons were sent to Molecular 
Research DNA (Shallowater, TX, USA) for sequencing via Illumina Miseq (v.3). Colonic 
bacterial density was determined as reported in Unger et al. [18]. 
 
A.3.4 Statistical analysis 
 Metabolic parameters were analyzed with a linear mixed model (MIXED function) with 
an unstructured covariance in IBM SPSS Statistics for Macintosh, Version 25.0 (IBM Corp., 
Armonk, NY, USA). Facility, sex, diet, and age were included in the model as fixed effects, 
with cage number as a random effect and body weight as a covariate. For post hoc testing, the 
COMPARE function was used to assess unadjusted pairwise comparisons due to the large 




dependent variable, the residuals were assessed for normal distribution via Q-Q plots. The 
following dependent variables were transformed as follows: feed efficiency, body weight gain, 
and fed glucose via square root; body weight, fed insulin, fasted glucose and insulin, GTT and 
ITT area under the curve (AUC), insulinogenic index, and HOMA-IR via log. Bacterial density 
was analyzed via three-way ANOVA (including the effects of cohort, sex, and diet) in JMP® 
(Version 14, SAS Institute Inc., Cary, NC, USA). Dependent variables with residuals that were 
normally distributed were not transformed. Tables and figures display non-transformed data.  
 
A.3.5 Bioinformatics analysis 
Sequencing files are accessible via the Sequence Read Archive (SRA) under the 
accession number PRJNA484010. Paired-end sequencing was performed and OTUs were 
generated using the MRDNA pipeline consisting of usearch, uchime, and taxonomic 
classification using BLASTn top hit. The mean sequencing depth was 28,104 reads, with 
a minimum of 8,473 and a maximum of 76,653 reads. 
Normalization, abundance, and diversity analyses were conducted in R version 
3.5.1. Raw OTU counts were normalized by sample, visualized via ordination, and alpha 
diversity metrics (Richness, Fisher alpha, Shannon, and Pielou’s Evenness) calculated 
using ampvis2 [21]. Cohort and sex level ordination is shown using PCA after Hellinger 
transformation and using Euclidean distances. For relative abundance between cohorts at 
the genus level, counts were aggregated and any taxa <0.01% relative abundance were 
grouped into a single category named accordingly. Alpha diversity differences between 




Differential abundance of taxa was calculated using DESeq2 [23] at the genus level 
with the design of ~0+CohortSex, a feature created to collapse the effects of cohort and sex 
(i.e., males in Cohort A vs males in Cohort B), and an FDR cutoff of <0.05 as determined 
by Benjamini-Hochberg correction. The effect of diet was not considered in this model in 
order to increase statistical power, as inclusion of this feature resulted in one group of n = 
2 (CO-fed males in Cohort B). An adjusted P-value <0.05 and log2 fold change >|1.5| was 
considered significant. Abundance of significant taxa were then correlated using the rstatix 
package. Spearman’s rank correlations were used with a significance threshold of P<0.05 
and visualized using the cor_mat function.  
 
A.4 Results 
A.4.1 Parameters of metabolic health 
 Data displaying the metabolic parameters of mice and the effects of cohort (A and 
B), sex (male and female), diet (CO: control diet, FO: CO supplemented with fish oil, BO: 
CO supplemented with butter oil, and EO: CO supplemented with echium oil), and age (3, 
6, 9 months of intervention) are shown in the Supplemental Information (Tables A.S1-4, 
respectively). Body weight of mice was greater (4%) at baseline in Cohort A compared to 
Cohort B, and the difference remained during the entirety of the study (5, 6, and 3% greater 
after 3, 6, and 9 months, respectively; Fig 1A; P < 0.05). Particularly, body weight (Fig 
1A; P < 0.05) and weight gain (Fig 1B; P < 0.05) differed among females within each 
cohort. While a difference across cohorts was not observed for feed intake (Fig 1C), feed 
efficiency was 38% greater in Cohort A than in Cohort B (Fig 1D; P < 0.001). Notably, 




B, FO-, BO-, and EO-fed males had a greater body weight (20, 19, and 16%, respectively) 
than CO-fed males after three months (P < 0.05), and BO-fed males sustained this greater 
body weight compared to CO-fed males as mice aged (31 and 30% greater after 6 and 9 
months, respectively; Fig 1E; P < 0.05). Yet, no diet-induced differences in body weight 
were observed in males of Cohort A (Fig 1E). In contrast, no variations among diet groups 
in body weight were observed in females of Cohort B until nine months, whereas body 
weight was greater in EO-fed females than in other diet groups after three months (Fig 1F; 
P < 0.05). 
Fasting glucose (Fig A.2A) did not vary in mice by cohort, yet, mice in Cohort B 
exhibited 56% higher fasting insulin levels (Fig A.2B) suggesting impaired insulin 
sensitivity, compared to mice in Cohort A (P < 0.05). In particular, fasted insulin levels 
overall were 71% higher in males of Cohort B than Cohort A (Fig A.2B; P < 0.05). Sex-
differences evaluated at three, six, and nine months were present within each cohort for 
certain parameters of glucose homeostasis, including insulin sensitivity via HOMA-IR (Fig 
A.2C; P < 0.05) and glucose tolerance via GTT AUC (Fig A.2D; P < 0.05). Yet, differences 
in males compared to females in insulin sensitivity via ITT AUC were not detectable in 
Cohort A until six months (Fig A.2E; P < 0.05). Additionally, differences in ITT AUC 
results between sexes were observed in Cohort B at three and six months, but dissipated 
by nine months (P < 0.05). Collectively, our data demonstrate that the effects of dietary 






A.4.2 Colonic bacterial composition 
Principal component analysis revealed distinct differences in colonic bacterial 
composition of mice between the two cohorts (Fig A.3A). At the genus level, 23 bacterial 
taxa were found to be differentially abundant between Cohort A and Cohort B (Table A.S5; 
P < 0.05 calculated with Benjamini-Hochberg adjustment determined by DESeq2). 
Specifically, the abundance of Bacteroides was greater (log2(fold change) = -1.2), while 
Lactobacillus was lower (log2(fold change) = 1.5), in Cohort A compared to Cohort B 
(Table A.S5; P < 0.05). These differences found in bacterial taxa via DESeq2 between 
cohorts correspond with changes in relative abundance of these two major genera (Fig 
A.3B). Furthermore, bacterial genera were found to be differentially abundant between 
males in Cohort A versus Cohort B, as well as females in Cohort A versus Cohort B (Figs 
3C and 3D, respectively; P < 0.05). Box and whisker plots displaying the abundance of the 
top 10 most abundant genera in mice by cohort, sex, and diet are shown in the Supplemental 
Information (Fig A.S1). 
 Alpha diversity of colonic bacterial genera was greater in Cohort B than in Cohort 
A (P < 0.05), although alpha diversity was similar across sex and diet groups (Fig A.S2). 
Notably, sex differences in richness of bacterial taxa were found within Cohort A (P < 
0.05), but not Cohort B (Fig A.3E). Overall, in females of Cohort A, alpha diversity of 
bacteria was enriched in EO-fed mice and diminished in CO-fed mice (Fig A.S3; P < 0.05). 
Yet, diet did not influence the alpha diversity of bacteria in females of Cohort B or males, 
regardless of cohort (Fig A.S3). Thus, our findings highlight distinct sex- and diet-
dependent differences in the colonic bacterial abundance and diversity of mice originating 





A.4.3 Correlations between metabolic parameters and colonic bacterial composition  
Spearman correlation matrices were generated to compare the associations between 
metabolic parameters and colonic bacterial composition of mice in Cohort A (Fig A.4A) 
and Cohort B (Fig A.4B). Specifically, bacterial genera that were found to be differentially 
abundant (P <0.05 calculated with Benjamini-Hochberg adjustment) via DESeq2 were 
evaluated. In Cohort A, Lactobacillus was positively correlated with fasting insulin levels 
(r = 0.44) and HOMA-IR (r = 0.45), indicating an association of this taxon with insulin 
resistance (P < 0.05). Ruminococcus, although a bacterial taxon found to be in minor 
relative abundance in mice (< 0.01%), was also positively associated with fasting insulin 
levels (r = 0.43) and HOMA-IR (r = 0.53; P < 0.05). Correlations were found between 
several other minor genera and metabolic parameters in mice of Cohort A. 
Fusicatenibacter had a moderately positive association with body weight (r = 0.43; P < 
0.05) and weight gain (r = 0.42; P < 0.05). In contrast, Adlercreutzia and Odoribacter were 
negatively associated with body weight (r = - 0.46 and -0.64, respectively) and weight gain 
(r = - 0.40 and -0.52, respectively; P < 0.05). Dysgonomonas was correlated with ITT AUC 
(r = 0.50; P < 0.05), suggesting a relationship of this genus with insulin resistance. Fasting 
blood glucose had a strong correlation the genera Acetanaerobacterium (r = 0.61) and 
Bacillus (r = 0.58), suggesting a relationship between these genera and impaired glucose 
homeostasis. Moreover, fasting glucose was positively associated with alpha diversity 
indices, including richness (r = 0.38) and Shannon’s index (r = 0.41; P < 0.05).  
Minimal correlations were found between colonic bacterial composition and 




correlation with body weight, weight gain, and feed efficiency (r = 0.36, 0.36, 0.40; P < 
0.05). In addition, alpha diversity (Pielou’s evenness) was negatively correlated with body 
weight (r = -0.37), weight gain (r = -0.37), and feed efficiency (r = -0.38; P < 0.05). Taken 
together, our data indicate that observed differences in metabolic phenotype of mice 
received from different animal husbandry facilities may be influenced by the underlying 
variance in their colonic bacterial compositions, including abundance and alpha diversity. 
 
A.4.4 Colonic bacterial density 
 Colonic bacterial density, determined as bacterial copies per μg wet fecal pellet, did 
not differ in mice of different sexes and diet groups, nor were any interactions among any 
main effects observed. Of note, bacterial density differed by cohort (14.2 ± 0.05 and 13.9 
± 0.05 log copies/μg fecal pellet in Cohort A versus Cohort B, respectively, when collapsed 
by sex and diet; P < 0.001). Thus, colonic bacterial density of mice may be an additional 
factor in the distinctions observed among mice of different cohorts. 
 
A.5 Discussion 
The utilization of murine models in biomedical research is often an important and 
necessary step in developing a better understanding of a disease pathology, yet, there is a 
growing concern regarding the reproducibility of results from murine-based studies [7]. 
We initially designed a study to examine the effect of a dietary intervention (i.e., fat quality) 
on parameters of glucose homeostasis in male and female outbred CD-1 mice during aging. 




facilities of the same commercial vendor, we observed variations in diet-induced metabolic 
phenotype from the different facilities over the course of the study. Thus, we sought to 
determine the differences in colonic bacterial composition of mice from each facility 
(Cohort A and B, respectively) and to assess the influence of colonic bacterial composition 
on the metabolic phenotype of mice. 
Recent work [24,25] highlights that inconsistent phenotypes of mice in response to 
an intervention across vendors, even among inbred strains, continues to be a widespread 
issue in biomedical research. For example, Hull et al. [25] described that substrains of male 
C57BL/6, a commonly utilized mouse strain in diabetes research, had variable blood 
glucose levels and insulin response after an 18-week high-fat diet. Importantly, however, 
these studies did not evaluate the gut microbial composition of these substrains of mice as 
a potential factor [24]. However, other work confirms clear disparities in gut bacterial 
composition of mice, particularly by vendor [8–12,26] as well as facility [10,11,13,14]. In 
our study, we found that colonic bacterial community structure differed between the two 
cohorts of mice. Moreover, colonic bacterial taxa and indices of alpha diversity correlated 
with disparate metabolic outcomes in mice from each cohort, exposing a strong effect of 
facility of origin on phenotype. In accordance with our work, Randall et al. [27] originally 
sought to assess the effects of an intervention (i.e., uremia on the urinary metabolome and 
gut microbiome) in an outbred rodent model, while instead finding that differences in the 
cecal bacterial abundance and alpha diversity of Wistar rats from separate shipments 
significantly altered experimental results. Yet, sex differences were not assessed within 




 Diet is considered to be a primary risk factor in the pathogenesis of metabolic 
diseases [28–30], and in particular, changes in dietary fat quality (i.e., fatty acid 
composition) are shown to have an influential role in the development of metabolic 
impairments [31]. Research indicates that one of the avenues in which dietary fat quality 
likely modulates disease risk is through manipulation of the gut microbiome [18,32–36]. 
However, it would be challenging to assess long-term effects of dietary fat quality and its 
interaction with gut microbiota during aging in humans without interference from 
confounding variables, thus rationalizing the use of a mouse model. Despite the original 
objective of our research, we found that several differentially abundant taxa were 
associated with parameters of weight gain and glucose homeostasis, suggesting that 
underlying diversity in the gut bacterial composition between cohorts had a distinct impact 
on systemic metabolism and overall disease risk. For example, in Cohort A, but not Cohort 
B, a relationship was observed between the genera Lactobacillus and Ruminococcus and 
insulin resistance, a key feature of type 2 diabetes pathogenesis [37–40]. Indeed, previous 
research has reported a greater abundance of Ruminococcus in individuals with prediabetes 
[41] and type 2 diabetes  [42–44] compared to individuals with normal glucose control. 
Similar associations have been found regarding Lactobacillus [42,45,46]. Thus, it is 
conceivable that these two genera played a role in the divergent insulin sensitivity observed 
between the two cohorts of mice. Due to the nature of our study design and ad-hoc 
scientific inquiry, however, it is important to note that it is not possible to determine a 





 Our work provides evidence that variance in commensal bacteria in mice from 
different facilities of the same vendor likely impact the metabolic phenotype in response 
to a dietary intervention. Indeed, should we have used mice from only one of these cohorts, 
our conclusions regarding the effects of diet, sex, and aging on metabolic health would 
have been misrepresented and incomplete. Specific to this work, there are important 
considerations to address as part of the interpretation of our findings. For example, as our 
study employed a genetically-diverse outbred mouse stock, genetic variation would be 
expected to be a contributory factor in phenotypic variation. CD-1 mice purchased for this 
study, however, were bred in accordance with the International Genetic Standardization 
(IGS) Program [47] through Charles River, and as such there is an expectation that mice 
from different facilities would have comparable genetic variation. Nevertheless, we cannot 
determine if the observed differences were due to naturally occurring genetic drift among, 
and even within, animal husbandry facilities over time. Another limitation is that 
sequencing of a mock community was not performed, and thus we cannot fully assess the 
potential occurrence of contamination. Importantly, any presence of sequencing bias would 
have impacted all samples in a similar manner, and thus our findings (i.e., differences in 
colonic bacteria of cohorts) would be consistent. Sequencing accuracy was also enforced 
both by filtering for low quality bases (<Q25) and removal of low abundance OTUs 
(<0.01%) that may have resulted from error throughout the extraction and sequencing 
process. Additionally, we did not collect fecal samples from the time of baseline to analyze 
differences in colonic bacterial composition between cohorts before the start of the 
experiment. Yet, the analysis of the colonic bacterial composition was not the original 




in the phenotype of mice within and across animal husbandry facilities over time (e.g., 
shipments of mice two weeks apart), is essential to develop a robust understanding of the 
scope of such observed phenotypic differences. In particular, more in-depth analysis of the 
microbiome (e.g., whole genome and/or whole exome sequencing) would be highly 
valuable for this effort. Overall, our findings serve as a precautionary warning that 
experimental outcomes can drastically differ in mice depending on their animal husbandry 
facility of origin. Future studies along these lines should consider obtaining a specific 
mouse strain derived from several geographically separate facilities to validate a given set 
of phenotypic/metabolic outcomes. Moving forward, reproducibility of work in mouse 
models also hinges on a rigorous commitment to collect and report relevant metadata for 
the benefit of all areas of research. 
 
A.6 Acknowledgements 
The authors would like to extend thanks to all the individuals who assisted with sample 
and data collection, including Keara McElroy-Yaggy, Dr. Melissa Bainbridge, Hope 
Dunbar, Scott Weiner, and Ali Attenasio. We also would like to acknowledge Alan Howard 
for advice regarding statistical analysis. 
 
A.7 References 
1.  Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An 
obesity-associated gut microbiome with increased capacity for energy harvest. 
Nature. 2006;444: 1027–1031. doi:10.1038/nature05414 
2.  Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes 





3.  Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic 
analysis identifies association of Fusobacterium with colorectal carcinoma. Genome 
Res. Cold Spring Harbor Laboratory Press; 2012;22: 292–298. 
doi:10.1101/gr.126573.111 
4.  Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal 
microbiota metabolism of l-carnitine, a nutrient in red meat, promotes 
atherosclerosis. Nat Med. Nature Publishing Group; 2013;19: 576–585. 
doi:10.1038/nm.3145 
5.  Gilbert JA, Quinn RA, Debelius J, Xu ZZ, Morton J, Garg N, et al. Microbiome-
wide association studies link dynamic microbial consortia to disease. Nature. Nature 
Publishing Group; 2016. pp. 94–103. doi:10.1038/nature18850 
6.  Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria 
cells in the body. PLOS Biol. 2016;14: e1002533. 
doi:10.1371/journal.pbio.1002533 
7.  Hewitt JA, Brown LL, Murphy SJ, Grieder F, Silberberg SD. Accelerating 
biomedical discoveries through rigor and transparency. ILAR J. Oxford University 
Press; 2017;58: 115–128. doi:10.1093/ilar/ilx011 
8.  Ericsson AC, Davis JW, Spollen W, Bivens N, Givan S, Hagan CE, et al. Effects of 
vendor and genetic background on the composition of the fecal microbiota of inbred 
mice. Heimesaat MM, editor. PLoS One. 2015;10: e0116704. 
doi:10.1371/journal.pone.0116704 
9.  Hufeldt MR, Nielsen DS, Vogensen FK, Midtvedt T, Hansen AK. Variation in the 
gut microbiota of laboratory mice is related to both genetic and environmental 
factors. Comp Med. 2010;60: 336–342.  
10.  Rausch P, Basic M, Batra A, Bischoff SC, Blaut M, Clavel T, et al. Analysis of 
factors contributing to variation in the C57BL/6J fecal microbiota across German 
animal facilities. Int J Med Microbiol. Elsevier GmbH; 2016;306: 343–355. 
doi:10.1016/j.ijmm.2016.03.004 
11.  Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D. Naturally transmitted 
segmented filamentous bacteria segregate with diabetes protection in nonobese 
diabetic mice. Proc Natl Acad Sci U S A. National Academy of Sciences; 2011;108: 
11548–11553. doi:10.1073/pnas.1108924108 
12.  Rasmussen TS, de Vries L, Kot W, Hansen LH, Castro-Mejía JL, Vogensen FK, et 
al. Mouse vendor influence on the bacterial and viral gut composition exceeds the 
effect of diet. Viruses. MDPI AG; 2019;11. doi:10.3390/v11050435 
13.  Parker KD, Albeke SE, Gigley JP, Goldstein AM, Ward NL. Microbiome 
composition in both wild-type and disease model mice is heavily influenced by 
mouse facility. Front Microbiol. Frontiers Media S.A.; 2018;9. 
doi:10.3389/fmicb.2018.01598 
14.  Choo JM, Trim PJ, Leong LEX, Abell GCJ, Brune C, Jeffries N, et al. Inbred mouse 
populations exhibit intergenerational changes in intestinal microbiota composition 
and function following introduction to a facility. Front Microbiol. Frontiers 
Research Foundation; 2017;8. doi:10.3389/fmicb.2017.00608 
15.  Rogers GB, Kozlowska J, Keeble J, Metcalfe K, Fao M, Dowd SE, et al. Functional 




identical mice. Sci Rep. Nature Publishing Groups; 2014;4. doi:10.1038/srep05437 
16.  Hildebrand F, Nguyen TLA, Brinkman B, Yunta R, Cauwe B, Vandenabeele P, et 
al. Inflammation-associated enterotypes, host genotype, cage and inter-individual 
effects drive gut microbiota variation in common laboratory mice. Genome Biol. 
2013;14: R4. doi:10.1186/gb-2013-14-1-r4 
17.  Deloris Alexander A, Orcutt RP, Henry JC, Baker J, Bissahoyo AC, Threadgill DW. 
Quantitative PCR assays for mouse enteric flora reveal strain-dependent differences 
in composition that are influenced by the microenvironment. Mamm Genome. 
2006;17: 1093–1104. doi:10.1007/s00335-006-0063-1 
18.  Unger AL, Eckstrom K, Jetton TL, Kraft J. Colonic bacterial composition is sex-
specific in aged CD-1 mice fed diets varying in fat quality. Loor JJ, editor. PLoS 
One. 2019;14: e0226635. doi:10.1371/journal.pone.0226635 
19.  Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and β-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia. Springer-Verlag; 
1985;28: 412–419. doi:10.1007/BF00280883 
20.  Goedecke JH, Dave JA, Faulenbach M V., Utzschneider KM, Lambert E V., West 
S, et al. Insulin response in relation to insulin sensitivity: An appropriate β-cell 
response in black South African women. Diabetes Care. 2009;32: 860–865. 
doi:10.2337/dc08-2048 
21.  Andersen KS, Kirkegaard RH, Karst SM, Albertsen M. ampvis2: an R package to 
analyse and visualise 16S rRNA amplicon data. bioRxiv (preprint). Cold Spring 
Harbor Laboratory; 2018; 299537. doi:10.1101/299537 
22.  Alboukadel Kassambara. Pipe-Friendly Framework for Basic Statistical Tests - 
rstatix [Internet]. 2020 [cited 19 Jun 2020]. Available: 
https://rpkgs.datanovia.com/rstatix/ 
23.  Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion 
for RNA-seq data with DESeq2. Genome Biol. BioMed Central Ltd.; 2014;15: 550. 
doi:10.1186/s13059-014-0550-8 
24.  Chang HYS, Mitzner W, Watson J. Variation in airway responsiveness of male 
C57BL/6 mice from 5 vendors. J Am Assoc Lab Anim Sci. 2012;51: 401–406.  
25.  Hull RL, Willard JR, Struck MD, Barrow BM, Brar GS, Andrikopoulos S, et al. 
High fat feeding unmasks variable insulin responses in male C57BL/6 mouse 
substrains. J Endocrinol. BioScientifica Ltd.; 2017;233: 53–64. doi:10.1530/JOE-
16-0377 
26.  Xiao L, Feng Q, Liang S, Sonne SB, Xia Z, Qiu X, et al. A catalog of the mouse gut 
metagenome. Nat Biotechnol. Nature Publishing Group; 2015;33: 1103–1108. 
doi:10.1038/nbt.3353 
27.  Randall DW, Kieswich J, Swann J, McCafferty K, Thiemermann C, Curtis M, et al. 
Batch effect exerts a bigger influence on the rat urinary metabolome and gut 
microbiota than uraemia: a cautionary tale. Microbiome. BioMed Central Ltd.; 
2019;7: 127. doi:10.1186/s40168-019-0738-y 
28.  Yakoob MY, Shi P, Willett WC, Rexrode KM, Campos H, Orav EJ, et al. 
Circulating Biomarkers of Dairy Fat and Risk of Incident Diabetes Mellitus Among 




Circulation. Lippincott Williams and Wilkins; 2016;133: 1645–1654. 
doi:10.1161/CIRCULATIONAHA.115.018410 
29.  Zheng JS, Sharp SJ, Imamura F, Chowdhury R, Gundersen TE, Steur M, et al. 
Association of plasma biomarkers of fruit and vegetable intake with incident type 2 
diabetes: EPIC-InterAct case-cohort study in eight European countries. BMJ. BMJ 
Publishing Group; 2020;370. doi:10.1136/bmj.m2194 
30.  Ericson U, Sonestedt E, Gullberg B, Hellstrand S, Hindy G, Wirfält E, et al. High 
intakes of protein and processed meat associate with increased incidence of type 2 
diabetes. Br J Nutr. Br J Nutr; 2013;109: 1143–1153. 
doi:10.1017/S0007114512003017 
31.  Wu JHY, Micha R, Mozaffarian D. Dietary fats and cardiometabolic disease: 
mechanisms and effects on risk factors and outcomes [Internet]. Nature Reviews 
Cardiology. Nature Publishing Group; 2019. pp. 581–601. doi:10.1038/s41569-019-
0206-1 
32.  Caesar R, Tremaroli V, Kovatcheva-Datchary P, Cani PD, Bäckhed F. Crosstalk 
between gut microbiota and dietary lipids aggravates WAT inflammation through 
TLR signaling. Cell Metab. 2015;22: 658–668. doi:10.1016/j.cmet.2015.07.026 
33.  Huang EY, Leone VA, Devkota S, Wang Y, Brady MJ, Chang EB. Composition of 
dietary fat source shapes gut microbiota architecture and alters host inflammatory 
mediators in mouse adipose tissue. J Parenter Enter Nutr. 2013;37: 746–54. 
doi:10.1177/0148607113486931 
34.  de Wit N, Derrien M, Bosch-Vermeulen H, Oosterink E, Keshtkar S, Duval C, et al. 
Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota 
composition by an enhanced overflow of dietary fat to the distal intestine. AJP 
Gastrointest Liver Physiol. 2012;303: 589–599. doi:10.1152/ajpgi.00488.2011 
35.  Menni C, Zierer J, Pallister T, Jackson MA, Long T, Mohney RP, et al. Omega-3 
fatty acids correlate with gut microbiome diversity and production of N-
carbamylglutamate in middle aged and elderly women. Sci Rep. 2017;7: 11079. 
doi:10.3390/ijms18122645 
36.  Gentile CL, Weir TL. The gut microbiota at the intersection of diet and human 
health. Science. American Association for the Advancement of Science; 2018. pp. 
776–780. doi:10.1126/science.aau5812 
37.  Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and 
increased insulin resistance are independently related to the 7-year risk of NIDDM 
in Mexican- Americans. Diabetes. American Diabetes Association Inc.; 1995;44: 
1386–1391. doi:10.2337/diab.44.12.1386 
38.  Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al. Insulin 
Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-
Dependent Diabetes Mellitus: Prospective Studies of Pima Indians. N Engl J Med. 
N Engl J Med; 1993;329: 1988–1992. doi:10.1056/NEJM199312303292703 
39.  Martin BC, Warram JH, Krolewski AS, Soeldner JS, Kahn CR, Martin BC, et al. 
Role of glucose and insulin resistance in development of type 2 diabetes mellitus: 
results of a 25-year follow-up study. Lancet. Lancet; 1992;340: 925–929. 
doi:10.1016/0140-6736(92)92814-V 




removal rate and hyperinsulinemia precede the development of type II diabetes in 
the offspring of diabetic parents. Ann Intern Med. Ann Intern Med; 1990;113: 909–
915. doi:10.7326/0003-4819-113-12-909 
41.  Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut 
microbiota in type 2 diabetes pathophysiology. EBioMedicine. Elsevier B.V.; 2020. 
p. 102590. doi:10.1016/j.ebiom.2019.11.051 
42.  Candela M, Biagi E, Soverini M, Consolandi C, Quercia S, Severgnini M, et al. 
Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic 
Ma-Pi 2 diet. Br J Nutr. Cambridge University Press; 2016;116: 80–93. 
doi:10.1017/S0007114516001045 
43.  Salamon D, Sroka-Oleksiak A, Kapusta P, Szopa M, Mrozińska S, Ludwig-
Słomczyńska AH, et al. Characteristics of gut microbiota in adult patients with type 
1 and type 2 diabetes based on next-generation sequencing of the 16S rRNA gene 
fragment. Polish Arch Intern Med. Medycyna Praktyczna; 2018;128: 336–343. 
doi:10.20452/pamw.4246 
44.  Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, et al. Human Gut Microbiota 
Changes Reveal the Progression of Glucose Intolerance. Federici M, editor. PLoS 
One. Public Library of Science; 2013;8: e71108. doi:10.1371/journal.pone.0071108 
45.  Sedighi M, Razavi S, Navab-Moghadam F, Khamseh ME, Alaei-Shahmiri F, 
Mehrtash A, et al. Comparison of gut microbiota in adult patients with type 2 
diabetes and healthy individuals. Microb Pathog. Academic Press; 2017;111: 362–
369. doi:10.1016/j.micpath.2017.08.038 
46.  Ni Y, Mu C, He X, Zheng K, Guo H, Zhu W. Characteristics of gut microbiota and 
its response to a Chinese Herbal Formula in elder patients with metabolic syndrome. 
Drug Discov Ther. NLM (Medline); 2018;12: 161–169. 
doi:10.5582/ddt.2018.01036 





A.8 Supporting information 
Table A.S1 Daily feed intake, feed efficiency, body weight, and parameters of 
glucose homeostasis of CD-1 mice received from two different animal husbandry 
facilitates (cohort A and B, respectively). Values are expressed as mean ± standard error 
of the mean. Means without a common letter differ (P < 0.05).  
Table A.S2 Daily feed intake, feed efficiency, body weight, and parameters of 




standard error of the mean. Means without a common letter differ (P < 0.05). 
Table A.S3 Daily feed intake, feed efficiency, body weight, and parameters of 
glucose homeostasis of CD-1 mice fed a control fat blend (CO) or a control fat blend 
supplemented (30%) with fish oil (FO), butter oil (BO), or echium oil (EO). Values are 
expressed as mean ± standard error of the mean. Means without a common letter differ (P 
< 0.05). 
Table A.S4 Daily feed intake, feed efficiency, body weight, and parameters of 
glucose homeostasis of CD-1 mice at three, six, and nine months of consuming a high-fat 
experimental diet. Values are expressed as mean ± standard error of the mean. Means 
without a common letter differ (P < 0.05). 
Table A.S5 Results of DESeq2 displaying differentially abundant (P < 0.05) 
bacterial genera between CD-1 mice received from two different animal husbandry 
facilities (Cohort A and B, respectively). 
Figure A.S1 Box and whisker plots of the top 10 most abundant colonic bacterial 
genera of male and female CD-1 mice received from two different animal husbandry 
facilities (Cohort A and B, respectively). Mice were fed a high-fat diet either consisting of 
100% control fat (CO) or CO fat supplemented with 30% of fish oil (FO), butter oil (BO), 
or echium oil (EO). Abundance of colonic bacterial genera of mice is displayed by cohort 
(A), sex (B), and dietary intervention (C). 
Figure A.S2 Alpha diversity indices (richness, Fisher’s alpha, Shannon’s index, 
Pielou’s evenness) of colonic bacteria of male and female CD-1 mice received from two 
different animal husbandry facilities (Cohort A and B, respectively). Mice were fed a high-




fish oil (FO), butter oil (BO), or echium oil (EO). Alpha diversity indices of colonic 
bacteria of mice are displayed by cohort (A), sex (B), and dietary intervention (C). * = P < 
0.05, ** = P < 0.01.   
Figure A.S3 Diet-induced changes in alpha diversity indices (richness, Fisher’s 
alpha, Shannon’s index, Pielou’s evenness) of colonic bacteria of male and female CD-1 
mice received from two different animal husbandry facilities (Cohort A and B, 
respectively). Mice were fed a high-fat diet either consisting of 100% control fat (CO) or 
CO fat supplemented with 30% of fish oil (FO), butter oil (BO), or echium oil (EO). Alpha 
diversity indices of colonic bacteria of mice are displayed for males in Cohort A (A), males 
in Cohort B (B), females in Cohort A (C), and females in Cohort B (D). * = P < 0.05, ** = 
P < 0.01. CO-fed males from Cohort B were not included in analysis due to insufficient 





Table A.S1 Daily feed intake, feed efficiency, body weight, and parameters of glucose homeostasis of CD-1® mice received from 
two different animal husbandry facilitates (Cohort A and B, respectively). Values are expressed as mean ± standard error of the mean. 
Means without a common letter differ (P < 0.05). 
 Cohort  P value 
 A1 B2  C3 S4 D5 T6 S x C D x C C x T 
S x 
D S x T 
D x 
T 
S x D 
x C 
S x C 
x T 
D x C x 
T 
S x D 
x T 
S x D x 
C x T 

















± 0.9b  0.006 <0.001 - <0.001 <0.001 - - - <0.001 0.002 0.012 0.002 - - 0.006 
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 A1 B2  C3 S4 D5 T6 S x C D x C C x T 
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± 627  - <0.001 - 0.082 - - - - 0.038 0.001 - - - 0.001 - 
Area under the 














± 0.80  - 0.007 - <0.001 - 0.04 - - - 0.042 - - - 0.022 - 
1 CD-1® mice received from Charles River animal husbandry facility in Kingston, NY. 2 CD-1® mice received from Charles 
River animal husbandry facility in Raleigh, NC.3 C = Cohort.4 S = Sex. 5 D = Diet. 6 T= Time (month of data collection). 7 
Feed efficiency = total weight gain (g) / total feed intake (kcal). 8 GTT = Glucose tolerance test. 9 ITT = Insulin tolerance test. 
10 HOMA-IR = Homeostatic model of assessment of insulin resistance (glucose0 min*insulin0 min) / 405. 11 Insulinogenic index 






Table A.S2 Daily feed intake, feed efficiency, body weight, and parameters of glucose homeostasis of male and female CD-1® mice. 
Values are expressed as mean ± standard error of the mean. Means without a common letter differ (P < 0.05). 
 Sex  P value 
 Male Female  C1 S2 D3 T4 S x C D x C C x T 
S x 
D S x T 
D x 
T 
S x D 
x C 
S x C 
x T 
D x C x 
T 
S x D 
x T 
S x D x 
C x T 



















± 0.7b  0.006 <0.001 - <0.001 <0.001 - - - <0.001 0.002 0.012 0.002 - - 0.006 





























± 0.04b  0.03 <0.001 - <0.001 0.001 - - - 0.004 - - 0.004 - - - 





± 248b  - <0.001 - 0.082 - - - - 0.038 0.001 - - - 0.001 - 


















± 0.36b  - 0.007 - <0.001 - 0.04 - - - 0.042 - - - 0.022 - 
1 C = Cohort.2 S = Sex. 3 D = Diet. 4 T= Time (month of data collection). 5 Feed efficiency = total weight gain (g) / total feed intake 
(kcal). 6 GTT = Glucose tolerance test. 7 ITT = Insulin tolerance test. 8 HOMA-IR = Homeostatic model of assessment of insulin 





Table A.S3 Daily feed intake, feed efficiency, body weight, and parameters of glucose homeostasis of CD-1® mice fed a high-fat 
diet either consisting of 100% control fat (CO) or CO fat supplemented with 30% of fish oil (FO), butter oil (BO), or echium oil 
(EO). Values are expressed as mean ± standard error of the mean. Means without a common letter differ (P < 0.05). 
 Diet   P value 
 CO FO BO EO  C1 S2 D3 T
4 S x C D x C C x T 
S x 
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 0.09 <0.001 - 
<0.00
1 0.004 - - - 0.011 - - 
0.01















 - 0.007 - <0.001 - 
0.0
4 - - - 
0.04
2 - - - 
0.02
2 - 
1 C = Cohort.2 S = Sex. 3 D = Diet. 4 T= Time (month of data collection). 5 Feed efficiency = total weight gain (g) / total feed intake 
(kcal). 6 GTT = Glucose tolerance test. 7 ITT = Insulin tolerance test. 8 HOMA-IR = Homeostatic model of assessment of insulin 





Table A.S4 Daily feed intake, feed efficiency, body weight, and parameters of glucose homeostasis of CD-1® mice at three, six, and 
nine months of consuming a high-fat experimental diet. Values are expressed as mean ± standard error of the mean. Means without 
a common letter differ (P < 0.05). 
 Month  P value 
 3 6 9  C1 S2 D3 T4 S x C D x C C x T 
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± 714  - <0.001 - 0.082 - - - - 0.038 0.001 - - - 0.001 - 

































 - 0.007 - <0.001 - 0.04 - - - 0.042 - - - 0.022 - 
1 C = Cohort.2 S = Sex. 3 D = Diet. 4 T= Time (month of data collection). 5 Feed efficiency = total weight gain (g) / total feed intake 
(kcal). 6 GTT = Glucose tolerance test. 7 ITT = Insulin tolerance test. 8 HOMA-IR = Homeostatic model of assessment of insulin 





Table A.S5 Results of DEseq2 displaying differentially abundant (P < 0.05) bacterial genera between CD-1® mice received from 
two different animal husbandry facilities (Cohort A and B, respectively). 
Genus Base Mean1 Log2 Fold Change2 SE3 Stat4 P value Adjusted P value5 
Acetanaerobacterium 33.661 0.870 0.318 2.741 0.006 0.031 
Adlercreutzia 1.687 -4.082 0.677 -6.027 0.000 0.000 
Anaerotruncus 22.259 -1.346 0.338 -3.978 0.000 0.001 
Bacillus 3.131 1.812 0.390 4.643 0.000 0.000 
Bacteroides 6642.494 -1.228 0.368 -3.334 0.001 0.006 
Bilophila 102.663 7.142 0.639 11.170 0.000 0.000 
Coprococcus 55.178 1.942 0.297 6.545 0.000 0.000 
Dorea 121.853 -1.583 0.555 -2.851 0.004 0.025 
Dysgonomonas 2.895 2.091 0.639 3.274 0.001 0.007 
Faecalibacterium 1.015 1.498 0.585 2.562 0.010 0.046 
Fusicatenibacter 4.197 -1.259 0.412 -3.052 0.002 0.014 
Intestinimonas 133.250 -0.857 0.199 -4.311 0.000 0.000 
Kopriimonas 30.943 -5.648 0.612 -9.229 0.000 0.000 
Lactobacillus 4525.116 1.522 0.565 2.692 0.007 0.033 
Megasphaera 2.081 -3.103 0.880 -3.526 0.000 0.003 
Moryella 0.711 2.139 0.770 2.780 0.005 0.029 
Odoribacter 164.341 -3.481 0.632 -5.504 0.000 0.000 
Parabacteroides 441.781 1.957 0.342 5.719 0.000 0.000 
Paraprevotella 0.478 -2.458 0.975 -2.521 0.012 0.049 
Pelotomaculum 1.127 -2.368 0.869 -2.726 0.006 0.031 
Ruminococcus 202.629 1.381 0.322 4.290 0.000 0.000 
Tannerella 6.484 -1.837 0.424 -4.331 0.000 0.000 
Tyzzerella 69.071 -1.212 0.308 -3.938 0.000 0.001 
1Mean of normalized counts for all samples. 2Effect size estimate. 3Standard error for log2(fold change). 4Log2(fold change) divided 








Figure A.1 (A) Body weight, (B) weight gain, (C) feed intake, and (D) feed efficiency of 
male and female CD-1 mice acquired from two different animal husbandry facilities 
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 (Cohorts A and B, respectively). Body weight is displayed for (E) male and (F) female 
CD-1 mice fed a high-fat diet either consisting of 100% control fat (CO) or CO fat 
supplemented with 30% of fish oil (FO), butter oil (BO) or echium oil (EO). Mice of each 
cohort were allocated to one of four diet groups at four weeks of age (n=10-
11/cohort/sex/diet). Values are expressed as mean ± standard error of the mean. ** = P < 
0.01, Cohort A vs. Cohort B collapsed by time, sex, and diet. *** = P < 0.001, Cohort A 
vs. Cohort B collapsed by time, sex, and diet. Ɨ = P = 0.067, Cohort A vs. Cohort B 
collapsed by time, sex, and diet. Ø = P < 0.05, males vs. females collapsed by cohort, time, 
and diet. # = P < 0.05, females of Cohort A vs. females of Cohort B collapsed by time and 
diet.  $ = P < 0.05, FO-, BO-, or EO-fed males vs. CO-fed males within each respective 
month and cohort. § = P < 0.05, CO-, FO-, or BO-fed females vs. EO-fed females within 





Figure A.2 (A) Fasting glucose, (B) fasting insulin, (C) homeostatic model assessment of 
insulin resistance (HOMA-IR), (D) area under the curve of glucose tolerance test, and (E) 
area under the curve of insulin tolerance test of CD-1 mice received from two different 

























































































































animal husbandry facilities (Cohort A and B, respectively). Mice of each cohort were 
allocated to one of four diet groups at four weeks of age (n=10-11/cohort/sex/diet). Values 
are expressed as mean ± standard error of the mean. * = P < 0.05, Cohort A vs. Cohort B 
collapsed by time, sex, and diet. Ø = P < 0.05, males vs. females collapsed by cohort, time, 
and diet. # = P < 0.05, males of Cohort A vs. males of Cohort B collapsed by time and diet. 






Figure A.3 Colonic bacterial composition of male and female CD-1 mice received from 
two different animal husbandry facilities (Cohort A and B, respectively). (A) Principal 
component analysis of bacterial composition, (B) relative abundance of bacterial genera, 
(C) enhanced volcano plot of bacterial genera that were differentially abundant in males of 
Cohort A (negative x-axis) and males of Cohort B (positive x-axis), (D) enhanced volcano 
plot of bacterial genera that were differentially abundant in females of Cohort A (negative 
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 Fisher’s alpha, Shannon’s index, Pielou’s evenness) of bacteria in CD-1 mice. For colonic 
bacterial analysis, fecal samples were collected at ten months of age from a subset of mice 
from each diet group (n = 2-5/diet/sex, n=28-31/cohort). NS = not significant and < 
log2(fold change), Log2 FC = > log2(fold change), P-value and log2 FC = > log2(fold 








Figure A.4 Spearman correlation matrices between metabolic parameters, alpha diversity indices of colonic bacteria, and differentially 
abundant colonic bacterial genera (P <0.05 calculated with Benjamini-Hochberg adjustment determined by DESeq2) of male and female 
mice in Cohort A (A) and Cohort B (B). For colonic bacterial analysis, fecal samples were collected at ten months of age from a subset 
of mice from each diet group (n = 2-5/diet/sex, n=28-31/cohort). A positive correlation (closer to 1) is signified by a darker shade of 







































Figure A.S1 Box and whisker plots of the top 10 most abundant colonic bacterial genera of male and female CD-1® mice received 
from two different animal husbandry facilities (Cohort A and B, respectively). Mice were fed a high-fat diet either consisting of 100% 
control fat (CO) or CO fat supplemented with 30% of fish oil (FO), butter oil (BO), or echium oil (EO). Abundance of colonic bacterial 






















S1 Fig. Box and whisker plots of the top 10 most abundant colonic bacterial genera of male and female CD-1® mice received from two different 
ani al husbandry facilities (Cohort A and B, respectively). Mice were fed a high-fat diet either consisting of 100% control fat (CO) or CO fat 
supplemented with 30% of fish oil (FO), butter oil (BO), or echium oil (EO). Abundance of colonic bacterial genera of mice is displayed by cohort (A), 


























Figure A.S2 Alpha diversity indices (richness, Fisher’s alpha, Shannon’s index, Pielou’s evenness) of colonic bacteria of male and 
female CD-1® mice received from two different animal husbandry facilities (Cohort A and B, respectively). Mice were fed a high-fat 
diet either consisting of 100% control fat (CO) or CO fat supplemented with 30% of fish oil (FO), butter oil (BO), or echium oil (EO). 
Alpha diversity indices of colonic bacteria of mice are displayed by cohort (A), sex (B), and dietary intervention (C). * = P < 0.05, ** = 


























S2 Fig. Alpha diversity indices (richness, Fisher’s alpha, Shannon’s index, Pielou’s evenness) of colonic bacteria of male and female CD-1® mice 
received from two different animal husbandry facilities (Cohort A and B, respectively). Mice were fed a high-fat diet either consisting of 100% control 
fat (CO) or CO fat supplemented with 30% of fish oil (FO), butter oil (BO), or echium oil (EO). Alpha diversity indices of colonic bacteria of mice are 





















Figure A.S3 Diet-induced changes in alpha diversity indices (richness, Fisher’s alpha, Shannon’s index, Pielou’s evenness) of colonic 
bacteria of male and female CD-1® mice received from two different animal husbandry facilities (Cohort A and B, respectively). Mice 
were fed a high-fat diet either consisting of 100% control fat (CO) or CO fat supplemented with 30% of fish oil (FO), butter oil (BO), 









































S3 Fig. Diet-induced changes in alpha diversity indices (richness, Fisher’s alpha, Shannon’s index, Pielou’s evenness) of colonic bacteria of male and 
female CD-1® mice r ceived from two different animal husbandry facilities (Cohort A and B, respectiv ly). Mice were fed a high-fat diet either 
consisting of 100% control fat (CO) or CO fat supplemented with 30% of fish oil (FO), butter oil (BO), or echium oil (EO). Alpha diversity indices of 
colonic bacteria of mice are displayed for males in Cohort A (A), males in Cohort B (B), females in Cohort A (C), and females in Cohort B (D). * = P < 







females in Cohort A (C), and females in Cohort B (D). * = P < 0.05, ** = P < 0.01. CO-fed males from Cohort B were not included in 
analysis due to insufficient power (n = 2). 
